Parallax Health Sciences 10-K/A 20 May 20 2019 FY Annual report (amended) Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	May 15, 2020
Details
Registrant CIK	0001388410
Fiscal Year End	--12-31
Registrant Name	PARALLAX HEALTH SCIENCES, INC.
SEC Form	10-K/A
Period End date	Dec. 31, 2019
Tax Identification Number (TIN)	46-4733512
Number of common stock shares outstanding		270,723,289
Public Float	$ 12,850,866
Filer Category	Non-accelerated Filer
Current with reporting	Yes
Interactive Data Current	Yes
Voluntary filer	No
Well-known Seasoned Issuer	No
Shell Company	false
Small Business	true
Emerging Growth Company	true
Ex Transition Period	false
Amendment Description	XBRL Files
Document Annual Report	true
Document Transition Report	false
Entity File Number	000-52534
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	1327 Ocean Avenue, Suite B
Entity Address, City or Town	Santa Monica
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90401
City Area Code	310
Local Phone Number	899-4442
Amendment Flag	true
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 6,445	$ 262
Operating lease asset	52,176	0
Total current assets	58,621	262
Investments	50,000	0
Goodwill	785,060	785,060
Intangible assets, net	458,415	579,035
Deposit Assets	7,800	0
TOTAL ASSETS	1,359,896	1,364,357
Current liabilities
Accounts payable and accrued expenses	2,082,978	2,655,138
Operating lease liability	52,176	0
Settlements payable, net of unamortized discount	2,824,200	0
Derivative liability, short-term	62,800	23,925
Debentures, convertible	0	724,903
Debentures, convertible, related party	0	411,006
Notes payable	345,000	0
Note payable, bank	18,616	0
Note payable, related party	126,152	0
Notes payable, convertible, net of unamortized discount	1,102,364	296,000
Related party payables	1,108,480	1,004,720
Total current liabilities	7,722,766	5,115,692
Long-term liabilities
Settlements payable, net of unamortized discount	1,240,000	0
License fees payable, net of unamortized discount	442,000	430,000
Royalties payable	325,165	310,000
Derivative liability, long-term	0	34,000
Debentures, convertible, net of unamortized discount	0	184,870
Note payable, bank	0	28,995
Note payable, related party	633,294	0
Notes payable, convertible	760,154	720,154
Notes payable, related party, convertible	491,100	491,100
Total long-term liabilities	3,891,713	2,199,119
Total liabilities	11,614,479	7,314,811
Stockholders' deficit
Preferred stock, $.001 par, 10,000,000 shares authorized,	978	1,014
Common stock, $.001 par, 500,000,000 shares authorized,	250,124	158,113
Additional paid in capital - preferred	1,599,036	1,699,000
Additional paid in capital - common	19,952,533	11,382,341
Accumulated deficit	(32,057,254)	(19,190,922)
Total stockholders' deficit	(10,254,583)	(5,950,454)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 1,359,896	$ 1,364,357

Consolidated Balance Sheets - P

Consolidated Balance Sheets - Parenthetical - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Details
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Outstanding	977,352	863,691
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares, Outstanding	250,124,755	158,113,141

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Net Income (Loss) Available to Common Stockholders, Basic
Revenue	$ 128,600	$ 11,739
Cost of sales	16,827	20,339
Gross profit (loss)	111,773	(8,600)
General and administrative expenses	6,505,461	6,626,063
Operating loss	(6,393,688)	(6,634,663)
Other expenses
Gain on disposal of subsidiary	0	4,478,268
Gain (loss) on extinguishment of debt	(927,399)	22,858,009
Gain (loss) on fair value adjustments	194,511	(123,875)
Loss on settlements	(4,134,972)	0
Impairment losses	(1,002,276)	0
Discount amortization	(20,000)	(2,805,000)
Interest expense	(582,508)	(2,164,530)
Total other expenses	(6,472,644)	22,242,872
Net income (loss) - continuing operations	(12,866,332)	15,608,209
Net loss - discontinued operations	0	(824,398)
Net income (loss)	$ (12,866,332)	$ 14,783,811
Continuing operations	$ (0.064)	$ 0.105
Discontinued operations	0	(0.006)
Net income (loss) per common share - diluted
Continuing operations	(0.049)	0.072
Discontinued operations	$ 0	$ (0.004)
Weighted average common shares outstanding - basic	201,920,901	148,335,736
Weighted average common shares outstanding - diluted	261,528,105	215,576,153

Statement of Stockholders' Defi

Statement of Stockholders' Deficit - USD ($)	Preferred Stock, Shares	Preferred Stock	Common Stock, Shares	Common Stock, Value	Preferred Stock, Paid In Capital	Common Stock, Paid In Capital	Deferred Compensation, Value	Subscriptions Receivable	Accumulated Deficit	Total
Equity Balance at Dec. 31, 2017		$ 864		$ 136,754	$ 665,803	$ 9,637,860	$ (3,188,092)	$ (592)	$ (33,691,386)	$ (26,438,789)
Shares, Outstanding, Beginning Balance at Dec. 31, 2017	863,691		136,754,530
Deemed dividend on Series C preferred stock						283,347			(283,347)	0
Dividends paid in kind on preferred stock to treasury										0
Issuance of common stock for cash				2,000		238,000				240,000
Issuance of common stock for cash			2,000,000
Issuance of common stock for cash-officers/directors				6,000		984,000				985,000
Issuance of common stock for cash-officers/directors			6
Issuance of common stock for debt service				2,810		278,190	(281,000)			0
Issuance of common stock for debt service			2,810,000
Conversion of debt for common stock				6,881		668,733				675,614
Conversion of debt for common stock			6,881,130
Exercise of stock options-employees				847		268,479				269,326
Exercise of stock options-employees			846,051
Exercise of stock options-officers/directors				1,071		186,429				187,500
Exercise of stock options-officers/directors			1,071,430
Grant of stock awards for services				1,750		277,360	(153,000)			126,110
Grant of stock awards for services			1,750,000
Grant of stock options to consultants						539,200	(539,200)			0
Grant of stock options to officers/directors						294,500	(294,500)			0
Grant of stock warrants						114,603	(113,210)			1,393
Forfeiture of stock options						(184,373)	184,373			0
Change in derivative liability to equity						750,200				750,200
Beneficial conversion feature of debt						(27,643)				(27,643)
Amortization of stock awards							1,095,193			1,095,193
Amortization of stock options							572,869			572,869
Amortization of stock warrants							73,370			73,370
Subscriptions received								5,592		5,592
Net Income (loss)									14,783,811	14,783,811
Equity Balance at Dec. 31, 2018		1,014		158,113	1,699,000	14,025,538	(2,643,197)	0	(19,190,922)	(5,950,454)
Shares, Outstanding, Ending Balance at Dec. 31, 2018	1,013,691		158,113,141
Issuance of preferred stock for cash	60,000
Issuance of preferred stock for cash		60			299,940					300,000
Issuance of preferred stock for debt-officers/directors	90,000
Issuance of preferred stock for debt-officers/directors		90			449,910					450,000
Net Income (loss)									14,783,811	14,783,811
Dividends paid in kind on preferred stock to treasury		21			58,211					58,232
Dividends paid in kind on preferred stock to treasury	21,161
Cancellation of preferred stock to treasury		(57)			(158,175)					(158,232)
Cancellation of preferred stock to treasury	(57,500)
Sale of preferred treasury stock		57			68,943					69,000
Sale of preferred treasury stock	57,500
Conversion of preferred stock to common stock		(57)		1,150	(68,943)	67,850				0
Conversion of preferred stock to common stock	(57,500)		1,150,000
Issuance of common stock for cash				24,261		1,738,239		(500,000)		1,262,500
Issuance of common stock for cash			24,260,000
Issuance of common stock for cash-officers/directors				6,000		369,000				375,000
Issuance of common stock for cash-officers/directors			6,000,000
Issuance of common stock for services				240		14,760				15,000
Issuance of common stock for services			240,000
Issuance of common stock for debt service				3,010		356,504	(33,000)			326,514
Issuance of common stock for debt service			3,010,811
Issuance of common stock for investment				6,666		993,334				1,000,000
Issuance of common stock for investment			6,666,667
Conversion of debt for common stock				24,682		1,710,648				1,735,330
Conversion of debt for common stock			24,682,217
Conversion of debt for common stock-officers/directors				12,370		824,630				837,000
Conversion of debt for common stock-officers/directors			12,370,000
Exercise of stock warrants				1,875		176,825				178,700
Exercise of stock warrants			1,875,000
Grant of stock awards for services				8,757		865,791	20,237			894,785
Grant of stock awards for services			8,756,919
Grant of stock awards for services-officers/directors				3,000		198,300	(198,300)			3,000
Grant of stock awards for services-officers/directors			3,000,000
Grant of stock options to consultants						584,000	(584,000)			0
Grant of stock options to officers/directors						291,700	(291,700)			0
Grant of stock warrants						40,730				40,730
Amortization of stock awards							699,803			699,803
Amortization of stock options							718,391			718,391
Amortization of stock warrants							6,450			6,450
Subscriptions received								500,000		500,000
Net Income (loss)									(12,866,332)	(12,866,332)
Equity Balance at Dec. 31, 2019	$ 977,352	$ 978	$ 250,124,755	$ 250,124	$ 1,599,036	$ 22,257,849	$ (2,305,316)	$ 0	(32,057,254)	(10,254,583)
Net Income (loss)									$ (12,866,332)	$ (12,866,332)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows	12 Months Ended
	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Cash flows from operating activities:
Net income (loss)	$ (12,866,332)	$ 15,608,209
Adjustments to reconcile net income (loss) to net cash used by operating activities:
Depreciation and amortization	187,381	120,620
Stock compensation/stock option expense	2,782,426	3,513,710
Securities received in exchange for licenses sold	(50,000)	0
Discount amortization	24,791	2,805,000
Allowance for bad debt	0	236
Gain on disposal of subsidairy	0	(4,478,268)
Gain on extinguishment of debt	927,399	(22,858,009)
(Gain) loss on fair value adjustments	(194,511)	123,875
Loss on settlements	4,134,972	0
Impairment loss	1,002,276	0
Debt accretion	183,600	1,107,753
Changes in operating assets and liabilities:
Decrease in trade and other receivables	0	3,039
Increase in deposits	(7,800)	0
Increase in accounts payable and accrued expenses	45,790	1,980,979
Increase in royalties payable	7,165	0
Increase in related party payables	877,270	780,872
Net cash used by operating activities	(2.945573)	(1,291,984)
Cash flows from investing activities:
Purchase of professional equipment	(2,628)	0
Net cash used by investing activities	(2,628)	0
Cash flows from financing activities:
Lease payments	(71,200)	0
Proceeds from notes and loans payable	330,000	0
Repayment of notes and loans payable	(150,379)	(9,245)
Proceeds from convertible notes payable	1,592,280	825,000
Repayment of convertible notes payable	(398,580)	(50,000)
Proceeds from issuance of debentures	0	225,000
Repayment of debentures	(754,369)	0
Proceeds from issuance of preferred shares	69,000	300,000
Proceeds from issuance of common shares	2,337,632	41,250
Net cash provided by financing activities	2,954,384	1,332,005
Net cash provided by continuing operations	6,183	40,021
Cash flows from discontinued operations:
Net cash used by operating activities	0	(39,942)
Net cash used by discontinued operations	0	(39,942)
Net increase in cash	6,183	79
Cash - beginning of period	262	183
Cash - end of period	6,445	262
NON-CASH ACTIVITIES
Discounts on long-term liabilities	24,791	2,805,000
Beneficial conversion feature of convertible promissory notes	0	347,487
Fair value of stock warrants	57,000	1,393
Embedded conversion option of convertible promissory notes	30,620	60,350
Intrinsic value of beneficial conversion feature upon extinguishment of debt	0	375,100
Dividends paid in kind on preferred stock returned to treasury	58,232	0
Conversion of preferred stock to common stock	69,000	0
Cancellation of preferred stock for debt settlement	100,000	0
Conversion of accounts payable to convertible note payable	20,000	0
Conversion of accounts payable to related party convertible note payable	20,000	0
Conversion of accounts payable to related party debentures	0	128,132
Conversion of accounts payable into common stock	200,000	0
Conversion of related party payables to preferred stock	0	450,000
Conversion of related party payable to common stock	753,510	0
Conversion of related party convertible notes payable to common stock	$ 369,815	$ 0
Conversion of convertible notes payable into common stock	135,443	675,614
Conversion of convertible notes payable to debentures	$ 0	$ 755,627
Conversion of convertible debentures to common stock	785,479	0
Conversion of related party convertible note payable to non-related party convertible note payable	0	576,154
Conversion of related party payables to non-related party payables	0	42,356
Issuance of common stock for investment	1,000,000	0
Securities received in exchange for license fee	50,000	0
Interest paid:
Continuing operations	470,101	185,937
Discontinued operations	0	106
Income taxes paid	$ 0	$ 0

Overview and Nature of Business

Overview and Nature of Business	12 Months Ended
	Dec. 31, 2019
Notes
Overview and Nature of Business	NOTE 1. OVERVIEW AND NATURE OF BUSINESS Corporate History Parallax Health Sciences, Inc. (the “Company”) was incorporated in the State of Nevada on July 6, 2005. The Company’s principal focus is to build and expand an integrated digital healthcare network with products and services that can provide remote communication, diagnosis, treatment, and monitoring of patients on a proprietary platform. On August 31, 2016, the Company entered into an agreement (the “Qolpom® Agreement”) with Qolpom®, Inc., an Arizona corporation in the remote healthcare monitoring and telehealth business (“Qolpom®”) and its shareholders (the “Seller”) to purchase 100% of the issued and outstanding shares of Qolpom®’s common stock and its assets, inventory and intellectual property. The Qolpom® Agreement was fully executed on September 20, 2016, and the transaction was completed. The consideration for the acquisition resulted in a fair market value of $290,000, and goodwill of $785,060. In addition, the Qolpom® Agreement included contingent royalties and revenue sharing for future revenues generated from the Qolpom® technology. The Qolpom® name was later changed to Parallax Health Management, Inc. (“PHM”). On March 22, 2017, the Company formed a wholly-owned subsidiary, Parallax Behavioral Health, Inc. (“PBH”), a Delaware corporation and, on April 26, 2017, completed the asset acquisition of 100% of certain intellectual property (“Intellectual Property”) from ProEventa Inc., a Virginia Corporation (“ProEventa”), in accordance with the Intellectual Property Purchase Agreement between the Company, PBH and ProEventa (the “ProEventa Agreement”). ProEventa has an expertise in the development of behavioral health technologies, and is the wholly-owned subsidiary of Grafton Integrated Health Network, Inc., a non-profit Virginia corporation (“Grafton”). Pursuant to the ProEventa Agreement, the initial consideration for the Intellectual Property was paid to ProEventa in the form of a stock purchase agreement to purchase 2,500,000 shares of the Company’s Common Stock for $2,500, resulting in a net cost for the Intellectual Property of $622,500. In addition, the ProEventa Agreement included conditional contingent royalties and revenue sharing for future revenues generated from the Intellectual Property. On September 20, 2018, the Company formed Parallax Communications, Inc., a Delaware corporation and wholly-owned subsidiary of Parallax Health Management, Inc. to pursue additional opportunities for connected healthcare through the use of telecommunications technology. In May 2019, the Company established a second location at 28 West 36th Street, 8th Floor, New York, NY 10018. In June 2019, the Company filed a Registration Statement on form S-1 for the registration, as amended, of 32,583,436 shares of Common Stock, and, after resolving the comments and questions from the SEC in relation to the filing, the Company received an effective date from the SEC of December 20, 2019. In June 2019, pursuant to a resolution of the board of directors, the Company adopted the 2019 Stock Incentive Plan (the “2019 Plan”), wherein forty million (40,000,000) shares of the Company’s restricted Common Stock were reserved for issuance. The 2019 Plan was intended to assist the Company in securing and retaining key employees, directors and consultants by allowing them to participate in the Company's ownership and growth through the grant of incentive and non-qualified options. The 2019 Plan is currently administered by the Company's Board. Subject to the provisions of the plan, the board will determine who shall receive options, the number of shares of Common Stock that may be purchased under the options. On June 17, 2019, the Company filed a Registration Statement on form S-8 for the registration of shares reserved under the 2019 Plan. On August 28, 2019, the Company entered into a Purchase Agreement (the “Purchase Agreement”) with Global Career Networks Inc., a Delaware corporation, (“GCN”) to acquire a 19% interest in GCN. The Purchase Agreement was fully executed on September 6, 2019, with an effective date of October 15, 2019. Pursuant to the Purchase Agreement, in exchange for 6,666,667 shares of the Company’s restricted Common Stock, valued at $1,000,000, the Company acquired 760 shares of GCN common stock. In addition, in the event the market value of Parallax Common Stock one (1) year from Effective Date, is greater than $0.075 per share but less than $0.30 per share, the Company is required to issue GCN up to an additional 20,000,000 shares of restricted Common Stock, for an aggregate value of the Company’s Common Stock held by GCN of $2,000,000. At December 31, 2019, the Company recorded an impairment on the investment of $1,000,000. Business Overview The Company’s principal focus is on personalized patient care through remote healthcare services, behavioral health systems, and Point-of-Care (“POC”) diagnostic testing. Parallax’s current family of companies that serve as the foundation for its cross-over business model of operations include: ● Parallax Diagnostics, Inc. ● Parallax Health Management, Inc. ● Parallax Behavioral Health, Inc. Good Health Outcomes™ is the Company’s technology-enabled digital healthcare system, structured with three separate divisions that can operate independently of one another, or integrate services to meet the various needs of the Company’s clientele: Optimized Outcomes, Connected Health and Smart Data. Each of these divisions target a separate vertical market that are synergistic, compliment, and strengthen each other. Optimized Outcomes REBOOT™ / COMPASS™ Behavioral modification Connected Health Fotodigm® platform Remote patient monitoring, telehealth, and POC diagnostic testing Smart Data Intrinsic Code™ Actionable insights to behavior modification Operating Segments The Company’s operations include the following operating segments for financial statement presentation: Remote Patient Monitoring (RPM), Behavioral Health Services (BHS), and Diagnostics/Corporate. ● Remote Patient Monitoring The Company provides a distinctive technology platform that provides for the complete remote patient care delivery system: the patent-pending Fotodigm® platform, which utilizes proprietary software and technology to bridge clinical behavioral science with technology and logistics for payers, providers and clinical professionals across a variety of wellness and clinical devices, including both fitness and clinical applications. Fotodigm® is a secure and scalable platform for collecting, transmitting and analyzing biometric, pharmaceutical, and health data to healthcare providers, primarily hospitals, accredited nursing operations, and physicians. The RPM segment generates revenues through fees charged for the license and utilization of its proprietary system that provides software integrations of the Fotodigm® platform. Additionally, the RPM segment will generate incremental revenues through the delivery of acute, post-acute and chronic health patient management software systems that enable Parallax customers to bill for and collect payments from patients and third-party payers for telemonitoring and remote services that they deliver. ● Behavioral Health Services The BHS segment commenced with the acquisition of the REBOOT™ and Intrinsic Code™ technologies in April 2017. The BHS segment will generate revenues primarily through licensing and subscription of software and systems. As of December 31, 2019, the BHS segment had not yet begun full operations, generating limited test market sales. ● Diagnostics/Corporate The Diagnostics/Corporate Segment supports the costs and operating expenses related to the continued development and exploitation of the Company’s proprietary Target System POS diagnostic platform and processes. In addition, the Diagnostics/Corporate Segment provides management and administrative services to support the Company and consists of certain aspects of the Company’s executive management, corporate relations, legal, compliance, human resources, corporate information technology and finance departments. RoxSan Pharmacy On August 13, 2015, the Company entered into an agreement with RoxSan Pharmacy, Inc., a California corporation (“RoxSan” or the “Pharmacy”), and its sole shareholder, Shahla Melamed (“Melamed” or “Former Owner”), to purchase 100% of the issued and outstanding shares of RoxSan's common stock and its assets and inventory. Pursuant to the agreement, the Company, among other things, issued the Seller a Secured Promissory Note in the amount of $20.5 million. As a result, effective August 13, 2015, RoxSan became the Company's wholly-owned subsidiary. Concurrently, Mrs. Melamed resigned from all positions within RoxSan, and Mr. J. Michael Redmond was appointed RoxSan's President and Chief Executive Officer, and Ms. Calli R. Bucci its Chief Financial Officer. Mr. Redmond and Ms. Bucci were also appointed as Chairman and member, respectively, of RoxSan’s board of directors. RoxSan provided a full range of pharmacy services including retail, compounding and fertility medications, and generated revenues primarily by dispensing prescription drugs, both through local channels by direct delivery as well as mail order. RoxSan also sold a wide assortment of general merchandise, including over-the-counter drugs, beauty products and cosmetics, seasonal merchandise and convenience foods, through the Company’s pharmacy. The pharmacy was fully licensed and qualified to conduct business in over 40 US States. In October 2015, shortly following the Company’s acquisition of RoxSan, Melamed, initiated two (2) legal actions against the Company in the Superior Court of the State of California, County of Los Angeles, West District, Shahla Melamed v. Parallax Health Sciences, Inc., action numbers SC 124873 and SC 125702. In the matter, action No. SC 124873, Melamed sought rescission of the August 13, 2015, Purchase Agreement. In the Matter, action No. SC125702, Melamed alleged that the Company was in default under the terms of the Purchase Agreement and Secured Note and Melamed’s employment agreement. The Company also initiated legal action against Melamed and filed a complaint in October 2015, action number SC 124898, in the Superior Court of the State of California, County of Los Angeles, West District, Parallax Health Sciences, Inc., et al. v. Shahla Melamed, et al. The complaint in that action alleges that Melamed breached several obligations under the Purchase Agreement, and the Company sought to reduce the Secured Note due to undisclosed material changes in the business. Since the Company’s acquisition of RoxSan, the deleterious actions against the pharmacy by the Former Owner, including, among other things, interference with management and operations, and attempts to damage and/or divert customer and vendor relationships, had a significant adverse impact on the pharmacy. Furthermore, the discovery of the Former Owner’s alleged involvement in suspected insurance fraud caused RoxSan’s contract with its primary In Vitro Fertilization (“IVF”) drug rebate program to be terminated in August 2016. As a result, RoxSan was no longer eligible to receive incentive rebates for the majority of its IVF drug purchases, which were key to the profitability of the IVF drug sales; and for which without the rebates, RoxSan was unable to provide its customers with comparably priced IVF drugs. This, among other things, caused a precipitous drop of over 90% in RoxSan’s IVF revenues, and ultimate exit from the IVF market in mid-2017. Soon thereafter, in July 2017, RoxSan’s contract with its primary drug supplier was terminated for similar reasons connected to the Former Owner and alleged criminal activities associated with the Melamed family name, despite the Company’s new ownership and management. After careful consideration, the Company determined that RoxSan was unable to generate enough profits to sustain its pharmacy business, and on December 22, 2017, the pharmacy ceased operations and closed the business location in Beverly Hills, CA; however, some residual operations were still ongoing during 2018 to wind down the business. On May 14, 2018, pursuant to unanimous resolutions of the boards of directors of RoxSan Pharmacy, Inc. and Parallax Health Sciences, Inc., RoxSan filed a Chapter 7 petition in the United States Bankruptcy Court for the Central District of California. Mr. Timothy Yoo was appointed trustee on May 15, 2018. In connection with this filing, RoxSan sought to discharge approximately $5 million of liabilities owed to various parties, and intercompany loans in excess of $1 million owed to the Company. The Chapter 7 bankruptcy proceeding by RoxSan Pharmacy, Inc. was fully discharged, and the case was closed on March 13, 2019, in U.S. Bankruptcy Court, Central District of California. Due to, among other things, the reduction in RoxSan’s cash flows during 2016 and 2017, RoxSan became delinquent in its payroll tax depository obligations, resulting in a liability owed to federal and state taxing agencies in the aggregate of $1,148,811, which includes $601,148 in taxes withheld from employees (“Trust Fund Taxes”), employer taxes of $183,172, and penalties and interest of $364,491 through December 31, 2018. The liability was included as part of the Chapter 7 bankruptcy petition, and certain portions of the liability may be discharged. However, in accordance with California bankruptcy laws, federal and state Trust Fund Taxes are not dischargeable. The Company has retained a tax resolution specialist and is in communications with the taxing agencies in order to resolve RoxSan’s liability. During the year ended December 31, 2019, payments for Trust Fund Taxes in the amount of $485,498 were made, and $115,650 in Trust Fund Taxes were outstanding at December 31, 2019. As a result of the loss of financial control of RoxSan, the Company derecognized the subsidiary effective May 14, 2018. The derecognition resulted in a gain of $4,478,268. The Company also extinguished $22,778,281 in debt and accrued interest related to the acquisition of RoxSan. In January 2019, Melamed requested mediation, seeking settlement of the pending litigation with the Company, including that which was initiated against the Company by her son, Hootan Melamed (Shahla and Hootan, collectively, the “Melameds”). Through mediation, the Company and the Melamed reached agreeable settlement terms, and on February 19, 2020, the Company received a counter-signed Settlement and Release Agreement (the “Settlement”). Effective February 12, 2020 (the “Effective Date”), the Settlement is by and between Parallax Health Sciences, Inc., RoxSan Pharmacy, Inc., Michael Redmond, Edward Withrow III, Huntington Chase Financial Group, LLC, Calli Bucci and Dave Engert (collectively, “Parallax”), and the Melameds, and resolves all pending lawsuits between the parties in connection with the acquisition of RoxSan Pharmacy. The Settlement terms include (i) three installment payments, totaling $4,000,000, to the Melameds; (ii) ten (10) million shares of the Company’s Common Stock issued as directed by Melamed; and (iii) 10% of proceeds from the sale or merger of the Company within two (2) years, if any, up to $3,000,000 (See Note 8). In the event the Company fails to cure a breach of timely payment of any portion of the Settlement Sum within thirty (30) days of a notice of default, a Stipulated Judgement may be filed by Melamed in the sum of $20,000,000, less any Settlement Sum amounts previously paid by the Company. Going Concern The Company has incurred losses since inception resulting in an accumulated deficit of $32,057,254, and a working capital deficit of $7,664,145, and further losses are anticipated. The Company’s ability to continue as a going concern is dependent upon its ability to generate profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due, which may not be available at commercially reasonable terms. There can be no assurance that the Company will be able to continue to raise funds, in which case the Company may be unable to meet its obligations and the Company may cease operations. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The Company will require additional financing in order to proceed with its plan of operations, including approximately $5,000,000 over the next 12 months to pay for its ongoing expenses and debt obligations. These cash requirements include working capital, general and administrative expenses, the development of the Company’s product line, the reduction of contractual debt obligations, and the pursuit of acquisitions. These cash requirements are in excess of the Company’s current cash and working capital resources. Accordingly, the Company will require additional financing in order to continue operations and to repay its liabilities. There is no assurance that the financing will be completed as planned or at all. If the Company is unable to secure adequate capital to continue the Company’s planned operations, the Company’s shareholders may lose some or all of their investment and the Company’s business may fail. The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and that effect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The consolidated financial statements reflect all adjustments consisting of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of the results for the periods shown. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue as a going concern. NOTE: The following notes and any further reference made to “the Company”, “we”, “us”, “our” and “Parallax” shall mean Parallax Health Sciences, Inc., and its wholly-owned subsidiaries, Parallax Diagnostics, Inc., Parallax Health Management, Inc., Parallax Behavioral Health, Inc., and Parallax Communications, Inc., unless otherwise indicated. The Company’s former wholly-owned subsidiary, RoxSan Pharmacy, Inc., was derecognized effective May 14, 2018 (See “RoxSan Pharmacy” section above).

Restatement

Restatement	12 Months Ended
	Dec. 31, 2019
Notes
Restatement	NOTE 2. RESTATEMENT On October 18, 2019, the Company concluded that the previously issued audited consolidated financial statements as of and for the years ended December 31, 2018 and 2017, should no longer be relied upon. The Company reached its conclusion after consultation with its Audit Committee and a joint discussion with the Company’s independent registered public accounting firm. The Company has restated its audited consolidated financial statements as of and for the years ended December 31, 2018 and 2017, to reflect adjustments made in connection with the accounting treatment of certain convertible debt (the “Subject Debt”), warrants (the “Subject Warrants”), and convertible preferred stock (the “Subject Preferred Stock”). The adjustments resulted in material overstatements and understatements, the nature and impact of which are further described below. Valuation of Convertible Debt and Warrant Liabilities: The Company reviewed the accounting treatment of the Subject Debt, Subject Warrants, and Subject Preferred Stock, and concluded that it was not in accordance with U.S. generally accepted accounting principles. Specifically, the Subject Debt, Subject Warrants and Subject Preferred Stock were not evaluated to determine the impact (if any) of 1) embedded conversion option; 2) beneficial conversion feature; 3) bifurcation; 4) derivative liability; and 5) fair value adjustments and other expenses thereto. A third-party valuation was performed on the Subject Debt, Subject Warrants and Subject Preferred Stock, and the accounting treatment was determined. The effects of the accounting treatment, all non-cash in nature, resulted in a restatement of convertible debentures and convertible notes payable, additional paid in capital, and accumulated deficit, and the establishment of a derivative liability, resulting in changes to total liabilities and total stockholders’ deficit on the consolidated balance sheets; and a restatement of general and administrative expenses, gain on extinguishment of debt, discount amortization, and interest expense, and the establishment of a loss on fair value adjustments, resulting in changes to net income (loss), net loss per share-basic, and net loss per share-diluted on the consolidated statements of operations; and the restatement of stock compensation/stock option expense, discount amortization, gain on extinguishment of debt, loss on fair value adjustments, debt accretion, and the increase in accounts payable and accrued expenses from operating activities on the consolidated statements of cash flows. The following tables summarize the impacts on the Company’s consolidated financial statements as of and for the years ended December 31, 2018 and 2017. There was no impact from this restatement on the years ended prior to December 31, 2017: December 31, 2018 December 31, 2017 As Previously Reported As Restated Increase (Decrease) As Previously Reported As Restated Increase (Decrease) CONSOLIDATED BALANCE SHEETS Derivative liability, short-term –– 23,925 23,925 –– –– –– Debentures, convertible 755,627 724,903 (30,724 ) –– –– –– Debentures, convertible, related party 428,132 411,006 (17,126 ) –– –– –– Notes payable, convertible, net of discount 296,000 296,000 –– 741,000 1,706 (739,294 ) Total current liabilities 5,139,617 5,115,692 (23,925 ) 4,418,915 3,679,621 (739,294 ) Derivative liability, long-term –– 34,000 34,000 –– –– –– Debentures, convertible, net of unamortized discount 226,050 184,870 (41,180 ) –– –– –– Total liabilities 7,345,916 7,314,811 (31,105 ) 28,930,119 28,190,825 (739,294 ) Additional paid in capital - preferred 1,415,653 1,699,000 283,347 665,803 665,803 –– Additional paid in capital - common 9,715,921 11,382,341 1,666,420 5,580,668 6,449,768 869,100 Accumulated deficit (17,272,260 ) (19,190,922 ) 1,918,662 [1] (33,561,580 ) (33,691,386 ) 129,806 Total stockholders' deficit (5,981,559 ) (5,950,454 ) (31,105 ) (27,178,083 ) (26,438,789 ) (739,294 ) CONSOLIDATED STATEMENTS OF OPERATIONS General and administrative expenses $ 6,552,693 $ 6,626,063 $ 73,370 $ 3,997,512 $ 4,125,612 $ 128,100 Operating loss (6,561,293 ) (6,634,663 ) 73,370 (4,044,619 ) (4,172,719 ) 128,100 Gain on extinguishment of debt 23,215,862 22,858,009 (357,853 ) –– –– –– Loss on fair value adjustments –– (123,875 ) 123,875 –– –– –– Discount amortization (2,806,050 ) (2,805,000 ) (1,050 ) –– –– –– Interest expense, net of income (1,213,069 ) (2,164,530 ) 951,461 (1,016,773 ) (1,018,479 ) (1,706 ) Total other income (expenses) 23,675,011 22,242,872 (1,432,139 ) (6,466,773 ) (6,468,479 ) (1,706 ) Net income (loss) - continuing operations 17,113,718 15,608,209 (1,505,509 ) (10,511,392 ) (10,641,198 ) 129,806 Net income (loss) 16,289,320 14,783,811 (1,505,509 ) (13,664,945 ) (13,794,751 ) 129,806 Net income (loss) per common share - continuing operations - basic $ 0.115 $ 0.105 $ (0.010 ) $ (0.087 ) $ (0.088 ) $ (0.001 ) Net income (loss) per common share - continuing operations - diluted $ 0.079 $ 0.072 $ (0.007 ) $ (0.059 ) $ (0.060 ) $ 0.001 CONSOLIDATED STATEMENTS OF CASH FLOWS Net income (loss) $ 17,113,718 $ 15,608,209 $ (1,505,509 ) $ (10,511,392 ) $ (10,641,198 ) $ 129,806 Stock compensation/stock option expense 3,440,340 3,513,710 73,370 2,473,510 2,601,608 128,098 Discount amortization 2,806,050 2,805,000 (1,050 ) –– –– –– Gain on extinguishment of debt (23,215,862 ) (22,858,009 ) 357,853 –– –– –– Loss on fair value adjustments –– 123,875 123,875 –– –– –– Debt accretion –– 1,107,753 1,107,753 –– 1,706 1,706 Increase in accounts payable and accrued expenses 2,137,271 1,980,979 (156,292 ) 1,731,757 1,731,759 2 Non-Cash Activities: Discounts on long-term liabilities $ 2,806,050 $ 2,805,000 $ (1,050 ) $ 5,450,000 $ 5,450,000 $ –– Beneficial conversion feature of convertible promissory notes –– 347,487 347,487 –– 592,582 592,582 Fair value of stock warrants –– 1,393 1,393 –– 148,418 148,418 Embedded conversion option of convertible promissory notes –– 60,350 60,350 –– –– –– Supplemental Information: Interest paid-continuing operations 342,230 185,937 (156,293 ) 52,566 52,566 –– [1]

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Notes
Significant Accounting Policies	NOTE 3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation This summary of significant accounting policies is presented to assist in understanding the Company’s financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements. The Company’s fiscal year-end is December 31. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated. Changes in the Company’s ownership interests in subsidiaries that do not result in the Company losing control over the subsidiaries are accounted for as equity transactions. When the Company loses control of a subsidiary, a gain or loss is recognized and is calculated as the difference between: ● ● Upon deconsolidation of a subsidiary, any loans to the former subsidiary made by the Company are measured at fair value at the deconsolidation date. Any difference between the carrying amount of the loan to the subsidiary and its fair value is included as part of the gain or loss calculation upon deconsolidation. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Fair Value Hierarchy The Company utilizes the three-level valuation hierarchy for the recognition and disclosure of fair value measurements. The categorization of assets and liabilities within this hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy consist of the following: Level 1: Level 2: Level 3: Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. As of December 31, 2019 and 2018, the Company had no cash equivalents. Fair Value of Financial Instruments As of December 31, 2019 and 2018, the carrying values of Company’s Level 1 financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, and short-term debt, approximate fair value. The fair value of Level 3 instruments is calculated as the net present value of expected cash flows based on externally provided or obtained inputs. Certain Level 3 instruments may also be based on sales prices of similar assets. The Company’s fair value calculations take into consideration the credit risk of both the Company and its counterparties as of the date of valuation. See Note 6 for additional information about long-term debt. ● Derivatives of financial instruments: Derivatives are initially recognized at fair value at the date a derivative contract is entered into and are subsequently remeasured to their fair value at the end of each reporting period, with changes in fair value recognized in profit or loss. A derivative is presented as a non-current asset or a non-current liability if the remaining maturity of the instrument is more than 12 months and it is not expected to be realized or settled within 12 months. Other derivatives are presented as current assets or current liabilities. ● Embedded derivatives: Derivatives embedded in other financial instruments or other host contracts are treated as separate derivatives when their risks and characteristics are not closely related to those of the host contracts and the host contracts are not measured at fair value with changes in fair value recognized in profit or loss. An embedded derivative is presented as a non-current asset or a non-current liability if the remaining maturity of the hybrid instrument to which the embedded derivative relates is more than 12 months and it is not expected to be realized or settled within 12 months. Other embedded derivatives are presented as current assets or current liabilities. The following table represents the Company’s derivative financial instruments: December 31, 2019 December 31, 2018 Convertible debentures $ –– $ 23,925 Convertible promissory notes-embedded conversion option 5,800 –– Warrants 57,000 34,000 Total derivative liability $ 62,800 $ 57,925 The following table represents the changes in the Company’s derivative financial instruments: December 31, 2019 December 31, 2018 Fair value of derivative liability, beginning $ 57,925 $ –– Increase in derivative liability-debentures –– 60,350 Increase in derivative liability-convertible promissory notes 30,620 –– Increase in derivative liability-warrants 182,000 623,900 Fair value adjustment-debentures (26,691 ) (2,500 ) Fair value adjustment-convertible promissory notes (24,820 ) –– Fair value adjustment-warrants (143,000 ) 126,375 Reclassification of warrant carrying value due to reset of exercise price –– (750,200 ) Reclassification of carrying value due to extinguishment (13,234 ) –– Fair value of derivative liability, ending $ 62,800 $ 57,925 Investments The Company records investments at cost, net of impairment. During the year ended December 31, 2019, the Company acquired $1,050,000 of equity securities without readily determinable fair value, and recorded an impairment of.$1,000,000. At December 31, 2019, the Company held $50,000 of equity securities without readily determinable fair value, net of impairment. Property and Equipment Property and equipment is comprised of office and computer equipment and software, furniture and fixtures, and leasehold improvements, recorded at cost and depreciated using the double declining balance method over the estimated useful lives of 5 to 7 years. Repairs and maintenance costs are charged directly to expense as incurred. Major renewals or replacements that substantially extend the useful life of an asset are capitalized and depreciated. See Note 5 for additional information about property and equipment. Intangible Assets Product processes, patents and customer lists are amortized on a straight-line basis over their estimated useful lives between 4 and 20 years. Application development stage costs for significant internally developed software projects are capitalized and amortized on a straight-line basis over the useful life, between 2 and 5 years. Costs to extend and maintain patents and trademarks are charged directly to expense as incurred. See Note 6 for additional information about intangible assets. Goodwill and other Indefinitely-lived assets Goodwill and other indefinitely-lived assets are not amortized, but are subject to impairment reviews annually, or more frequently if necessary. Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that their net book value may not be recoverable. When such factors and circumstances exist, the Company compares the projected undiscounted future cash flows associated with the related asset or group of assets over their estimated useful lives against their respective carrying amount. Impairment, if any, is based on the excess of the carrying amount over the fair value, based on market value when available, or discounted expected cash flows, of those assets and is recorded in the period in which the determination is made. During the year ended December 31, 2019, the Company recognized $1,002,276] in impairment losses related to its long-lived assets. The Company believes that future projected cash flows are sufficient for the recoverability of the remainder of its long-lived assets, and no other impairment exists. There can be no assurance, however, that market conditions will not change or demand for the Company’s products and products under development will continue. Either of these could result in future impairment losses. Convertible Debt The Company recognizes the advantageous value of conversion rights attached to convertible debt. Such rights give the debt holder the ability to convert debt into Common Stock at a price per share that is less than the trading price to the public on the date of the debt. The beneficial value is calculated as the intrinsic value (the market price of the stock at the commitment date in excess of the conversion rate) of the beneficial conversion feature of the debt, and is recorded as a discount to the related debt and an addition to additional paid in capital. The discount is amortized over the remaining outstanding period of related debt using the interest method. Net Income (Loss) Per Common Share The computation of basic earnings per share ("EPS") is based on the weighted average number of shares that were outstanding during the period, including shares of Common Stock that are issuable at the end of the reporting period. The computation of diluted EPS is based on the number of basic weighted-average shares outstanding plus the number of common shares that would be issued assuming the exercise of all potentially dilutive Common Stock equivalents. Dilutive Common Stock equivalents consist of shares issuable upon conversion of convertible debt, convertible preferred shares and the exercise of the Company’s stock options and warrants. Comprehensive Loss As of December 31, 2019 and 2018, the Company has no items that represent comprehensive loss and, therefore, has not included a schedule of comprehensive loss in the financial statements. Revenue Recognition The Company recognizes revenue when it satisfies a performance obligation by transferring control over a product or service to a customer. Revenue is measured based on a consideration specified in a contract with a customer, and excludes any amounts collected on behalf of third parties. Income Taxes Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. These assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the temporary differences are expected to reverse. The Company may have net operating loss carryforwards available to reduce future taxable income. Future tax benefits for these net operating loss carryforwards are recognized to the extent that realization of these benefits is considered more likely than not. To the extent that the Company will not realize a future tax benefit, a valuation allowance is established. As of December 31, 2019, the Company has not yet filed its 2012 through 2018 annual corporate income tax returns. Due to the Company’s recurring losses, it is anticipated that no corporate income taxes are due for these periods. Stock-Based Compensation The Company records stock-based compensation using the fair value method. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. Equity instruments issued to employees and the cost of the services received as consideration are measured and recognized based on the fair value of the equity instruments issued. Recently Adopted Accounting Standards The Company evaluates the pronouncements of various authoritative accounting organizations, primarily the Financial Accounting Standards Board (“FASB”), the US Securities and Exchange Commission (“SEC”), and the Emerging Issues Task Force (“EITF”), to determine the impact of new pronouncements on US GAAP and the impact on the Company. The Company has recently adopted the following new accounting standards: Adopted In January 2016, the FASB issued ASU No. 2016-01 (“ASU 2016-01”), Financial Instruments-Overall (Subtopic 825-10) Recognition and Measurement of Financial Assets and Financial Labilities. ASU 2016-01 addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments in an effort to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information. ASU 2016-01 is effective for the Company for annual periods beginning after December 15, 2017, and interim periods. Early adoption is permitted. In July 2017, the FASB issued ASU No. 2017-11 (“ASU 2017-11”), Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). ASU 2017-11 addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. ASU 2017-11 also addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification®. ASU 2017-11 is effective for the Company for annual periods beginning after December 15, 2018, and interim periods. Early adoption is permitted. In June 2018, the FASB issued ASU No. 2018-07 (“ASU 2018-07”), Compensation-Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 is effective for the Company for annual periods beginning after December 15, 2018, and interim periods. Early adoption is permitted. In July 2018, the FASB issued ASU No. 2018-11 (“ASU 2018-11”), Leases (Topic 842), Targeted Improvements. ASU 2018-11 addresses certain issues in implementing ASU 2016-02, Leases, which was issued to increase transparency ad comparability by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing transaction. ASU 2018-11 clarifies 1) comparative reporting requirements for initial adoption; and 2) for lessors only, separating lease and non-lease components in a contract and allocating the consideration in the contract to the separate components. The amendments in this Update related to separating components of a contract affect the amendments in Update 2016-02, which is effective for the Company for annual periods beginning after December 15, 2018, and interim periods. Early adoption is permitted. In August 2018, the FASB issued ASU No. 2018-13 (“ASU 2018-13”), Fair Value Measurement (Topic 820), Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. ASU 2018-13 modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. ASU 2018-13 is effective for the Company for annual periods beginning after December 15, 2019, and interim periods. Early adoption is permitted. In August 2018, the FASB issued ASU No. 2018-15 (“ASU 2018-15”), Intangibles-Goodwill and Other Internal-Use Software (Subtopic 350-40). ASU 2018-15 was issued to help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement) by providing guidance for determining when the arrangement includes a software license. ASU 2018-15 is effective for the Company for annual periods beginning after December 15, 2019, and interim periods. Early adoption is permitted. Not Yet Adopted: In April 2019, the FASB issued ASU No. 2019-04 (“ASU 2019-04”), Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments. The amendments to Topic 326 and other Topics in ASU 2019-04 clarify or address stakeholders’ specific issues about certain aspects of the amendments in Update 2016-13. The amendments to Topic 815 in ASU 2019-04 include items related to Update 2017- 12 and clarify certain aspects of Topic 815. The amendments to Topic 321 and other Topics in ASU 2019-04 relate to the amendments in Update 2016-01 and clarify certain aspects of the amendments in Update 2016-01. ASU 2019-04 will be effective for the Company for annual periods beginning after December 15, 2019, and interim periods. Early adoption is permitted. The Company is currently evaluating the impact of the application of this accounting standard update on its financial statements and related disclosures. In November 2019, the FASB issued ASU No. 2019-10 (“ASU 2019-10”), Financial Instruments-Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842), Effective Dates. ASU 2019-10 was issued to apply changes in how to determine the effective dates for ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (Credit Losses); ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities (Hedging); and ASU No. 2016-02, Leases (Topic 842) (Leases). Following ASU-2019-10, ASU 2016-13 will be effective for the Company for annual periods beginning after December 15, 2019, and interim periods; and ASU 2017-12 and ASU 2016-01 will be effective for the Company for annual periods beginning after December 15, 2018, and interim periods. Early adoption is permitted. The Company is currently evaluating the impact of the application of this accounting standard update on its financial statements and related disclosures. In December 2019, the FASB issued ASU No. 2019-12 (“ASU 2019-12”), Income Taxes (Topic 740). ASU 2019-12 was issued to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 will be effective for the Company for annual periods beginning after December 15, 2020, and interim periods. Early adoption is permitted. The Company is currently evaluating the impact of the application of this accounting standard update on its financial statements and related disclosures. Recently Issued Accounting Standards Updates There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries. None of the updates are expected to a have a material impact on the Company's consolidated financial position, results of operations or cash flows.

Operating Leases

Operating Leases	12 Months Ended
	Dec. 31, 2019
Notes
Operating Leases	NOTE 4. OPERATING LEASES The Company entered into a sub-lease agreement with PearTrack Security Systems, Inc. (“PearTrack”), whose principal is a related party, on December 1, 2017, for its headquarters in Santa Monica, California, with a monthly sub-lease payment of $5,600, on a month-to-month basis, consistent with the underlying lease between PearTrack and property owner. Due to the short-term nature of the sub-lease, the Company has elected to not recognize the operating lease asset and liability, and will expense the rent as incurred. The Company entered into a sub-lease agreement with AI Assist, Inc. (“AI Assist”) on May 1, 2019, for certain office space located in New York, New York, with a monthly sub-lease payment of $8,900 for a term of fourteen (14) months, maturing June 30, 2020. The right-of-use present value of the sub-lease has been calculated as $118,585, utilizing an implied interest rate of 8%. The operating lease asset and liability will be amortized over the term of the lease. During the year ended December 31, 2019, the Company recognized $66,409 in amortization. The present value of future lease payments at December 31, 2019, was $52,176. As of December 31, 2019, the future minimum lease payments are as follows: For the year ended December 31, 2020 Operating lease minimum payments $ 53,400 Less: amount treated as interest 1,224 Present value of minimum lease payments $ 52,176 The total lease costs are summarized as follows: December 31, 2019 December 31, 2018 Operating lease costs $ 71,200 $ –– Short-term lease costs 68,320 73,351 Total lease costs $ 139,520 $ 73,351 Lease costs were $139,520 and $73,351 for the years ended December 31, 2019 and 2018, respectively.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2019
Notes
Property and Equipment	NOTE 5. PROPERTY AND EQUIPMENT Property and equipment, net, consists of the following: December 31, 2019 December 31, 2018 Computer equipment $ 6,615 $ 3,987 Medical devices 45,194 45,194 Property and equipment, gross 51,809 49,181 Accumulated depreciation (49,533 ) (49,181 ) Impairment loss (2,276 ) –– Property and equipment, net $ –– $ –– During the years ended December 31, 2019 and 2018, respectively, the Company recognized $2,276 and $0 in impairment loss related to its property and equipment. Depreciation expense for the years ended December 31, 2019 and 2018, respectively, was $352 and $0.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2019
Notes
Intangible Assets	NOTE 6. INTANGIBLE ASSETS The following are the components of finite-lived intangible assets: December 31, 2019 December 31, 2018 Products and processes $ 12,500 $ 12,500 Trademarks and patents / technology 150,700 150,700 Customer lists / relationships 30,000 30,000 Non-compete agreement 30,000 30,000 Marketing related 64,000 64,000 Software 510,300 510,300 Sub-total 797,500 797,500 Accumulated amortization (339,085 ) (218,465 ) Intangible assets, net $ 458,415 $ 579,035 Amortization expense for the years ended December 31, 2019 and 2018, was $120,620 and $120,620, respectively.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2019
Notes
Accounts Payable and Accrued Expenses	NOTE 7. ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses consist of: December 31, 2019 December 31, 2018 Accounts payable-vendors $ 1,128,381 $ 830,590 Credit cards payable 42,552 42,552 Payroll taxes payable 81,718 78,608 Accrued interest 376,065 450,187 Accrued payroll and payroll taxes 338,612 402,053 Other liabilities 115,650 601,148 2,082,978 2,405,138 Reserve-legal fees –– 250,000 Total accounts payable and accrued expenses $ 2,082,978 $ 2,655,138 Payroll taxes payable includes $17,475 and $17,475 in penalties, and $7,312 and $4,202 in interest, related to unpaid payroll taxes as of December 31, 2019 and 2018, respectively. Other liabilities consists of certain payroll tax liabilities in the amount of $115,650 and $601,148 owed as of December 31, 2019, and 2018, respectively, owed by the bankrupt entity, RoxSan Pharmacy, Inc., that were not discharged under California bankruptcy laws. The Company has retained a tax resolution specialist to aid the Company in resolving the liability with the taxing agencies on behalf of RoxSan. During the years ended December 31, 2019 and 2018, respectively, accounts payable and accrued expenses was reduced by $101,367 and $341,606, resulting from the extinguishment of debt consisting of accounts payable-vendors in the amount of $101,367 and $284,714, and accrued interest in the amount of $0 and $56,892. The Company established an estimated reserve of $0 and $250,000 at December 31, 2019 and 2018, respectively, for legal fees to be incurred in connection with pending legal actions (Note 18).

Settlments Payable

Settlments Payable	12 Months Ended
	Dec. 31, 2019
Notes
Settlments Payable	NOTE 8. SETTLEMENT PAYABLE On August 13, 2015, the Company issued a secured promissory note in the amount of $20,500,000 (the “Promissory Note”) in connection with the acquisition of RoxSan Pharmacy, Inc. (“RoxSan”) to Shahla Melamed (“Melamed”), the former owner of RoxSan. The Promissory Note bore interest at a rate of 6% per annum, and matured August 13, 2018 (“Maturity”). At the time of issuance, management determined that the Promissory Note did not fairly represent the fair market value for the related acquisition. As a result, a discount of $15,300,000, representing the difference between the face value and the estimated fair market value of the Promissory Note was recorded and has been fully expensed. On May 14, 2018, pursuant to unanimous resolutions of the boards of directors of RoxSan Pharmacy, Inc. and Parallax Health Sciences, Inc., RoxSan filed a Chapter 7 petition in the United States Bankruptcy Court for the Central District of California (the “Court”). Mr. Timothy Yoo was appointed trustee (“Trustee”) on May 15, 2018. In connection with this filing, RoxSan sought to discharge approximately $5 million in liabilities owed to various parties, and intercompany loans in excess of $1 million owed to Parallax. The Chapter 7 bankruptcy proceeding was fully discharged by the Court, and the case was closed on March 13, 2019. As part of the derecognition of RoxSan resulting from the bankruptcy in 2018, management reevaluated the characteristics of the Promissory Note. Included in the evaluation were the following considerations: 1) the related asset was no longer a part of the parent financial statements due to a loss of financial control; 2) the Company is currently in litigation as a result of material breaches by the note holder, Melamed; 3) the Company has claims against Melamed for losses and damages directly related to the Promissory Note and its underlying assets; 4) there was a high likelihood that no obligation existed. After careful consideration, management determined that the characteristics of the liability were contingent in nature at December 31, 2018, and extinguished the debt of $20,500,000 and related $2,278,281 in accrued interest, resulting in a gain of $22,778,281. In January 2019, Melamed requested mediation, seeking settlement of the pending litigation with the Company, including that which was initiated against the Company by her son, Hootan Melamed (Shahla and Hootan, collectively, the “Melameds”). Through mediation, the Company and the Melameds reached agreeable settlement terms, and on February 19, 2020, the Company received a counter-signed Settlement and Release Agreement (the “Settlement”). Effective February 12, 2020 (the “Effective Date”), the Settlement is by and between Parallax Health Sciences, Inc., RoxSan Pharmacy, Inc., Michael Redmond, Edward Withrow III, Huntington Chase Financial Group, LLC, Calli Bucci and Dave Engert (collectively, “Parallax”), and the Melameds, and resolves all pending lawsuits between the parties in connection with the acquisition of RoxSan Pharmacy. In consideration of the resolution of all existing and potential claims between the parties, including the cancellation of the Company’s contingent liability in the principal sum of $20,500,000, and accrued interest of approximately $4,500,000, and without further action or litigation and without admission of liability by either party, the Settlement terms include the following: ● § § § ● In addition, in the event forty percent (40%) or more of the Company and/or its subsidiaries (including by way of merger) is sold within two (2) years of the Effective Date, the Company shall pay the Melameds, within two (2) weeks of receipt of the proceeds from such sale (the “Sale Proceeds”), any outstanding unpaid Settlement Sum plus an additional 10% of the Sale Proceeds received, up to a total of an additional $3,000,000 over and above the Settlement Sum. In the event the Company fails to cure a breach of timely payment of any portion of the Settlement Sum within thirty (30) days of a notice of default, a Stipulated Judgement may be filed by Melamed in the sum of $20,000,000, less any Settlement Sum amounts previously paid by the Company. The following table represents the liabilities recognized in connection with the Settlement: December 31, 2019 Cash settlement, gross $ $4,000,000 Less: unamortized present value discount (415,800 ) Net present value of settlement 3,584,200 Common stock, at FMV 480,000 Total settlement $ 4,064,200 Due within 12 months $ 2,824,200 Due December 31, 2021 1,240,000 $ 4,064,200

Debt Disclosure

Debt Disclosure	12 Months Ended
	Dec. 31, 2019
Notes
Debt Disclosure	NOTE 9. NOTES AND LOANS PAYABLE Notes and loans payable consists of the following: December 31, 2019 December 31, 2018 Short-term Debentures, convertible $ –– $ 724,903 Notes payable 345,000 –– Note payable, bank 18,616 [1] –– Notes payable, convertible 1,102,364 296,000 Total short-term notes payable 1,465,980 1,020,903 Long-term Debentures, convertible, net of unamortized discount –– 184,870 Note payable, bank –– 28,995 [1] Notes payable, convertible 760,154 720,154 Total long-term notes and loans payable 760,154 934,019 Total notes and loans payable $ 2,226,134 $ 1,954,922 [1] Note payable, bank, maturing in July 2020, has been reclassified as short-term liability at December 31, 2019. Non-related party convertible debt consist of the following convertible promissory notes: Holder Principal APR Accrued Interest Conversion Price Term/Due Short-Term Investor Group A $ 91,000 10% $ 21,013 $0.10 02/28/2020 Lender Group A 20,000 12% 10,000 $0.10 02/28/2020 Lender Group B 519,641 12% 59,688 $0.10 to $0.12 04/30/2020 to 12/31/2020 Lender Group C 471,723 10% 5,944 65% to 70% of Market 10/31/2020 to 12/31/2020 1,102,364 96,645 Long-Term The Kasper Group, Ltd. 184,000 7% 85,431 $0.10 12/31/2021 Joseph M. Redmond 576,154 [1] 5% 148,358 [1] $0.10 07/31/2017 760,154 233,789 Total convertible debt $ 1,862,518 $ 330,434 [1] During the year ended December 31, 2019, the Company issued four (4) short-term non-related party non-convertible promissory notes (the “Notes”) in the aggregate principal of $375,000, of which repayments in the amount of $30,000 were made. The Notes bear interest at a rate of 8% per annum, and mature between 12/31/2019 to 08/20/2020. As additional consideration, three of the note holders received 400,000 shares of the Company’s restricted Common Stock each, for an aggregate of 1,200,000 shares, valued at $190,200, and one note holder received 2,400,000 shares, valued at $240,000. During the years ended December 31, 2019 and 2018, respectively, the Company issued short-term non-related party convertible promissory notes (the “Convertible Notes”) in the aggregate principal of $1,490,000 and $825,000], along with 5,800,000 and 6,025,000 warrants (Note 14). Upon issuance, the Convertible Notes were discounted by a total of $308,840 and $605,000, representing $96,220 and $0 in original issue discount, $0 and $223,607 for beneficial conversion feature, $30,620 and $0 for embedded conversion option, and $182,000 and $381,393 for value of warrants, of which $212,620 and $380,000 was classified as derivative liability. Effective November 14, 2018, $600,000 in principal, plus $55,627 in accrued interest, was exchanged for short-term convertible debentures, at which time $240,000 was reclassified to equity for intrinsic value of warrants, $30,725 was classified as derivative liability for embedded conversion option, and $105,320 was recognized as a loss on extinguishment of debt. The short-term non-related party convertible notes and debentures bear interest at a rate of 10% to 12% per annum, mature in 2020, and are convertible into shares of the Company’s Common Stock at a conversion price equal to the lower of 1) between $0.10 to $0.12 per share; or 2) between 65% to 70% of the 2nd lowest trading prices during the twenty (20) trading days preceding the conversion date. During the years ended December 31, 2019 and 2018, respectively, a total of $173,784 and $1,098,974 in debt accretion was expensed; repayments on Convertible Notes totaling $564,023 and $670,000 were made, of which $428,580 and $50,000 was repaid in cash, and $135,443 and $620,000 was converted into the Company’s Common Stock; repayments on debentures totaling $1,169,299 and $0 were made, of which $542,369 and $0 was repaid in cash, and $626,930 and $0 was converted in to the Company’s Common Stock; and a loss on extinguishment of $305,912 and $0 was recognized. During the year ended December 31, 2018, the Company issued long-term non-related party convertible debentures in the aggregate principal sum of $250,000, along with 600,000 warrants (Note 14). Upon issuance, the long-term convertible debentures were discounted by a total of $67,500, representing $25,000 in original issue discount, $12,500 for embedded conversion option, and $30,000 for value of warrants, of which $42,500 was classified as derivative liability. The debentures maturing in 2021, are convertible into the Company’s Common Stock at a conversion price of $0.10 per share. During the years ended December 31, 2019 and 2018, respectively, a total of $9,816 and $2,370 in debt accretion was expensed, cash repayments of $212,000 and $0 were made; $158,549 and $0 was converted into the Company’s Common Stock, and, a loss on extinguishment of $168,159 and $0 was recognized. During the years ended December 31, 2019 and 2018, respectively, principal payments of $10,379 and $9,245 in and $1,423 and $632 in interest were made on the note payable to bank. The term loan bears interest at a rate of 7.48%, with monthly payments of principal and interest in the amount of $1,475, maturing July 17, 2020. The principal remaining on the note at December 31, 2019, of $18,616 was reclassified from long-term to short-term. During the year ended December 31, 2018, the long-term convertible promissory note issued to The Kasper Group was modified to extend the maturity date to October 1, 2019, in exchange for a fee of $40,000. As a result, the principal amount owed was increased from $144,000 to $184,000. Upon maturity, the Kasper Group note was further modified to extend the maturity to December 31, 2021. The long-term non-related party convertible promissory notes bear interest at a rate of 5% to 7% per annum, mature between 2017 to 2021, and are convertible into the Company’s Common Stock at a conversion price of $0.10 per share. During the year ended December 31, 2018, long-term unsecured non-related party loans and promissory notes in the principal sum of $95,975, and accrued interest in the amount of $56,892, were extinguished, resulting in a gain of $152,867. During the year ended December 31, 2018, a long-term secured non-related party promissory note in the principal sum of $20,500,000, and accrued interest in the amount of $2,278,281, was extinguished in connection with RoxSan’s Chapter 7 petition filed in May 2018 (Note 18), and recharacterized as a contingent liability (Note 11), resulting in a gain of $22,778,281. As of December 31, 2019 and 2018, respectively, short-term non-related party debt in the amount $1,465,980 and $1,020,903 consists of $0 and $724,903 in convertible debentures; $345,000 and $0 in notes payable; $18,616 and $0 in note payable, bank, and $ 1,102,364 296,000 As of December 31, 2019 and 2018, respectively, long-term non-related party debt in the amount of $760,154 and $934,019 consists of $0 and $207,500 in convertible debentures, less unamortized discount of $0 and $22,630; $760,154 and $720,154 in convertible notes payable, of which $576,154 and $576,154 is related to pending litigation with a former executive (see Note 18), and subject to compromise; and $0 and $28,995 in notes payable to banks. During the years ended December 31, 2019 and 2018, respectively, interest in the amount of $85,469 and $739,383 was expensed. As of December 31, 2019 and 2018, respectively, a total of $234,432 and $190,386 in accrued interest remains, and is included as an accrued expense on the accompanying consolidated balance sheet. The future maturities of long-term notes payable are summarized as follows: Year Principal 2020 $ 778,770 2021 184,000 $ 962,770 During the years ended December 31, 2019 and 2018, respectively, interest on non-related party notes and loans payable in the amount of $287,127 and $1,009,525 was expensed. As of December 31, 2019 and 2018, respectively, a total of $339,804 and $376,127 in interest, net of debt extinguishments of $0 and $2,335,173, and conversions to Common Stock of $10,398 and $55,613, remains accrued and is included as part of accrued expenses on the accompanying consolidated balance sheets.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2019
Notes
Related Party Transactions	NOTE 10. RELATED PARTY TRANSACTIONS Related party transactions consist of the following: December 31, 2019 December 31, 2018 Related party payables Accrued compensation $ 796,175 $ 869,859 [1] Accrued benefits and cash advances 312,305 134,861 Total related party payables 1,108,480 1,004,720 Debentures, convertible –– 411,006 Notes payable, related party, convertible 491,100 491,100 Notes payable, related party 759,446 –– Total related party transactions $ 2,359,026 $ 1,906,826 [1] As of December 31, 2019 and 2018, respectively, related parties are due a total of $2,359,026 1,906,826 Related party convertible debt consists of the following: Note Holder Principal APR Accrued Interest Conversion Price Term/Due Convertible promissory notes: Huntington Chase, Beneficial Owner $ 491,100 7% $ 9,795 $0.08 12/31/2023 During the years ended December 31, 2019 and 2018, respectively, $1,586,724 and $1,371,446 in related party compensation was accrued, $802,500 and $510,500 was paid, $753,510 and $0 was converted to Common Stock; and $0 and $450,000 was converted to Preferred Stock. During the years ended December 31, 2019 and 2018, respectively, $399,249 and $104,151 in benefits were accrued and cash advances were made to the Company by related parties for overhead requirements, of which $221,805 and $97,587 was paid/repaid to related parties. In June 2019, $575,132 of related party debt was purchased by non-related-parties (the “Proceeds”). The Proceeds were collected from the non-related parties by the Company on behalf of the related parties. The Proceeds were subsequently loaned to the Company by the related parties for operating expenses, including accrued compensation owed. Promissory Notes On September 30, 2015, the Company issued a modified convertible promissory note in the principal sum of $631,100, representing cash loans and unpaid compensation to a related party, of which principal repayments in the aggregate of $100,000 were made in prior years, and $40,000 of which was converted into Common Stock in prior years. The note bears interest at a rate of 7% per annum, and contains a repayment provision to convert the debt into restricted shares of the Company’s Common Stock at a price of $0.10 per share. On December 31, 2018, the note was modified to 1) reduce the principal balance to $491,100; and 2) mature December 31, 2023. During the year ended December 31, 2019, the note holder converted $437,000 in principal into 4,370,000 shares of the Company’s Common Stock. Subsequently, the holder loaned the Company $437,000. As a result, the principal balance was not affected. However, on December 31, 2019, the promissory note was modified to change the conversion price to $0.08. Between April 26, 2018 and May 8, 2018, the Company issued senior secured convertible promissory notes (the “Notes”) to a related party in the aggregate principal sum of $337,750, along with 3,377,500 warrants (Note 14). Upon issuance, the Notes were discounted by a total of $337,750, representing $123,850 for beneficial conversion feature, and $213,900 for fair value of warrants. During the year ended December 31, 2018, a total of $6,409 in debt accretion was expensed. The Notes bore interest at rate of 12% per annum, contained a repayment provision to convert the Notes into restricted shares of the Company’s Common Stock at a price of $0.10 per share, and included warrant coverage for a period of three (3) years to purchase shares of the Company’s Common Stock at an exercise price of $0.10 per share. Effective November 14, 2018, the Notes and related accrued interest of $34,090 were exchanged into convertible debentures (“Debentures”) in the principal amount of $428,132, at which time $17,125 was reclassified as a derivative liability for embedded conversion option, $135,100 was reclassified to equity for the intrinsic value of warrants issued with the Notes, and $252,533 was recognized as a loss on extinguishment of the Notes. The Debentures bore interest at a rate of 10% per annum, matured February 28, 2019, and were convertible into shares of the Company’s restricted Common Stock at a conversion rate of $0.12 per share. On July 25, 2019, the Debentures in the principal sum of $411,006, plus accrued interest of $42,778, were converted to non-convertible Senior Secured Promissory Notes (the “Senior Notes”) in the aggregate principal of $759,446. The Senior Notes bear interest at a rate of 8% per annum, with payments of $126,152 plus interest accrued thereon due December 31, 2019; $300,000 due December 31, 2020; and the remaining principal and accrued interest due December 31, 2021. In connection with the exchange, the Company issued the following in favor of the lender: 1,380,811 shares of the Company’s restricted Common Stock, valued at $131,315; and warrants, valued at $92,150, to purchase 2,528,413 shares of the Company’s Common Stock for a period of five (5) years at an exercise price of $0.10461. As a result, the Company recognized a net loss on the exchange in the amount of $434,837, net of $2,140 in derivative liability remaining from the warrants issued with the Debentures. As of December 31, 2019 and 2018, respectively, related party promissory notes in the amount of $1,250,546 and $491,100 are owed, of which $491,100 and $491,100 are convertible. During the years ended December 31, 2019 and 2018, respectively, interest in the amount of $105,111 and $66,840 was expensed, $0 and $798 was paid to the note holders in cash, $100,132 and $0 was converted to restricted shares of the Company’s Common Stock, and $42,778 and $71,839 was converted to principal. As of December 31, 2019 and 2018, respectively, a total of $36,261 and $74,060 in accrued interest remains and is included as part of accrued expenses on the accompanying consolidated balance sheets. Stock Issuances On January 11, 2018, pursuant to a resolution of the board of directors, the Company issued 6,000,000 shares of its restricted Common Stock to certain officers and directors. The shares were purchased at par, or $0.001 per share, for cash in the amount of $6,000. On August 13, 2018, in connection with the exercise of certain employee stock options, the Company issued 1,071,430 shares of its restricted Common Stock at a conversion rate of $0.05 per share. The shares were issued on a cashless basis, resulting in a net value of $187,500.   On September 30, 2018, in connection with the Series C convertible Preferred Stock equity offering (Note 11), three officers of the Company were issued an aggregate of 90,000 Series C preferred shares at a price of $5.00 per share in exchange for accrued compensation in the aggregate of $450,000. Upon issuance, a beneficial conversion feature of $100,578 was recorded as a deemed dividend. In connection with the Series C preferred shares, the officers were also issued an aggregate of 1,250,000 warrants, valued at an aggregate of $75,000, and exercisable for a period of three (3) years at an exercise price of $0.25 per share. On May 15, 2019, in connection with a certain employment agreement with Mr. David Appell, the Company issued 3,000,000 shares of its restricted Common Stock, valued at $201,300, of which 25% vest immediately, and the remainder vest when certain earnings goals are met. On July 31, 2019, in connection with the settlement of certain related party convertible debentures, the Company issued 1,380,811 shares of its restricted Common Stock, valued at $131,315. In connection with the settlement, the related parties were also issued an aggregate of 2,528,413 warrants, valued at an aggregate of $92,150, and exercisable for a period of five (5) years at an exercise price of $0.10 per share On September 18, 2019, in connection with the conversion of certain convertible debt in the amount of $437,000, the, Company issued 4,370,000 shares of its restricted Common Stock, to Huntington Chase, LLC, a beneficial owner. On September 30, 2019, in connection with a Simple Agreement Future Equity (“SAFE”) offering, the Company issued 6,000,000 shares of its restricted Common Stock to certain officers and directors in exchange for the reduction in accrued compensation in the aggregate of $375,000. In connection with the SAFE offering, the officers and directors were also issued an aggregate of 6,000,000 warrants, valued at an aggregate of $45,600, and exercisable for a period of three (3) years at an exercise price of $0.25 per share. On December 31, 2019, in connection with debt settlement agreements, the Company issued 8,000,000 shares of its restricted Common Stock to certain officers and directors in exchange for the reduction in accrued compensation in the aggregate of $400,000. Agreements On January 1, 2018, the Company entered into an Executive Agreement with its Chief Financial Officer. The agreement replaces any other written agreement with the Company, is for a term of one (1) year, with the option to extend, and includes annual compensation of $216,000 in year 1, as well as a bonus plan and customary executive benefits. In addition, the agreement provides for a non-refundable, fully-vested signing bonus of $100,000, as well as a grant of stock options to purchase 1,000,000 shares of the Company's Common Stock at an exercise price of $0.25 per share. The options are for a period of five (5) years, and vest quarterly over a one (1) year period. On January 1, 2018, the Company entered into a Consulting Agreement with Huntington Chase, LLC, whose managing member is a related party. The agreement replaces any other written agreement with the Company, is for a term of three (3) years, and includes monthly compensation of $25,000 in year 1; $30,000 in year 2, and $35,000 in year 3, of which the year 2 and 3 increases are deferred until completion of certain development projects, as well as customary expense allowances. In addition, the agreement provides for a grant of stock options to purchase 4,000,000 shares of the Company's Common Stock at an exercise price of $0.25 per share. The options are for a period of five (5) years, of which 25% vest immediately, and the remainder vest when certain market share prices of the Company’s Common Stock are met. On January 1, 2019, the Company entered into a Consulting Agreement with JL Ogden & Company LLC, for the services of John L. Ogden, a member of the Company’s board of directors, and Chair of the Audit Committee. The agreement is for a term of one (1) year, with the option to extend, and includes annual compensation in the amount of $60,000. In addition, the agreement provides for a non-refundable, fully-vested signing bonus of $50,000, a convertible promissory note in the amount of $20,000 maturing in one (1) year with an annual interest rate of ten percent (10%), a restricted stock award equal to $70,000 worth of Units in the Company’s 2019 private placement offering, as well as a grant of stock options to purchase 1,000,000 shares of the Company's Common Stock at an exercise price of $0.25 per share. The options are for a period of five (5) years, and vest quarterly over a one (1) year period. On May 15, 2019, the Company entered into an employment agreement with Mr. David Appell to serve as the Company’s Chief Operating Officer. The agreement is for an initial term of two (2) years, and provides a base compensation of $250,000 year one, and $275,000 in year two, as well as various performance bonuses, and customary employee benefits. In addition, the agreement includes a grant to purchase 3,000,000 restricted common shares, valued at $201,300, for cash in the amount of $3,000, of which 25% vest immediately, and the remainder vest when certain earnings goals are met; as well as options granted to purchase 3,000,000 shares of the Company's Common Stock at an exercise price of $0.25 per share. The options valued at $195,600 using the Black-Scholes method, are for a period of five (5) years, and vest annually over the term of the agreement, with an initial vesting of 25%. The assumptions used in valuing the options were: expected term 4.75 years, expected volatility 2.21, risk free interest rate 2.15%, and dividend yield 0%.

Commitments And Contingencies

Commitments And Contingencies	12 Months Ended
	Dec. 31, 2019
Notes
Commitments And Contingencies	NOTE 11. COMMITMENTS AND CONTINGENCIES On August 31, 2016, as part of the Company’s acquisition of 100% of the issued and outstanding shares of Qolpom®’s common stock and its assets, inventory and intellectual property, the agreement provides for, among other things, the seller to receive up to $2,000,000 through a percentage of revenue generated from RPM business segment (“Revenue Share”), as well as a royalty of 3% (“Royalties”) of certain revenues generated from the Qolpom® intellectual property, as defined in the agreement. As of December 31, 2019 and 2018, respectively, the present value of future Revenue Share was $442,000 and $430,000; and the present value of future Royalties was $318,000 and $310,000. On April 26, 2017, as part of the Company’s acquisition of 100% of certain intellectual property (“Intellectual Property”) from ProEventa, Inc., a Virginia Corporation (“ProEventa”), the agreement provides for, among other things, ProEventa to receive a revenue sharing cash earn-out of up to $3,000,000 to be derived from certain net revenue generated by the Company; as well as Royalties of 3% of certain revenues generated from the Intellectual Property, ending at such time as the Company has paid ProEventa $25,000,000, as defined in the agreement. As of December 31, 2019 and 2018, respectively, the present value of future Revenue Share was $968,000 and $1,040,000; and the present value of future Royalties was $471,000 and $690,000.

Convertible Preferred Stock

Convertible Preferred Stock	12 Months Ended
	Dec. 31, 2019
Notes
Convertible Preferred Stock	NOTE 12. CONVERTIBLE PREFERRED STOCK The total number of authorized shares of Preferred Stock that may be issued by the Company is 10,000,000 with a par value of $0.001 per share. The holders of all series of Preferred Stock have no voting rights. Series A and Series B preferred shares are convertible into the Company’s Common Stock at a rate of 20 shares of Common Stock for each preferred share held. Series C preferred shares are convertible into the Company’s Common Stock at a rate of 41.67 shares of Common Stock for each preferred share held. Series B preferred shares were issued with 50% warrant coverage for a period of two (2) years, to purchase shares of the Company's Common Stock at a price of $0.75 per share. Series C preferred shares were issued with 50% warrant coverage for a period of three (3) years, to purchase shares of the Company's Common Stock at a price of $0.25 per share. The number of shares of Common Stock underlying the warrants and the exercise price are subject to adjustment upon certain events. Dividends are payable semi-annually on the Company’s Series A Preferred Stock at a rate of 7% per annum, 10% per annum on Series B, and 8% per annum on Series C. Dividends may be paid in kind, at the option of the Company, to the extent that if the Company is not legally permitted to distribute cash dividends, it shall pay dividends in the form of preferred shares equal to the amount of the dividend. No dividends have been declared on the Company’s Preferred Stock. In the event of any liquidation, dissolution, winding-up or sale or merger of the Company, whether voluntarily or involuntarily, each holder of Preferred Stock is entitled to receive, in preference to the holders of Common Stock, a per-share amount equal to the original issue price plus all declared but unpaid dividends and dividends in arrears. In August 2018, the Company established a private placement equity offering for the purchase of Series C convertible Preferred Stock (the “Series C Shares”). The offering provided for, among other thing, the purchase of Series C Shares at a price of $5.00 per share, with a minimum unit of 20,000 shares, or $100,000. All Series C Shares are convertible into Common Stock at a conversion rate of $0.12 per share, or a ratio of 41.67 shares of Common Stock for each Series C Share held (41.67:1) (“Conversion Ratio”) if converted within one (1) year, or at a lesser Conversion Ratio after one year. The shares also include warrants to purchase Common Stock for a period of 3 years at an exercise price of $0.25 per share, of which the number of warrants is determined at 50% of the prevailing Conversion Ratio. The Series C offering is closed to further investors. During the year ended December 31, 2018, in connection with the Series C Shares equity offering, 150,000 Series C Shares were issued at a price of $5.00 per share, of which 60,000 were issued to accredited investors for cash in the amount of $300,000, and 90,000 were issued to officers of the Company in exchange for debt in the principal sum of $450,000. As a result, $749,850 was recorded to preferred paid in capital, and a beneficial conversion feature of $283,347 was recorded as a deemed dividend, of which $100,578 was in connection with the shares issued to officers of the Company. On March 31, 2019, in connection with the settlement agreement with Mr. Dave Engert, 36,339 shares of the Company’s Series A Preferred Stock held by Mr. Engert, with a book value of $100,000, were returned to treasury. As a result, preferred paid in capital was reduced by $99,964. On April 1, 2019, dividends owed on the Series A Preferred Stock were paid in kind with the issuance and immediate return to treasury of 21,121 shares of Series A Preferred Stock, resulting in a total of 57,500 shares of Series A Preferred Stock held in treasury (the “Treasury Shares”). On May 15, 2019, the 57,500 Treasury Shares were reissued for cash in the amount of $69,000. Subsequently, the 57,500 shares of Series A Preferred Stock were converted into 1,150,000 shares of Common Stock at a ratio of 20 shares of Common Stock for each share of Preferred Stock held. As of December 31, 2019 and 2018, respectively, the Company had 977,352 and 1,013,691 shares of Preferred Stock issued and outstanding.

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2019
Notes
Common Stock	NOTE 13. COMMON STOCK The total number of authorized shares of Common Stock that may be issued by the Company at December 31, 2019 and 2018, is 500,000,000 with a par value of $0.001 per share. During the years ended December 31, 2019 and 2018, respectively, 24,682,217 and 6,881,130 shares of the Company’s restricted Common Stock were issued in connection with the conversion of non-related party debt in the amount of $1,735,330 and $675,614. As a result, $1,710,649 and $668,733 was recorded to paid in capital. During the years ended December 31, 2019 and 2018, respectively, 12,370,000 and 0 shares of the Company’s restricted Common Stock were issued in connection with the conversion of related party debt in the amount of $837,000 and $0. As a result, $824,630 and $0 was recorded to paid in capital. During the years ended December 31, 2019 and 2018, respectively, 0 and 846,051 shares of the Company’s restricted Common Stock were issued for the exercise of stock options, and 0 and 1,071,430 were issued for the exercise of related party stock options. As a result, $0 and $454,908 was recorded to paid in capital. During the years ended December 31, 2019 and 2018, respectively, 8,756,919 and 1,750,000 shares of the Company’s restricted Common Stock were issued in connection with stock awards to non-related parties, valued at $874,548 and $279,110. As a result, $20,237 and $153,000 was deferred, to be amortized over the next nine (9) months, and $865,191 and $277,360 was recorded to paid in capital. During the years ended December 31, 2019 and 2018, respectively, 3,000,000 and 0 shares of the Company’s restricted Common Stock were issued in connection with stock awards to related parties valued at $201,300 and $0. As a result, $198,300 and $0 was deferred, to be amortized over the next nine (9) months, and $198,300 and $0 was recorded to paid in capital. During the years ended December 31, 2019 and 2018, respectively, 12,500,000 and 2,000,000 shares of the Company’s restricted Common Stock were issued for cash in the amount of $1,027,500 and $240,000. As a result, $1,015,000 and $238,900 was recorded to paid in capital. During the years ended December 31, 2019 and 2018, respectively, 3,010,811 and 2,810,000 shares of the Company’s restricted Common Stock were issued in connection with debt and debt service in the amount of $359,514 and $281,000. As a result, $356,504 and $278,190 was recorded to paid in capital. During the years ended December 31, 2019 and 2018, respectively, 18,000,000 and 0 shares of the Company’s restricted Common Stock were issued in connection with a certain Simple Agreement Future Equity (“SAFE”) offering, including 6,000,000 and 0 shares issued to related parties, for cash in the amount of $735,000 and $0, services valued at $15,000 and $0, and the reduction of related party debt in the amount of $375,000 and $0. As a result, $1,107,000 and $0 was recorded to paid in capital. During the years ended December 31, 2019 and 2018, respectively, 0 and 6,000,000 shares of the Company’s restricted Common Stock were issued to officers, for cash in the amount of $0 and $6,000. As a result, $0 and $984,000 was recorded to paid in capital. During the years ended December 31, 2019 and 2018, respectively, 1,150,000 and 0 shares of the Company’s restricted Common Stock were issued in connection with the conversion of Preferred Stock valued at $69,000 and $0. As a result, $67,850 and $0 was recorded to paid in capital. During the years ended December 31, 2019 and 2018, respectively, 6,666,667 and 0 shares of the Company’s restricted Common Stock were issued in connection with an investment valued at $1,000,000 and $0. As a result, $993,333 and $0 was recorded to paid in capital. During the years ended December 31, 2019 and 2018, respectively, 1,875,000 and 0 shares of the Company’s restricted Common Stock were issued in connection with the exercise of warrants valued at $178,700 and $0. As a result, $176,825 and $0 was recorded to paid in capital. During the years ended December 31, 2019 and 2018, respectively, a total of 92,011,614 and 21,358,611 shares of the Company’s restricted Common Stock were issued. As of December 31, 2019 and 2018, respectively, the Company had 250,124,755 and 158,113,141 common shares issued and outstanding. Restricted Stock Awards During the years ended December 31, 2019 and 2018, respectively, 3,830,000 and 3,660,000 restricted stock awards were granted, valued at $264,350 and $434,000; and 4,237,595 and 6,827,368 restricted stock awards vested, for which $685,553 and $1,095,193 in deferred stock compensation was expensed. As of December 31, 2019 and 2018, respectively, there remains 4,805,600 and 5,888,195 shares to be vested, and $660,069 and $1,148,809 in deferred stock compensation to be expensed over the next fifteen (15) months. Restricted Stock Awards Activity Number of Deferred Shares Compensation Outstanding at December 31, 2017 9,055,563 $ 1,810,002 Granted 3,660,000 434,000 Vested (6,827,368 ) (1,095,193 ) Outstanding at December 31, 2018 5,888,195 1,148,809 Granted 3,830,000 264,350 Vested (4,237,595 ) (685,553 ) Forfeited/Canceled (675,000 ) (67,537 ) Outstanding at December 31, 2019 4,805,600 $ 660,069

Warrants And Options

Warrants And Options	12 Months Ended
	Dec. 31, 2019
Notes
Warrants And Options	NOTE 14. WARRANTS AND OPTIONS As of December 31, 2019 and 2018, respectively, the Company had 56,785,913 and 21,232.500 warrants, and 26,685,000 and 18,060,000 options issued and outstanding. During the years ended December 31, 2019 and 2018, respectively, 40,703,413 and 14,077,500 warrants were granted, and 300,000 and 100,000 expired, and 4,850,000 and 0 were retired/canceled. The warrants carry an exercise price of between $0.001 to $0.60 per share, expire between 2020 to 2024, and were valued at $498,840 and $851,610, using the Black-Scholes method. The assumptions used in valuing the warrants were: expected term between 2 to 5 years; expected volatility 40% to 45%; risk free interest rate between 1.56% to 2.95%; and a dividend yield of 0%. A total of $40,730 and $113,210 in deferred stock warrant compensation was recorded, and $47,180 and $73,370 was expensed during the years ended December 31, 2019 and 2018, respectively. There remains $92,470 and $98,920 in deferred compensation as of December 31, 2019 and 2018, respectively, to be expensed over the next twelve (12) months. Warrants Outstanding Number of Remaining Exercise Price Weighted Common Contractual Life Times Number Average Exercise Price Shares (in years) Of Shares Exercise Price $0.001 300,000 3.50 $ 300 $0.17 $0.01 500,000 2.75 5,000 $0.22 $0.01 75,000 1.00 750 $0.18 $0.10 5,028,413 4.75 502,841 $0.21 $0.10 62,500 3.25 6,250 $0.29 $0.10 250,000 1.50 25,000 $0.19 $0.10 4,877,500 1.25 487,750 $0.21 $0.10 250,000 0.75 25,000 $0.32 $0.12 100,000 2.75 12,000 $0.21 $0.12 125,000 2.00 15,000 $0.21 $0.15 600,000 4.25 90,000 $0.19 $0.15 1,000,000 1.00 150,000 $0.28 $0.17 62,500 3.25 10,625 $0.29 $0.18 62,500 3.25 11,250 $0.29 $0.20 2,600,000 4.25 520,000 $0.19 $0.21 62,500 3.25 13,125 $0.29 $0.21 100,000 0.75 21,000 $0.34 $0.25 6,000,000 2.75 1,500,000 $0.20 $0.25 1,050,000 2.50 262,500 $0.21 $0.25 10,400,000 2.25 2,600,000 $0.20 $0.25 800,000 2.00 200,000 $0.21 $0.25 3,250,000 1.75 812,500 $0.18 $0.25 13,500,000 1.25 3,375,000 $0.21 $0.25 475,000 1.00 118,750 $0.27 $0.25 3,255,000 0.75 813,750 $0.32 $0.25 1,500,000 0.50 375,000 $0.39 $0.35 250,000 0.75 87,500 $0.32 $0.60 250,000 0.75 150,000 $0.34 56,785,913 $ 12,190,891 $0.21 Warrant Activity Number of Weighted Average Shares Exercise Price Outstanding at December 31, 2017 7,255,000 $0.18 Issued 54,780,913 $0.20 Exercised –– –– Expired / Forfeited (5,250,000 ) $0.21 Outstanding at December 31, 2019 56,785,913 $0.21 During the years ended December 31, 2019 and 2018, respectively, 10,000,000 and 6,000,000 stock options were granted, which vest periodically over a two (2) year period, are exercisable for a period of between 3 to 5 years at an exercise price of between $0.05 to $0.25 per share, and were valued at $875,700 and $833,700, using the Black-Scholes method. The assumptions used in valuing the options were: expected term between 3.00 to 4.75 years; expected volatility between 1.82 to 2.29; risk free interest rate between 1.69% to 2.78%; and a dividend yield of 0%. Options Outstanding Remaining Exercise Price Weighted Number of Contractual Life times Number Average Exercise Price Shares (in years) of Shares Exercise Price $0.05 90,000 2.50 $ 4,500 $0.14 $0.05 1,140,000 2.25 57,000 $0.09 $0.05 100,000 1.75 5,000 $0.08 $0.05 60,000 1.00 3,000 $0.06 $0.05 170,000 0.75 8,500 $0.12 $0.09 5,500,000 2.50 467,500 $0.20 $0.10 500,000 0.75 50,000 $0.14 $0.15 1,000,000 0.75 150,000 $0.14 $0.25 3,125,000 4.25 781,250 $0.22 $0.25 1,000,000 4.00 250,000 $0.23 $0.25 5,000,000 3.25 1,250,000 $0.16 $0.25 7,000,000 2.50 1,750,000 $0.16 $0.25 1,000,000 0.75 250,000 $0.15 $0.25 1,000,000 0.25 250,000 $0.10 26,685,000 $ 5,276,750 $0.20 Options Activity Number of Weighted Average Shares Exercise Price Outstanding at December 31, 2017 20,675,000 $0.15 Issued 16,000,000 $0.19 Exercised (1,973,189 ) $0.18 Expired / Forfeited (3,891,811 ) $0.20 Outstanding at December 31, 2019 26,685,000 $0.20 During the years ended December 31, 2019 and 2018, respectively, 10,000,000 and 6,000,000 options were issued, 0 and 1,973,189 options were exercised, 0 and 1,000,000 options expired, and 375,000 and 5,641,811 options were forfeited. A total of $875,700 and $649,327 in deferred stock option compensation was recorded, net of forfeitures, and $718,392 and $572,870 was expensed during the years ended December 31, 2019 and 2018, respectively. There remains $1,552,774 and $1,395,466 in deferred compensation as of December 31, 2019 and 2018, respectively, to be expensed over the next twelve (12) months.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Notes
Income Taxes	NOTE 15. INCOME TAXES A reconciliation of the expected statutory federal and state taxes and the total income tax expense (benefit) at December 31, 2019 and 2018 was as follows: December 31, 2019 December 31, 2018 Income (loss) before taxes $ (12,866,332 ) $ 15,608,209 Statutory rate (Fed & State(s)) 30% 30% Computed expected tax payable (recovery) (3,351,800 ) 4,781,700 Effect of release of net operating loss carryforwards (2,240,900 ) (2,417,700 ) Tax effect of non-deductible expenses: Gain on extinguishment of debt-principal –– (6,124,000 ) Impairment losses 299,100 –– Stock compensation/amortization of stock options 830,200 1,048,500 Discount amortization 6,000 837,000 Other 2,100 1,500 Total tax effect of non-deductible expenses 1,137,400 (4,237,000 ) Change in valuation allowance 4,635,300 (1,873,000 ) Income tax expense $ –– $ –– Reported income taxes: Federal $ –– $ –– State –– –– Total $ –– $ –– The significant components of deferred income tax assets and liabilities at December 31, 2019 and 2018, are as follows: December 31, 2019 December 31, 2018 Net operating loss carried forward $ 4,666,500 $ –– Bad debt allowance –– –– Officers’ accrued compensation 222,800 243,400 Accrued related party interest 10,100 20,700 Valuation allowance (4,899,400 ) (264,100 ) Net deferred income tax asset $ –– $ –– During the year ended December 31, 2018, the company realized extinguishment of debt principal in the amount of $20,522,835. Per Internal Revenue Code (“IRC”) Section 108(a) (1) (A) the extinguishment of debt principal is excluded from taxable income for the Company. However, any available tax attributes must be released up and to the amount of the extinguishment. Therefore, net operating loss carryforwards were released for the amount of income excluded from taxable income. The remaining net operating losses available to use toward future taxable income are as follows: Tax Year Net Operating Loss Expires 2016 $ 1,192,900 2036 2017 2,117,100 2037 2018 548,900 No Expiration 2019 9,165,700 No Expiration Total $ 13,024,600 The Company is open to examinations for the tax year 2011 through the current tax year.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2019
Notes
Discontinued Operations	NOTE 16. DISCONTINUED OPERATIONS In December 2017, the Company discontinued all operations related to the Retail Pharmacy Segment involving the Company’s wholly-owned subsidiary, RoxSan Pharmacy, Inc. On May 14, 2018, pursuant to unanimous resolutions of the board of directors of RoxSan Pharmacy, Inc. (“RoxSan”) and Parallax Health Sciences, Inc., RoxSan filed a Chapter 7 petition in the United States Bankruptcy Court for the Central District of California. Mr. Timothy Yoo was appointed trustee on May 15, 2018. The pharmacy operations resulted in an accumulated deficit of $11,582,906 as of May 14, 2018. In addition, certain advances were made to RoxSan Pharmacy, Inc. for the purpose of overhead expenses for which a secured promissory note was issued to the Company. As of May 14, 2018, principal in the amount of $1,280,692 had been disbursed, and interest in the amount of $22,797 had been accrued in connection with the note. As of May 14, 2018, the assets and liabilities relating to the discontinued operations of RoxSan Pharmacy, Inc. were as follows: May 14, 2018 Liabilities subject to compromise Accounts payable and accrued expenses $ 2,942,012 [1] Related party payables 376,430 [1] Note payable 185,000 [1] Note payable-merchant 974,826 Total liabilities subject to compromise 4,478,268 Net liabilities of discontinued operations $ 4,478,268 [1] Included in accounts payable and accrued expenses as of May 14, 2018, are $181,580 in unpaid payroll taxes, $296,959 in penalties, and $50,167 in interest related to unpaid payroll taxes. The results of the discontinued operations of RoxSan Pharmacy, Inc. are summarized as follows: May 14, 2018 Revenue $ –– Cost of sales –– Gross profit –– Sales, marketing and pharmacy expenses 170,630 General and administrative expenses 586,993 Operating loss (757,623 ) Interest expense (56,775 ) Loss on disposal of equipment (10,000 ) Net loss from discontinued operations $ (824,398 )

Segment Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2019
Notes
Segment Reporting	NOTE 17. SEGMENT REPORTING The Company currently has three (3) business segments: Remote Care Systems, Behavioral Health Services and Diagnostics/Corporate. The Pharmacy segment ceased operations in December 2017, and was deconsolidated effective May 14, 2018. See Note 1 and 3 for a description of each segment and related significant accounting policies. The following table is a reconciliation of the Company’s business segments to the consolidated financial statements: Remote Care Systems Behavioral Health Services Diagnostics/ Corporate Pharmacy [1] Consolidated Totals December 31, 2019 Revenue $ 1,800 $ 76,800 $ 50,000 $ –– $ 128,600 Gross profit (loss) 480 61,293 50,000 –– 111,773 Operating loss (253,391 ) (169,485 ) (5,970,812 ) –– (6,393,688 ) Depreciation and amortization 9,196 109,760 2,016 –– 120,972 Interest expense 3,111 –– 579,397 –– 582,508 Gain (loss) on extinguishment of debt 101,367 –– (1,028,766 ) –– (927,399 ) Gain (loss) on fair value adjustments –– –– 194,511 –– 194,511 Loss on settlements (4,134,972 ) (4,134,972 ) Impairment loss –– –– 1,002,276 –– 1,002,276 Discount amortization 20,000 –– –– –– 20,000 Total assets 904,757 439,567 125,332 –– 1,359,896 Goodwill 785,060 –– –– 785,060 Additions to property and equipment –– –– 2,628 –– 2,628 December 31, 2018 Revenue $ 9,399 $ 1,800 $ –– $ –– $ 11,739 Gross profit (loss) (10,400 ) 1,800 –– –– (8,600 ) Operating loss (365,426 ) (191,446 ) (6,077,791 ) –– (6,634,663 ) Depreciation and amortization 9,196 109,760 1,664 –– 120,620 Interest expense 2,970 –– 2,161,560 –– 2,164,530 Gain on disposal of subsidiary –– –– 4,478,268 –– 4,478,268 Gain (loss) on extinguishment of debt –– –– 22,858,009 –– 22,858,009 Gain (loss) on fair value adjustments –– –– (123,875 ) –– (123,875 ) Discount amortization (340,000 ) –– 3,145,000 –– 2,805,000 Discontinued operations –– –– –– (824,398 ) (824,398 ) Total assets 913,636 439,567 11,154 –– 1,364,357 Goodwill 785,060 –– –– –– 785,060 Additions to property and equipment –– –– –– –– –– [1]

Legal Matters

Legal Matters	12 Months Ended
	Dec. 31, 2019
Notes
Legal Matters	NOTE 18. LEGAL MATTERS Dispute with Former Owner of RoxSan In October 2015, shortly following the Company's acquisition of RoxSan, Shahla Melamed (“Melamed”), initiated two (2) legal actions against the Company in the Superior Court of the State of California, County of Los Angeles, West District, Shahla Melamed v. Parallax Health Sciences, Inc The Company also initiated legal action against Melamed and filed a complaint in October 2015, action number SC 124898, in the Superior Court of the State of California, County of Los Angeles, West District, Parallax Health Sciences, Inc., et al. v. Shahla Melamed, et al. The complaint in that action alleges that Melamed breached several obligations under the Purchase Agreement, and the Company sought to reduce the Secured Note due to undisclosed material changes in the business. Settlement Reached In January 2019, Melamed requested mediation, seeking settlement of the pending litigation with the Company, including that which was initiated against the Company by her son, Hootan Melamed (Shahla and Hootan, collectively, the “Melameds”). Through mediation, the Company and the Melameds reached agreeable settlement terms, and on February 19, 2020, the Company received a counter-signed Settlement and Release Agreement (the “Settlement”). Effective February 12, 2020 (the “Effective Date”), the Settlement is by and between Parallax Health Sciences, Inc., RoxSan Pharmacy, Inc., Michael Redmond, Edward Withrow III, Huntington Chase Financial Group, LLC, Calli Bucci and Dave Engert (collectively, “Parallax”), and the Melameds, and resolves all pending lawsuits between the parties in connection with the acquisition of RoxSan Pharmacy. In consideration of the resolution of all existing and potential claims, including the cancellation of the Company’s contingent liability in the principal sum of $20,500,000, and accrued interest of approximately $4,500,000, and without further action or litigation and without admission of liability by either party, the Settlement terms include the following: ● § § § ● In addition, in the event forty percent (40%) or more of the Company and/or its subsidiaries (including by way of merger) is sold within two (2) years of the Effective Date, the Company shall pay the Melameds, within two (2) weeks of receipt of the proceeds from such sale (the “Sale Proceeds”), any outstanding unpaid Settlement Sum plus an additional 10% of the Sale Proceeds received, up to a total of an additional $3,000,000 over and above the Settlement Sum. In the event the Company fails to cure a breach of timely payment of any portion of the Settlement Sum within thirty (30) days of a notice of default, a Stipulated Judgement may be filed by Melamed in the sum of $20,000,000, less any Settlement Sum amounts previously paid by the Company. RoxSan Dissolution On May 14, 2018, pursuant to unanimous resolutions of the boards of directors of RoxSan Pharmacy, Inc. and Parallax Health Sciences, Inc., RoxSan filed a Chapter 7 petition in the United States Bankruptcy Court for the Central District of California (the “Court”). Mr. Timothy Yoo was appointed trustee (“Trustee”) on May 15, 2018. In connection with this filing, RoxSan seeks to discharge approximately $5 million of liabilities owed to various parties, and intercompany loans in excess of $1 million owed to Parallax. The Chapter 7 bankruptcy proceeding by RoxSan Pharmacy, Inc. was fully discharged and the case was closed on March 13, 2019, in U.S. Bankruptcy Court, Central District of California. Due to, among other things, the reduction in RoxSan’s cash flows during 2016 and 2017, RoxSan became delinquent in its payroll tax depository obligations, resulting in a liability owed to federal and state taxing agencies in the aggregate of $1,148,811, which includes $601,148 in taxes withheld from employees (“Trust Fund Taxes”), employer taxes of $183,172, and penalties and interest of $364,491 through December 31, 2018. The liability was included as part of the Chapter 7 bankruptcy petition, and certain portions of the liability may be discharged. However, in accordance with California bankruptcy laws, federal and state Trust Fund Taxes are not dischargeable. The Company has retained a tax resolution specialist and is in communications with the taxing agencies in order to resolve RoxSan’s liability. During the year ended December 31, 2019, payments for Trust Fund Taxes in the amount of $485,498 were made, and $115,650 in Trust Fund Taxes were outstanding at December 31, 2019. Disputes with Former Executives ● Action No. CV2017-052804 On March 9, 2017, Dave Engert former Executive Chairman and director of the Company filed a lawsuit in Arizona and then on or about May 5, 2017, Mr. Engert, changed the venue and filed suit against the Company and RoxSan Pharmacy, Inc. in the United States District Court, Central District of California for an amount exceeding $75,000. On October 23, 2017, the Company filed an answer and counterclaims against Mr. Engert for an amount exceeding $100,000. The counterclaims include possible fraud and negligence committed by Mr. Engert and Mr. J. Michael Redmond, former successor Chairman of Mr. Engert, director, President and Chief Executive Officer of the Company and former President, Chief Executive Officer, Chairman and director of RoxSan Pharmacy, Inc. On October 8, 2018, a settlement was reached between Mr. Engert and the Company (the “Engert Settlement”). The Engert Settlement includes, among other things, a cash payment to Mr. Engert in the amount of $139,000, and the cancellation of all of Mr. Engert’s equity holdings in the Company. The Engert Settlement resulted in a net loss to the Company of $33,272. On April 10, 2019, a stipulation for dismissal was filed, and the matter has been fully resolved. ● Action No. BC700070 On March 28, 2018, Mr. J. Michael Redmond filed a lawsuit against the Company and RoxSan Pharmacy, Inc. in the United States District Court, Central District of California for an amount exceeding $75,000. The Company intends to vigorously defend against this action. There are counterclaims that include possible fraud and negligence committed by Mr. Redmond, former President, Chief Executive Officer, Chairman and director of the Company and of RoxSan Pharmacy, Inc. An Arbitration is still pending. Disputes with Lenders ● There are two (2) legal matters currently pending.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Notes
Subsequent Events	NOTE 19. SUBSEQUENT EVENTS The Company has evaluated the events and transactions for recognition or disclosure subsequent to December 31, 2019, through the date of the issuance of the financial statements, and has determined that there have been no events that would require disclosure, except for the following: On January 22, 2020, the Company issued a short-term non-related party convertible promissory note in the principal sum of $78,000. The note bears interest at a rate of 12% per annum, matures in one (1) year, and is convertible into shares of the Company’s Common Stock at a conversion price equal to the lower of 1) $0.12 per share; or 2) 65% of the average of the lowest three (3) trading prices during the fifteen (15) trading days preceding the conversion date. On January 15, 2020, in connection with the exercise of certain warrants issued to a beneficial owner, 1,838,217 shares of the Company’s Common Stock were issued. The shares were valued at $108,455. On January 27, 2020, pursuant to a and resolution of the board of directors, the Company issued 1,351,181 shares of its restricted Common Stock at $0.001 per share, for $1,351, to Nathaniel T. Bradley, a director, in recognition of his contributions and achievements. The shares were valued at $67,559. On February 2, 2020, Mr. David Appell resigned as the Company’s Chief Operating Officer. His resignation was not the result of a disagreement with the Company on any matters relating to the Company’s operations, policies, or practices. Concurrent with his resignation as COO, Mr. Appell will serve as Managing Director of the Company’s wholly-owned subsidiary, Parallax Communications, Inc. (“PCOM”). As Managing Director, Mr. Appell will provide business advisory and strategic planning advice to the Company with PCOM. In exchange for these services, Mr. Appell will be paid $2,000 per month plus medical benefits. In connection with Mr. Appell’s resignation, the Company canceled 1,450,000 shares of Mr. Appell’s previously granted stock award, and 2,250,000 of unvested stock options. As a result, additional paid in capital was reduced by $207,324. On February 12, 2020, the Company filed a Certificate of Designation (“Designation”) with the secretary of state of Nevada for the designation of 10,000 shares of Series B1 Convertible Preferred Stock. The Series B1 Stock is redeemable at 120% of face value and unpaid dividends; is convertible into Common Stock at a conversion rate of $0.15; carries an annual dividend of 10%; and matures in two (2) years, at which time the Series B1 Stock will automatically convert into Common Stock. On February 12, 2020, in connection with a $5,000,000 maximum offering of the Company’s Series B1 Convertible Preferred Stock (the “Series B1 Stock”), the Company received a Subscription from an accredited investor (the “Subscription”) for the purchase of 69 shares of Series B1 Stock at a price of $10,000 per share, net of an original issue discount of 15%, or $8,500 per share, for proceeds in the amount of $586,500, pursuant to that certain Securities Purchase Agreement dated February 10, 2020. In addition, the Subscription includes 50% warrant coverage at an exercise price of $0.25 per share for a period of three (3) years. Effective February 12, 2020, in connection with the legal settlement between the Company and the Melameds (Note 18), the Company issued 10,000,000 shares of its restricted Common Stock, valued at $480,000. On February 14, 2020, in connection with a certain consulting agreement, the Company issued 1,000,000 shares of its restricted Common Stock for services, valued at $62,500. During the first quarter 2020, in connection with the conversion of debt in the amount of $65,000, the Company issued 3,412,292 shares of Common Stock, valued at $178,182. During the first quarter 2020, in connection with the conversion of debt in the amount of $41,580, the Company issued 2,200,000 shares of Common Stock, valued at $128,000. The Company has initiated legal action against the lender in the US District Court, Southern District of New York. On April 27, 2020, the lender filed an answer and counter claims. The matter is currently pending. (Note 18). During the first quarter 2020, in connection with a certain consulting agreement, the Company issued 246.844 shares of its restricted Common Stock for services, valued at $9,750. On or about March 5, 2020, the Company received subscriptions from accredited investors for the purchase of 36 shares of Series B1 Stock at a price of $10,000 per share, net of an original issue discount of 15%, or $8,500 per share, for proceeds in the amount of $306,000. On April 7, 2020, the Company executed an Executive Agreement (the “Executive Agreement”) for the appointment of Dr. David L. Stark as the Company’s President, with an effective date of March 1, 2020. The Executive Agreement replaces any other agreement between Dr. Stark and the Company or any of its subsidiaries, and provides a base compensation of $225,000 in year one, $250,000 in year two and $275,000 in year three, commencing after the initial term estimated at approximately six (6) months, during which time Dr. Stark will devote fifty percent (50%) of his time at a compensation proportionate to the year one base compensation. The Executive Agreement also provides for various performance bonuses, and customary employee benefits, as well as (i) a grant to purchase 2,000,000 restricted common shares at $0.001 per share, of which 25% vest immediately, and the remainder vest upon the Company’s achievement of certain earnings goals; and (ii) stock options to purchase 3,000,000 shares of the Company’s Common Stock at an exercise price of $0.25 per share for a period of five (5) years, of which 25% vest immediately, and the remainder vest quarterly in equal amounts over the term of the Agreement. On or about May 12, 2020, in connection with the Melamed Settlement, the initial payment of $1,250,000 was due. Due to cash flow constraints, the payment was not made at that time. Pursuant to the Settlement Agreement, the Company has thirty (30) days to cure the non-payment (See Note 8).

Significant Accounting Polici_2

Significant Accounting Policies: Basis of Presentation (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Basis of Presentation	Basis of Presentation This summary of significant accounting policies is presented to assist in understanding the Company’s financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements. The Company’s fiscal year-end is December 31.

Significant Accounting Polici_3

Significant Accounting Policies: Principles of Consolidation (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated. Changes in the Company’s ownership interests in subsidiaries that do not result in the Company losing control over the subsidiaries are accounted for as equity transactions. When the Company loses control of a subsidiary, a gain or loss is recognized and is calculated as the difference between: ● ● Upon deconsolidation of a subsidiary, any loans to the former subsidiary made by the Company are measured at fair value at the deconsolidation date. Any difference between the carrying amount of the loan to the subsidiary and its fair value is included as part of the gain or loss calculation upon deconsolidation.

Significant Accounting Polici_4

Significant Accounting Policies: Use of Estimates (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.

Significant Accounting Polici_5

Significant Accounting Policies: Fair Value Hierarchy (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Fair Value Hierarchy	Fair Value Hierarchy The Company utilizes the three-level valuation hierarchy for the recognition and disclosure of fair value measurements. The categorization of assets and liabilities within this hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy consist of the following: Level 1: Level 2: Level 3:

Significant Accounting Polici_6

Significant Accounting Policies: Cash and Cash Equivalents (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. As of December 31, 2019 and 2018, the Company had no cash equivalents.

Significant Accounting Polici_7

Significant Accounting Policies: Fair Value of Financial Instruments (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Fair Value of Financial Instruments	Fair Value of Financial Instruments As of December 31, 2019 and 2018, the carrying values of Company’s Level 1 financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, and short-term debt, approximate fair value. The fair value of Level 3 instruments is calculated as the net present value of expected cash flows based on externally provided or obtained inputs. Certain Level 3 instruments may also be based on sales prices of similar assets. The Company’s fair value calculations take into consideration the credit risk of both the Company and its counterparties as of the date of valuation. See Note 6 for additional information about long-term debt. ● Derivatives of financial instruments: Derivatives are initially recognized at fair value at the date a derivative contract is entered into and are subsequently remeasured to their fair value at the end of each reporting period, with changes in fair value recognized in profit or loss. A derivative is presented as a non-current asset or a non-current liability if the remaining maturity of the instrument is more than 12 months and it is not expected to be realized or settled within 12 months. Other derivatives are presented as current assets or current liabilities. ● Embedded derivatives: Derivatives embedded in other financial instruments or other host contracts are treated as separate derivatives when their risks and characteristics are not closely related to those of the host contracts and the host contracts are not measured at fair value with changes in fair value recognized in profit or loss. An embedded derivative is presented as a non-current asset or a non-current liability if the remaining maturity of the hybrid instrument to which the embedded derivative relates is more than 12 months and it is not expected to be realized or settled within 12 months. Other embedded derivatives are presented as current assets or current liabilities. The following table represents the Company’s derivative financial instruments: December 31, 2019 December 31, 2018 Convertible debentures $ –– $ 23,925 Convertible promissory notes-embedded conversion option 5,800 –– Warrants 57,000 34,000 Total derivative liability $ 62,800 $ 57,925 The following table represents the changes in the Company’s derivative financial instruments: December 31, 2019 December 31, 2018 Fair value of derivative liability, beginning $ 57,925 $ –– Increase in derivative liability-debentures –– 60,350 Increase in derivative liability-convertible promissory notes 30,620 –– Increase in derivative liability-warrants 182,000 623,900 Fair value adjustment-debentures (26,691 ) (2,500 ) Fair value adjustment-convertible promissory notes (24,820 ) –– Fair value adjustment-warrants (143,000 ) 126,375 Reclassification of warrant carrying value due to reset of exercise price –– (750,200 ) Reclassification of carrying value due to extinguishment (13,234 ) –– Fair value of derivative liability, ending $ 62,800 $ 57,925

Significant Accounting Polici_8

Significant Accounting Policies: Investments (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Investments	Investments The Company records investments at cost, net of impairment. During the year ended December 31, 2019, the Company acquired $1,050,000 of equity securities without readily determinable fair value, and recorded an impairment of.$1,000,000. At December 31, 2019, the Company held $50,000 of equity securities without readily determinable fair value, net of impairment.

Significant Accounting Polici_9

Significant Accounting Policies: Property and Equipment (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Property and Equipment	Property and Equipment Property and equipment is comprised of office and computer equipment and software, furniture and fixtures, and leasehold improvements, recorded at cost and depreciated using the double declining balance method over the estimated useful lives of 5 to 7 years. Repairs and maintenance costs are charged directly to expense as incurred. Major renewals or replacements that substantially extend the useful life of an asset are capitalized and depreciated. See Note 5 for additional information about property and equipment.

Significant Accounting Polic_10

Significant Accounting Policies: Intangible Assets (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Intangible Assets	Intangible Assets Product processes, patents and customer lists are amortized on a straight-line basis over their estimated useful lives between 4 and 20 years. Application development stage costs for significant internally developed software projects are capitalized and amortized on a straight-line basis over the useful life, between 2 and 5 years. Costs to extend and maintain patents and trademarks are charged directly to expense as incurred. See Note 6 for additional information about intangible assets.

Significant Accounting Polic_11

Significant Accounting Policies: Goodwill and Other Indefinitely-lived Assets (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Goodwill and Other Indefinitely-lived Assets	Goodwill and other Indefinitely-lived assets Goodwill and other indefinitely-lived assets are not amortized, but are subject to impairment reviews annually, or more frequently if necessary.

Significant Accounting Polic_12

Significant Accounting Policies: Impairment of Long-lived Assets (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Impairment of Long-lived Assets	Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that their net book value may not be recoverable. When such factors and circumstances exist, the Company compares the projected undiscounted future cash flows associated with the related asset or group of assets over their estimated useful lives against their respective carrying amount. Impairment, if any, is based on the excess of the carrying amount over the fair value, based on market value when available, or discounted expected cash flows, of those assets and is recorded in the period in which the determination is made. During the year ended December 31, 2019, the Company recognized $1,002,276] in impairment losses related to its long-lived assets. The Company believes that future projected cash flows are sufficient for the recoverability of the remainder of its long-lived assets, and no other impairment exists. There can be no assurance, however, that market conditions will not change or demand for the Company’s products and products under development will continue. Either of these could result in future impairment losses.

Significant Accounting Polic_13

Significant Accounting Policies: Convertible Debt (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Convertible Debt	Convertible Debt The Company recognizes the advantageous value of conversion rights attached to convertible debt. Such rights give the debt holder the ability to convert debt into Common Stock at a price per share that is less than the trading price to the public on the date of the debt. The beneficial value is calculated as the intrinsic value (the market price of the stock at the commitment date in excess of the conversion rate) of the beneficial conversion feature of the debt, and is recorded as a discount to the related debt and an addition to additional paid in capital. The discount is amortized over the remaining outstanding period of related debt using the interest method.

Significant Accounting Polic_14

Significant Accounting Policies: Net Income (loss) Per Common Share (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Net Income (loss) Per Common Share	Net Income (Loss) Per Common Share The computation of basic earnings per share ("EPS") is based on the weighted average number of shares that were outstanding during the period, including shares of Common Stock that are issuable at the end of the reporting period. The computation of diluted EPS is based on the number of basic weighted-average shares outstanding plus the number of common shares that would be issued assuming the exercise of all potentially dilutive Common Stock equivalents. Dilutive Common Stock equivalents consist of shares issuable upon conversion of convertible debt, convertible preferred shares and the exercise of the Company’s stock options and warrants.

Significant Accounting Polic_15

Significant Accounting Policies: Comprehensive Loss (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Comprehensive Loss	Comprehensive Loss As of December 31, 2019 and 2018, the Company has no items that represent comprehensive loss and, therefore, has not included a schedule of comprehensive loss in the financial statements.

Significant Accounting Polic_16

Significant Accounting Policies: Revenue Recognition (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Revenue Recognition	Revenue Recognition The Company recognizes revenue when it satisfies a performance obligation by transferring control over a product or service to a customer. Revenue is measured based on a consideration specified in a contract with a customer, and excludes any amounts collected on behalf of third parties.

Significant Accounting Polic_17

Significant Accounting Policies: Income Taxes (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Income Taxes	Income Taxes Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. These assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the temporary differences are expected to reverse. The Company may have net operating loss carryforwards available to reduce future taxable income. Future tax benefits for these net operating loss carryforwards are recognized to the extent that realization of these benefits is considered more likely than not. To the extent that the Company will not realize a future tax benefit, a valuation allowance is established. As of December 31, 2019, the Company has not yet filed its 2012 through 2018 annual corporate income tax returns. Due to the Company’s recurring losses, it is anticipated that no corporate income taxes are due for these periods.

Significant Accounting Polic_18

Significant Accounting Policies: Stock-based Compensation (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Stock-based Compensation	Stock-Based Compensation The Company records stock-based compensation using the fair value method. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. Equity instruments issued to employees and the cost of the services received as consideration are measured and recognized based on the fair value of the equity instruments issued.

Significant Accounting Polic_19

Significant Accounting Policies: Recently Adopted Accounting Standards (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards The Company evaluates the pronouncements of various authoritative accounting organizations, primarily the Financial Accounting Standards Board (“FASB”), the US Securities and Exchange Commission (“SEC”), and the Emerging Issues Task Force (“EITF”), to determine the impact of new pronouncements on US GAAP and the impact on the Company. The Company has recently adopted the following new accounting standards: Adopted In January 2016, the FASB issued ASU No. 2016-01 (“ASU 2016-01”), Financial Instruments-Overall (Subtopic 825-10) Recognition and Measurement of Financial Assets and Financial Labilities. ASU 2016-01 addresses certain aspects of recognition, measurement, presentation, and disclosure of financial instruments in an effort to enhance the reporting model for financial instruments to provide users of financial statements with more decision-useful information. ASU 2016-01 is effective for the Company for annual periods beginning after December 15, 2017, and interim periods. Early adoption is permitted. In July 2017, the FASB issued ASU No. 2017-11 (“ASU 2017-11”), Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815). ASU 2017-11 addresses the complexity of accounting for certain financial instruments with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity offerings. ASU 2017-11 also addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content in the FASB Accounting Standards Codification®. ASU 2017-11 is effective for the Company for annual periods beginning after December 15, 2018, and interim periods. Early adoption is permitted. In June 2018, the FASB issued ASU No. 2018-07 (“ASU 2018-07”), Compensation-Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 is effective for the Company for annual periods beginning after December 15, 2018, and interim periods. Early adoption is permitted. In July 2018, the FASB issued ASU No. 2018-11 (“ASU 2018-11”), Leases (Topic 842), Targeted Improvements. ASU 2018-11 addresses certain issues in implementing ASU 2016-02, Leases, which was issued to increase transparency ad comparability by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing transaction. ASU 2018-11 clarifies 1) comparative reporting requirements for initial adoption; and 2) for lessors only, separating lease and non-lease components in a contract and allocating the consideration in the contract to the separate components. The amendments in this Update related to separating components of a contract affect the amendments in Update 2016-02, which is effective for the Company for annual periods beginning after December 15, 2018, and interim periods. Early adoption is permitted. In August 2018, the FASB issued ASU No. 2018-13 (“ASU 2018-13”), Fair Value Measurement (Topic 820), Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. ASU 2018-13 modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. ASU 2018-13 is effective for the Company for annual periods beginning after December 15, 2019, and interim periods. Early adoption is permitted. In August 2018, the FASB issued ASU No. 2018-15 (“ASU 2018-15”), Intangibles-Goodwill and Other Internal-Use Software (Subtopic 350-40). ASU 2018-15 was issued to help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement) by providing guidance for determining when the arrangement includes a software license. ASU 2018-15 is effective for the Company for annual periods beginning after December 15, 2019, and interim periods. Early adoption is permitted. Not Yet Adopted: In April 2019, the FASB issued ASU No. 2019-04 (“ASU 2019-04”), Codification Improvements to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments. The amendments to Topic 326 and other Topics in ASU 2019-04 clarify or address stakeholders’ specific issues about certain aspects of the amendments in Update 2016-13. The amendments to Topic 815 in ASU 2019-04 include items related to Update 2017- 12 and clarify certain aspects of Topic 815. The amendments to Topic 321 and other Topics in ASU 2019-04 relate to the amendments in Update 2016-01 and clarify certain aspects of the amendments in Update 2016-01. ASU 2019-04 will be effective for the Company for annual periods beginning after December 15, 2019, and interim periods. Early adoption is permitted. The Company is currently evaluating the impact of the application of this accounting standard update on its financial statements and related disclosures. In November 2019, the FASB issued ASU No. 2019-10 (“ASU 2019-10”), Financial Instruments-Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842), Effective Dates. ASU 2019-10 was issued to apply changes in how to determine the effective dates for ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (Credit Losses); ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities (Hedging); and ASU No. 2016-02, Leases (Topic 842) (Leases). Following ASU-2019-10, ASU 2016-13 will be effective for the Company for annual periods beginning after December 15, 2019, and interim periods; and ASU 2017-12 and ASU 2016-01 will be effective for the Company for annual periods beginning after December 15, 2018, and interim periods. Early adoption is permitted. The Company is currently evaluating the impact of the application of this accounting standard update on its financial statements and related disclosures. In December 2019, the FASB issued ASU No. 2019-12 (“ASU 2019-12”), Income Taxes (Topic 740). ASU 2019-12 was issued to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 will be effective for the Company for annual periods beginning after December 15, 2020, and interim periods. Early adoption is permitted. The Company is currently evaluating the impact of the application of this accounting standard update on its financial statements and related disclosures. Recently Issued Accounting Standards Updates There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries. None of the updates are expected to a have a material impact on the Company's consolidated financial position, results of operations or cash flows.

Restatement_ Restatement (Table

Restatement: Restatement (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Restatement	December 31, 2018 December 31, 2017 As Previously Reported As Restated Increase (Decrease) As Previously Reported As Restated Increase (Decrease) CONSOLIDATED BALANCE SHEETS Derivative liability, short-term –– 23,925 23,925 –– –– –– Debentures, convertible 755,627 724,903 (30,724 ) –– –– –– Debentures, convertible, related party 428,132 411,006 (17,126 ) –– –– –– Notes payable, convertible, net of discount 296,000 296,000 –– 741,000 1,706 (739,294 ) Total current liabilities 5,139,617 5,115,692 (23,925 ) 4,418,915 3,679,621 (739,294 ) Derivative liability, long-term –– 34,000 34,000 –– –– –– Debentures, convertible, net of unamortized discount 226,050 184,870 (41,180 ) –– –– –– Total liabilities 7,345,916 7,314,811 (31,105 ) 28,930,119 28,190,825 (739,294 ) Additional paid in capital - preferred 1,415,653 1,699,000 283,347 665,803 665,803 –– Additional paid in capital - common 9,715,921 11,382,341 1,666,420 5,580,668 6,449,768 869,100 Accumulated deficit (17,272,260 ) (19,190,922 ) 1,918,662 [1] (33,561,580 ) (33,691,386 ) 129,806 Total stockholders' deficit (5,981,559 ) (5,950,454 ) (31,105 ) (27,178,083 ) (26,438,789 ) (739,294 ) CONSOLIDATED STATEMENTS OF OPERATIONS General and administrative expenses $ 6,552,693 $ 6,626,063 $ 73,370 $ 3,997,512 $ 4,125,612 $ 128,100 Operating loss (6,561,293 ) (6,634,663 ) 73,370 (4,044,619 ) (4,172,719 ) 128,100 Gain on extinguishment of debt 23,215,862 22,858,009 (357,853 ) –– –– –– Loss on fair value adjustments –– (123,875 ) 123,875 –– –– –– Discount amortization (2,806,050 ) (2,805,000 ) (1,050 ) –– –– –– Interest expense, net of income (1,213,069 ) (2,164,530 ) 951,461 (1,016,773 ) (1,018,479 ) (1,706 ) Total other income (expenses) 23,675,011 22,242,872 (1,432,139 ) (6,466,773 ) (6,468,479 ) (1,706 ) Net income (loss) - continuing operations 17,113,718 15,608,209 (1,505,509 ) (10,511,392 ) (10,641,198 ) 129,806 Net income (loss) 16,289,320 14,783,811 (1,505,509 ) (13,664,945 ) (13,794,751 ) 129,806 Net income (loss) per common share - continuing operations - basic $ 0.115 $ 0.105 $ (0.010 ) $ (0.087 ) $ (0.088 ) $ (0.001 ) Net income (loss) per common share - continuing operations - diluted $ 0.079 $ 0.072 $ (0.007 ) $ (0.059 ) $ (0.060 ) $ 0.001 CONSOLIDATED STATEMENTS OF CASH FLOWS Net income (loss) $ 17,113,718 $ 15,608,209 $ (1,505,509 ) $ (10,511,392 ) $ (10,641,198 ) $ 129,806 Stock compensation/stock option expense 3,440,340 3,513,710 73,370 2,473,510 2,601,608 128,098 Discount amortization 2,806,050 2,805,000 (1,050 ) –– –– –– Gain on extinguishment of debt (23,215,862 ) (22,858,009 ) 357,853 –– –– –– Loss on fair value adjustments –– 123,875 123,875 –– –– –– Debt accretion –– 1,107,753 1,107,753 –– 1,706 1,706 Increase in accounts payable and accrued expenses 2,137,271 1,980,979 (156,292 ) 1,731,757 1,731,759 2 Non-Cash Activities: Discounts on long-term liabilities $ 2,806,050 $ 2,805,000 $ (1,050 ) $ 5,450,000 $ 5,450,000 $ –– Beneficial conversion feature of convertible promissory notes –– 347,487 347,487 –– 592,582 592,582 Fair value of stock warrants –– 1,393 1,393 –– 148,418 148,418 Embedded conversion option of convertible promissory notes –– 60,350 60,350 –– –– –– Supplemental Information: Interest paid-continuing operations 342,230 185,937 (156,293 ) 52,566 52,566 –– [1]

Significant Accounting Polic_20

Significant Accounting Policies: Fair Value of Financial Instruments: Derivatives (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Derivatives	December 31, 2019 December 31, 2018 Convertible debentures $ –– $ 23,925 Convertible promissory notes-embedded conversion option 5,800 –– Warrants 57,000 34,000 Total derivative liability $ 62,800 $ 57,925

Significant Accounting Polic_21

Significant Accounting Policies: Fair Value of Financial Instruments: Schedule of Changes in Derivative Liabilities at Fair Value (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Changes in Derivative Liabilities at Fair Value	December 31, 2019 December 31, 2018 Fair value of derivative liability, beginning $ 57,925 $ –– Increase in derivative liability-debentures –– 60,350 Increase in derivative liability-convertible promissory notes 30,620 –– Increase in derivative liability-warrants 182,000 623,900 Fair value adjustment-debentures (26,691 ) (2,500 ) Fair value adjustment-convertible promissory notes (24,820 ) –– Fair value adjustment-warrants (143,000 ) 126,375 Reclassification of warrant carrying value due to reset of exercise price –– (750,200 ) Reclassification of carrying value due to extinguishment (13,234 ) –– Fair value of derivative liability, ending $ 62,800 $ 57,925

Operating Leases_ Operating Lea

Operating Leases: Operating Lease, Future Miinimum Payments (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Operating Lease, Future Miinimum Payments	For the year ended December 31, 2020 Operating lease minimum payments $ 53,400 Less: amount treated as interest 1,224 Present value of minimum lease payments $ 52,176

Operating Leases_ Operating L_2

Operating Leases: Operating Lease, Lease Costs (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Operating Lease, Lease Costs	December 31, 2019 December 31, 2018 Operating lease costs $ 71,200 $ –– Short-term lease costs 68,320 73,351 Total lease costs $ 139,520 $ 73,351

Property and Equipment_ Propert

Property and Equipment: Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Property and Equipment	December 31, 2019 December 31, 2018 Computer equipment $ 6,615 $ 3,987 Medical devices 45,194 45,194 Property and equipment, gross 51,809 49,181 Accumulated depreciation (49,533 ) (49,181 ) Impairment loss (2,276 ) –– Property and equipment, net $ –– $ ––

Intangible Assets_ Schedule of

Intangible Assets: Schedule of Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Intangible Assets, Net	December 31, 2019 December 31, 2018 Products and processes $ 12,500 $ 12,500 Trademarks and patents / technology 150,700 150,700 Customer lists / relationships 30,000 30,000 Non-compete agreement 30,000 30,000 Marketing related 64,000 64,000 Software 510,300 510,300 Sub-total 797,500 797,500 Accumulated amortization (339,085 ) (218,465 ) Intangible assets, net $ 458,415 $ 579,035

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses: Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Accounts Payable and Accrued Expenses	December 31, 2019 December 31, 2018 Accounts payable-vendors $ 1,128,381 $ 830,590 Credit cards payable 42,552 42,552 Payroll taxes payable 81,718 78,608 Accrued interest 376,065 450,187 Accrued payroll and payroll taxes 338,612 402,053 Other liabilities 115,650 601,148 2,082,978 2,405,138 Reserve-legal fees –– 250,000 Total accounts payable and accrued expenses $ 2,082,978 $ 2,655,138

Settlments Payable_ Schedule of

Settlments Payable: Schedule of Melamed Settlement (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Melamed Settlement	December 31, 2019 Cash settlement, gross $ $4,000,000 Less: unamortized present value discount (415,800 ) Net present value of settlement 3,584,200 Common stock, at FMV 480,000 Total settlement $ 4,064,200 Due within 12 months $ 2,824,200 Due December 31, 2021 1,240,000 $ 4,064,200

Debt Disclosure_ Schedule of No

Debt Disclosure: Schedule of Notes and Loans Payable (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Notes and Loans Payable	December 31, 2019 December 31, 2018 Short-term Debentures, convertible $ –– $ 724,903 Notes payable 345,000 –– Note payable, bank 18,616 [1] –– Notes payable, convertible 1,102,364 296,000 Total short-term notes payable 1,465,980 1,020,903 Long-term Debentures, convertible, net of unamortized discount –– 184,870 Note payable, bank –– 28,995 [1] Notes payable, convertible 760,154 720,154 Total long-term notes and loans payable 760,154 934,019 Total notes and loans payable $ 2,226,134 $ 1,954,922 [1] Note payable, bank, maturing in July 2020, has been reclassified as short-term liability at December 31, 2019.

Debt Disclosure_ Non-Related Pa

Debt Disclosure: Non-Related Party Convertible Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Non-Related Party Convertible Notes Payable	Holder Principal APR Accrued Interest Conversion Price Term/Due Short-Term Investor Group A $ 91,000 10% $ 21,013 $0.10 02/28/2020 Lender Group A 20,000 12% 10,000 $0.10 02/28/2020 Lender Group B 519,641 12% 59,688 $0.10 to $0.12 04/30/2020 to 12/31/2020 Lender Group C 471,723 10% 5,944 65% to 70% of Market 10/31/2020 to 12/31/2020 1,102,364 96,645 Long-Term The Kasper Group, Ltd. 184,000 7% 85,431 $0.10 12/31/2021 Joseph M. Redmond 576,154 [1] 5% 148,358 [1] $0.10 07/31/2017 760,154 233,789 Total convertible debt $ 1,862,518 $ 330,434 [1]

Debt Disclosure_ Schedule of Ma

Debt Disclosure: Schedule of Maturities of Long-term Debt (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Maturities of Long-term Debt	Year Principal 2020 $ 778,770 2021 184,000 $ 962,770

Related Party Transactions_ Tab

Related Party Transactions: Table of Related Party Transactios (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Table of Related Party Transactios	December 31, 2019 December 31, 2018 Related party payables Accrued compensation $ 796,175 $ 869,859 [1] Accrued benefits and cash advances 312,305 134,861 Total related party payables 1,108,480 1,004,720 Debentures, convertible –– 411,006 Notes payable, related party, convertible 491,100 491,100 Notes payable, related party 759,446 –– Total related party transactions $ 2,359,026 $ 1,906,826

Related Party Transactions_ Rel

Related Party Transactions: Related Party Convertible Debt, By Related Party (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Related Party Convertible Debt, By Related Party	Note Holder Principal APR Accrued Interest Conversion Price Term/Due Convertible promissory notes: Huntington Chase, Beneficial Owner $ 491,100 7% $ 9,795 $0.08 12/31/2023

Common Stock_ Schedule of Restr

Common Stock: Schedule of Restricted Stock Units Activity (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Restricted Stock Units Activity	Restricted Stock Awards Activity Number of Deferred Shares Compensation Outstanding at December 31, 2017 9,055,563 $ 1,810,002 Granted 3,660,000 434,000 Vested (6,827,368 ) (1,095,193 ) Outstanding at December 31, 2018 5,888,195 1,148,809 Granted 3,830,000 264,350 Vested (4,237,595 ) (685,553 ) Forfeited/Canceled (675,000 ) (67,537 ) Outstanding at December 31, 2019 4,805,600 $ 660,069

Warrants And Options_ Warrants

Warrants And Options: Warrants Outstanding (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Warrants Outstanding	Warrants Outstanding Number of Remaining Exercise Price Weighted Common Contractual Life Times Number Average Exercise Price Shares (in years) Of Shares Exercise Price $0.001 300,000 3.50 $ 300 $0.17 $0.01 500,000 2.75 5,000 $0.22 $0.01 75,000 1.00 750 $0.18 $0.10 5,028,413 4.75 502,841 $0.21 $0.10 62,500 3.25 6,250 $0.29 $0.10 250,000 1.50 25,000 $0.19 $0.10 4,877,500 1.25 487,750 $0.21 $0.10 250,000 0.75 25,000 $0.32 $0.12 100,000 2.75 12,000 $0.21 $0.12 125,000 2.00 15,000 $0.21 $0.15 600,000 4.25 90,000 $0.19 $0.15 1,000,000 1.00 150,000 $0.28 $0.17 62,500 3.25 10,625 $0.29 $0.18 62,500 3.25 11,250 $0.29 $0.20 2,600,000 4.25 520,000 $0.19 $0.21 62,500 3.25 13,125 $0.29 $0.21 100,000 0.75 21,000 $0.34 $0.25 6,000,000 2.75 1,500,000 $0.20 $0.25 1,050,000 2.50 262,500 $0.21 $0.25 10,400,000 2.25 2,600,000 $0.20 $0.25 800,000 2.00 200,000 $0.21 $0.25 3,250,000 1.75 812,500 $0.18 $0.25 13,500,000 1.25 3,375,000 $0.21 $0.25 475,000 1.00 118,750 $0.27 $0.25 3,255,000 0.75 813,750 $0.32 $0.25 1,500,000 0.50 375,000 $0.39 $0.35 250,000 0.75 87,500 $0.32 $0.60 250,000 0.75 150,000 $0.34 56,785,913 $ 12,190,891 $0.21

Warrants And Options_ Warrant A

Warrants And Options: Warrant Activity (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Warrant Activity	Warrant Activity Number of Weighted Average Shares Exercise Price Outstanding at December 31, 2017 7,255,000 $0.18 Issued 54,780,913 $0.20 Exercised –– –– Expired / Forfeited (5,250,000 ) $0.21 Outstanding at December 31, 2019 56,785,913 $0.21

Warrants And Options_ Options O

Warrants And Options: Options Outstanding (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Options Outstanding	Options Outstanding Remaining Exercise Price Weighted Number of Contractual Life times Number Average Exercise Price Shares (in years) of Shares Exercise Price $0.05 90,000 2.50 $ 4,500 $0.14 $0.05 1,140,000 2.25 57,000 $0.09 $0.05 100,000 1.75 5,000 $0.08 $0.05 60,000 1.00 3,000 $0.06 $0.05 170,000 0.75 8,500 $0.12 $0.09 5,500,000 2.50 467,500 $0.20 $0.10 500,000 0.75 50,000 $0.14 $0.15 1,000,000 0.75 150,000 $0.14 $0.25 3,125,000 4.25 781,250 $0.22 $0.25 1,000,000 4.00 250,000 $0.23 $0.25 5,000,000 3.25 1,250,000 $0.16 $0.25 7,000,000 2.50 1,750,000 $0.16 $0.25 1,000,000 0.75 250,000 $0.15 $0.25 1,000,000 0.25 250,000 $0.10 26,685,000 $ 5,276,750 $0.20

Warrants And Options_ Options A

Warrants And Options: Options Activity (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Options Activity	Options Activity Number of Weighted Average Shares Exercise Price Outstanding at December 31, 2017 20,675,000 $0.15 Issued 16,000,000 $0.19 Exercised (1,973,189 ) $0.18 Expired / Forfeited (3,891,811 ) $0.20 Outstanding at December 31, 2019 26,685,000 $0.20

Income Taxes_ Schedule of Effec

Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Effective Income Tax Rate Reconciliation	December 31, 2019 December 31, 2018 Income (loss) before taxes $ (12,866,332 ) $ 15,608,209 Statutory rate (Fed & State(s)) 30% 30% Computed expected tax payable (recovery) (3,351,800 ) 4,781,700 Effect of release of net operating loss carryforwards (2,240,900 ) (2,417,700 ) Tax effect of non-deductible expenses: Gain on extinguishment of debt-principal –– (6,124,000 ) Impairment losses 299,100 –– Stock compensation/amortization of stock options 830,200 1,048,500 Discount amortization 6,000 837,000 Other 2,100 1,500 Total tax effect of non-deductible expenses 1,137,400 (4,237,000 ) Change in valuation allowance 4,635,300 (1,873,000 ) Income tax expense $ –– $ –– Reported income taxes: Federal $ –– $ –– State –– –– Total $ –– $ ––

Income Taxes_ Components of Def

Income Taxes: Components of Deferred Tax Assets and Liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Components of Deferred Tax Assets and Liabilities	December 31, 2019 December 31, 2018 Net operating loss carried forward $ 4,666,500 $ –– Bad debt allowance –– –– Officers’ accrued compensation 222,800 243,400 Accrued related party interest 10,100 20,700 Valuation allowance (4,899,400 ) (264,100 ) Net deferred income tax asset $ –– $ ––

Income Taxes_ Summary of Operat

Income Taxes: Summary of Operating Loss Carryforwards (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Summary of Operating Loss Carryforwards	Tax Year Net Operating Loss Expires 2016 $ 1,192,900 2036 2017 2,117,100 2037 2018 548,900 No Expiration 2019 9,165,700 No Expiration Total $ 13,024,600

Discontinued Operations_ Schedu

Discontinued Operations: Schedule of Discontinued Operations, Balance Sheet (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Discontinued Operations, Balance Sheet	May 14, 2018 Liabilities subject to compromise Accounts payable and accrued expenses $ 2,942,012 [1] Related party payables 376,430 [1] Note payable 185,000 [1] Note payable-merchant 974,826 Total liabilities subject to compromise 4,478,268 Net liabilities of discontinued operations $ 4,478,268 [1]

Discontinued Operations_ Sche_2

Discontinued Operations: Schedule of Discontinued Operations, Income Statement (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Discontinued Operations, Income Statement	May 14, 2018 Revenue $ –– Cost of sales –– Gross profit –– Sales, marketing and pharmacy expenses 170,630 General and administrative expenses 586,993 Operating loss (757,623 ) Interest expense (56,775 ) Loss on disposal of equipment (10,000 ) Net loss from discontinued operations $ (824,398 )

Segment Reporting_ Schedule of

Segment Reporting: Schedule of Segment Reporting Information, by Segment (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Segment Reporting Information, by Segment	Remote Care Systems Behavioral Health Services Diagnostics/ Corporate Pharmacy [1] Consolidated Totals December 31, 2019 Revenue $ 1,800 $ 76,800 $ 50,000 $ –– $ 128,600 Gross profit (loss) 480 61,293 50,000 –– 111,773 Operating loss (253,391 ) (169,485 ) (5,970,812 ) –– (6,393,688 ) Depreciation and amortization 9,196 109,760 2,016 –– 120,972 Interest expense 3,111 –– 579,397 –– 582,508 Gain (loss) on extinguishment of debt 101,367 –– (1,028,766 ) –– (927,399 ) Gain (loss) on fair value adjustments –– –– 194,511 –– 194,511 Loss on settlements (4,134,972 ) (4,134,972 ) Impairment loss –– –– 1,002,276 –– 1,002,276 Discount amortization 20,000 –– –– –– 20,000 Total assets 904,757 439,567 125,332 –– 1,359,896 Goodwill 785,060 –– –– 785,060 Additions to property and equipment –– –– 2,628 –– 2,628 December 31, 2018 Revenue $ 9,399 $ 1,800 $ –– $ –– $ 11,739 Gross profit (loss) (10,400 ) 1,800 –– –– (8,600 ) Operating loss (365,426 ) (191,446 ) (6,077,791 ) –– (6,634,663 ) Depreciation and amortization 9,196 109,760 1,664 –– 120,620 Interest expense 2,970 –– 2,161,560 –– 2,164,530 Gain on disposal of subsidiary –– –– 4,478,268 –– 4,478,268 Gain (loss) on extinguishment of debt –– –– 22,858,009 –– 22,858,009 Gain (loss) on fair value adjustments –– –– (123,875 ) –– (123,875 ) Discount amortization (340,000 ) –– 3,145,000 –– 2,805,000 Discontinued operations –– –– –– (824,398 ) (824,398 ) Total assets 913,636 439,567 11,154 –– 1,364,357 Goodwill 785,060 –– –– –– 785,060 Additions to property and equipment –– –– –– –– –– [1]

Overview and Nature of Busine_2

Overview and Nature of Business (Details)	12 Months Ended
	Dec. 31, 2019USD ($)
Details
Deconsolidation, RoxSan Pharmacy, Gain	$ 4,478,268

Overview and Nature of Busine_3

Overview and Nature of Business: Going Concern (Details)	Dec. 31, 2019USD ($)
Details
Cumulative Earnings (Deficit)	$ 32,057,254
Working Capital Deficit	$ 7,664,145

Restatement_ Restatement (Detai

Restatement: Restatement (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Previously Reported
CONSOLIDATED BALANCE SHEETS
Derivative liability, short-term	$ 0	$ 0
Debentures, convertible	755,627	0
Debentures, convertible, related party	428,132	0
Notes payable, convertible, net of discount	296,000	741,000
Total current liabilities	5,139,617	4,418,915
Derivative liability, long-term	0	0
Debentures, convertible, net of unamortized discount	226,050	0
Total liabilities	7,345,916	28,930,119
Additional paid in capital - preferred	1,415,653	665,803
Additional paid in capital - common	9,715,921	5,580,668
Accumulated deficit	(17,272,260)	(33,561,580)
Total stockholders' deficit	(5,981,559)	(27,178,083)
CONSOLIDATED STATEMENTS OF OPERATIONS
General and administrative expenses	6,552,693	3,997,512
Operating loss	(6,561,293)	(4,044,619)
Gain on extinguishment of debt	23,215,862	0
Loss on fair value adjustments	0	0
Discount amortization	(2,806,050)	0
Interest expense, net of income	(1,213,069)	(1,016,773)
Total other income (expenses)	23,675,011	(6,466,773)
Net income (loss) - continuing operations	17,113,718	(10,511,392)
Net income (loss)	16,289,320	(13,664,945)
Net income (loss) per common share - continuing operations - basic	0.115	(0.087)
Net income (loss) per common share - continuing operations - diluted	0.079	(0.059)
CONSOLIDATED STATEMENTS OF CASH FLOWS
Net income (loss)	17,113,718	(10,511,392)
Stock compensation/stock option expense	3,440,340	2,473,510
Discount amortization	2,806,050	0
Gain on extinguishment of debt	(23,215,862)	0
Loss on fair value adjustments	0	0
Debt accretion	0	0
Increase in accounts payable and accrued expenses	2,137,271	1,731,757
Discounts on long-term liabilities	2,806,050	5,450,000
Beneficial conversion feature of convertible promissory notes	0	0
Fair value of stock warrants	0	0
Embedded conversion option of convertible promissory notes	0	0
Supplemental Information
Interest paid-continuing operations	342,230	52,566
As Restated
CONSOLIDATED BALANCE SHEETS
Derivative liability, short-term	23,925	0
Debentures, convertible	724,903	0
Debentures, convertible, related party	411,006	0
Notes payable, convertible, net of discount	296,000	1,706
Total current liabilities	5,115,692	3,679,621
Derivative liability, long-term	34,000	0
Debentures, convertible, net of unamortized discount	184,870	0
Total liabilities	7,314,811	28,190,825
Additional paid in capital - preferred	1,699,000	665,803
Additional paid in capital - common	11,382,341	6,449,768
Accumulated deficit	(19,190,922)	(33,691,386)
Total stockholders' deficit	(5,950,454)	(26,438,789)
CONSOLIDATED STATEMENTS OF OPERATIONS
General and administrative expenses	6,626,063	4,125,612
Operating loss	(6,634,663)	(4,172,719)
Gain on extinguishment of debt	22,858,009	0
Loss on fair value adjustments	(123,875)	0
Discount amortization	(2,805,000)	0
Interest expense, net of income	(2,164,530)	(1,018,479)
Total other income (expenses)	22,242,872	(6,468,479)
Net income (loss) - continuing operations	15,608,209	(10,641,198)
Net income (loss)	14,783,811	(13,794,751)
Net income (loss) per common share - continuing operations - basic	0.105	(0.088)
Net income (loss) per common share - continuing operations - diluted	0.072	(0.060)
CONSOLIDATED STATEMENTS OF CASH FLOWS
Net income (loss)	15,608,209	(10,641,198)
Stock compensation/stock option expense	3,513,710	2,601,608
Discount amortization	2,805,000	0
Gain on extinguishment of debt	(22,858,009)	0
Loss on fair value adjustments	123,875	0
Debt accretion	1,107,753	1,706
Increase in accounts payable and accrued expenses	1,980,979	1,731,759
Discounts on long-term liabilities	2,805,000	5,450,000
Beneficial conversion feature of convertible promissory notes	347,487	592,582
Fair value of stock warrants	1,393	148,418
Embedded conversion option of convertible promissory notes	60,350	0
Supplemental Information
Interest paid-continuing operations	185,937	52,566
Revision of Prior Period, Adjustment
CONSOLIDATED BALANCE SHEETS
Derivative liability, short-term	23,925	0
Debentures, convertible	(30,724)	0
Debentures, convertible, related party	(17,126)	0
Notes payable, convertible, net of discount	0	(739,294)
Total current liabilities	(23,925)	(739,294)
Derivative liability, long-term	34,000	0
Debentures, convertible, net of unamortized discount	(41,180)	0
Total liabilities	(31,105)	(739,294)
Additional paid in capital - preferred	283,347	0
Additional paid in capital - common	1,666,420	869,100
Accumulated deficit	1,918,662	129,806
Total stockholders' deficit	(31,105)	(739,294)
CONSOLIDATED STATEMENTS OF OPERATIONS
General and administrative expenses	73,370	128,100
Operating loss	73,370	128,100
Gain on extinguishment of debt	(357,853)	0
Loss on fair value adjustments	123,875	0
Discount amortization	(1,050)	0
Interest expense, net of income	951,461	(1,706)
Total other income (expenses)	(1,432,139)	(1,706)
Net income (loss) - continuing operations	(1,505,509)	129,806
Net income (loss)	(1,505,509)	129,806
Net income (loss) per common share - continuing operations - basic	(0.010)	(0.001)
Net income (loss) per common share - continuing operations - diluted	(0.007)	0.001
CONSOLIDATED STATEMENTS OF CASH FLOWS
Net income (loss)	(1,505,509)	129,806
Stock compensation/stock option expense	73,370	128,098
Discount amortization	(1,050)	0
Gain on extinguishment of debt	357,853	0
Loss on fair value adjustments	123,875	0
Debt accretion	1,107,753	1,706
Increase in accounts payable and accrued expenses	(156,292)	2
Discounts on long-term liabilities	(1,050)	0
Beneficial conversion feature of convertible promissory notes	347,487	592,582
Fair value of stock warrants	1,393	148,418
Embedded conversion option of convertible promissory notes	60,350	0
Supplemental Information
Interest paid-continuing operations	$ (156,293)	$ 0

Significant Accounting Polic_22

Significant Accounting Policies: Fair Value of Financial Instruments: Derivatives (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Details
Derivative Liability-Convertible debentures	$ 0	$ 23,925
Derivative Liability-Embedded Conversion Option	5,800	0
Derivative Liability-Warrants	57,000	34,000
Total derivative liability	$ 62,800	$ 57,925

Significant Accounting Polic_23

Significant Accounting Policies: Fair Value of Financial Instruments: Schedule of Changes in Derivative Liabilities at Fair Value (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Details
Fair value of derivative liability, beginning	$ 57,925	$ 0
Increase in derivative liability-debentures	0	60,350
Increase in derivative liability-convertible promissory notes	30,620	0
Increase in derivative liability-warrants	182,000	623,900
Fair value adjustment-debentures	(26,691)	(2,500)
Fair value adjustment-convertible promissory notes	(24,820)	0
Fair value adjustment-warrants	(143,000)	126,375
Reclassification of warrant carrying value due to reset of exercise price	0	(750,200)
Reclassification of carrying value due to extinguishment	(13,234)	0
Fair value of derivative liability, beginning	$ 62,800	$ 57,925

Operating Leases_ Sub-Lease-San

Operating Leases: Sub-Lease-Santa Monica (Details)	12 Months Ended
	Dec. 31, 2019USD ($)
Details
Related Party Transaction, Description of Transaction	The Company entered into a sub-lease agreement with PearTrack Security Systems, Inc.
Short-Term Lease, Date of Lease	Dec. 1, 2017
Short-term Lease Commitment, Amount	$ 5,600

Operating Leases_ Sub-Lease-New

Operating Leases: Sub-Lease-New York (Details) - New York, NY	12 Months Ended
	Dec. 31, 2019USD ($)
Operating Lease, Date of Lease	May 1, 2019
Operating Lease, Payments, Monthly	$ 8,900
Operating Lease, Term of Lease (Mos)	14
Operating Lease, Lease Maturity	Jun. 30, 2020
Operating Lease, Right-of-Use Asset	$ 118,585
Operating Lease, Discount Rate	8.00%

Operating Leases_ Lease Amortiz

Operating Leases: Lease Amortization (Details) - New York, NY	3 Months Ended
	Dec. 31, 2019USD ($)
Operating Lease, Expense	$ 66,409
Operating Lease Liability	$ 52,176

Operating Leases_ Operating L_3

Operating Leases: Operating Lease, Future Miinimum Payments (Details) - 2020	12 Months Ended
	Dec. 31, 2019USD ($)
Operating Lease, Minimum Payments	$ 53,400
Operating Lease, Amounts Treated as Interest	1,224
Operating Lease, Present Value of Lease Payments	$ 52,176

Operating Leases_ Operating L_4

Operating Leases: Operating Lease, Lease Costs (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Details
Operating lease costs	$ 71,200	$ 0
Short-term lease costs	68,320	73,351
Total lease costs	$ 139,520	$ 73,351

Operating Leases_ Lease Costs (

Operating Leases: Lease Costs (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Details
Total lease costs	$ 139,520	$ 73,351

Property and Equipment_ Prope_2

Property and Equipment: Property and Equipment (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Details
Computer equipment	$ 6,615	$ 3,987
Medical devices	45,194	45,194
Property and equipment, gross	51,809	49,181
Accumulated depreciation	(49,533)	(49,181)
Property and equipment, net	$ 0	$ 0

Property and Equipment_ Impairm

Property and Equipment: Impairment Losses (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Details
Impariment Loss	$ 2,276	$ 0

Property and Equipment_ Depreci

Property and Equipment: Depreciation Expense (Details) - USD ($)	3 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Details
Depreciation	$ 352	$ 0

Intangible Assets_ Schedule o_2

Intangible Assets: Schedule of Intangible Assets, Net (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Details
Products and processes	$ 12,500	$ 12,500
Trademarks, patents and technology	150,700	150,700
Customer lists/relationships	30,000	30,000
Non-compete agreement	30,000	30,000
Marketing related intangibles	64,000	64,000
Software	510,300	510,300
Total Intangible Assets, Gross	797,500	797,500
Accumulated amortization	(339,085)	(218,465)
Intangible Assets, Net	$ 458,415	$ 579,035

Intangible Assets_ Amortization

Intangible Assets: Amortization Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Details
Amortization Expense	$ 120,620	$ 120,620

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses: Summary (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Details
Accounts Payable, Vendors	$ 1,128,381	$ 830,590
Credit cards payable	42,552	42,552
Payroll taxes payable	81,718	78,608
Accrued Interest	376,065	450,187
Accrued payroll and payroll taxes	338,612	402,053
Other liabilities	115,650	601,148
Reserve-Legal Fees	0	250,000
Total accounts payable and accrued expenses	$ 2,082,978	$ 2,655,138

Accounts Payable and Accrued _4

Accounts Payable and Accrued Expenses: Payroll Taxes Payable (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Details
Payroll Taxes Payable, Penalties	$ 17,475	$ 17,475
Payroll Taxes Payable, Interest	$ 7,312	$ 4,202

Accounts Payable and Accrued _5

Accounts Payable and Accrued Expenses (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Extinguishment of Debt	$ 101,367	$ 341,606
Reserve-Legal Fees	0	250,000
Accounts Payable
Extinguishment of Debt	101,367	284,714
Accrued Interest
Extinguishment of Debt	0	56,892
RoxSan Pharmacy, Inc
Payroll Taxes Payable, Trust Fund Taxes	$ 115,650	$ 601,148

Settlments Payable_ Promissory

Settlments Payable: Promissory Note (Details)	12 Months Ended
	Dec. 31, 2019USD ($)
Pending Litigation
Gain Contingency, Promissory Note, Principal	$ 20,500,000
Gain Contingency, Promissory Note, Accrued Interest	2,278,281
Gain Contingency, Promissory Note, Total	$ 22,778,281
Secured Debt, In Litigation
Note Payable, Date	Aug. 13, 2015
Note Payable, Principal	$ 20,500,000
Note Payable, Interest Rate	6.00%
Note Payable, Maturity Date	Aug. 13, 2018
Note Payable, Discount, Total	$ 15,300,000

Settlments Payable (Details)

Settlments Payable (Details)	12 Months Ended
	Dec. 31, 2019USD ($)shares
Litigation Settlement, Date	Feb. 12, 2020
Pending Litigation
Litigation Settlement, Contingent Liability, Cancellation, Principal	$ 20,500,000
Litigation Settlement, Contingent Liability, Cancellation, Accrued Interest (Est)	4,500,000
Litigation Settlement, Amount, Cash, Total	4,000,000
Litigation Settlement, Amount, Cash, Due 90 days	1,250,000
Litigation Settlement, Amount, Cash, Due 1 year	1,250,000
Litigation Settlement, Amount, Cash, Due 2 years	$ 1,500,000
Litigation Settlement, Amount, Stock, Shares (Millions) | shares	10
Litigation Settlement, Amount, Sale Contingency, Pct	40.00%
Litigation Settlement, Amount, Sale Contingency, Years (Max)	2
Litigation Settlement, Amount, Sale Contingency, Pct to Melamed	10.00%
Litigation Settlement, Amount, Sale Contingency, Maximum Due	$ 3,000,000

Settlments Payable_ Schedule _2

Settlments Payable: Schedule of Melamed Settlement (Details) - Pending Litigation	Dec. 31, 2019USD ($)
Cash settlement, gross	$ 4,000,000
Less: unamortized present value discount	(415,800)
Net present value of settlement	3,584,200
Common stock, at FMV	480,000
Total settlement	4,064,200
Due within 12 months	2,824,200
Due December 31, 2021	$ 1,240,000

Debt Disclosure_ Summary (Detai

Debt Disclosure: Summary (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Short-term:
Debentures, Convertible	$ 0	$ 724,903
Notes Payable	345,000	0
Note Payable, Bank	18,616	0
Notes Payable, Convertible	1,102,364	296,000
Notes Payable, Short Term, Total	1,465,980	1,020,903
Long-term:
Debentures, Convertible, Net of Unamortized Discount	0	184,870
Notes Payalbe, Secured, Net of Unamortized Discount	0	28,995
Notes Payable, Convertible	760,154	720,154
Notes Payable, Long Term, Total	760,154	934,019
Notes Payable, Total	$ 2,226,134	$ 1,954,922

Debt Disclosure_ Non-Related _2

Debt Disclosure: Non-Related Party Convertible Notes Payable (Details)	12 Months Ended
	Dec. 31, 2019USD ($)$ / shares
Investor Group A
APR	10.00%
Accrued Interest | $	$ 21,013
Conversion Price	$ 0.10
Term/Due	02/28/2020
Lender Group A
APR	12.00%
Accrued Interest | $	$ 10,000
Conversion Price	$ 0.10
Term/Due	02/28/2020
Lender Group B
APR	12.00%
Accrued Interest | $	$ 59,688
Term/Due	04/30/2020 to 12/31/2020
Lender Group B | Minimum
Conversion Price	$ 0.10
Lender Group B | Maximum
Conversion Price	$ 0.12
Lender Group C
APR	10.00%
Accrued Interest | $	$ 5,944
Term/Due	10/31/2020 to 12/31/2020
Lender Group C | Minimum
Conversion Price	$ 0.6500
Lender Group C | Maximum
Conversion Price	$ 0.7000
The Kasper Group, Ltd
APR	7.00%
Accrued Interest | $	$ 85,431
Conversion Price	$ 0.10
Term/Due	12/31/2021
Joseph M. Redmond
APR	5.00%	[1]
Accrued Interest | $	$ 148,358	[1]
Conversion Price	$ 0.10	[1]
Term/Due	07/31/2017	[1]
Accrued Interest | $	$ 330,434
[1]	F91

Debt Disclosure_ Short-Term (De

Debt Disclosure: Short-Term (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Minimum | Lender Group B
Convertible Promissory Notes, Conversion Rate	$ 0.10
Convertible Promissory Notes, Conversion Rate, Discounted	65.00%
Maximum | Lender Group B
Convertible Promissory Notes, Conversion Rate	$ 0.12
Convertible Promissory Notes, Conversion Rate, Discounted	70.00%
Notes Payable, Non-Convertible
Notes Payable, Principal	$ 375,000
Notes Payable, Principal, Repayments	$ 30,000
Notes Payable, Interest Rate	8.00%
Notes Payable, Consideration, Stock, Group 1, Per Lender	400,000
Notes Payable, Consideration, Stock, Group 1, Total	1,200,000
Notes Payable, Consideration, Stock, Group 1, Total, Value	$ 190,200
Notes Payable, Consideration, Stock, Group 2, Total	2,400,000
Notes Payable, Consideration, Stock, Group 2, Total, Value	$ 240,000
Notes Payable, Non-Convertible | Minimum
Notes Payable, Maturity	Dec. 31, 2019
Notes Payable, Non-Convertible | Maximum
Notes Payable, Maturity	Aug. 20, 2020
Notes Payable, Convertible
Notes Payable, Convertible	$ 1,490,000	$ 825,000
Notes Payable, Convertible, Warrants	5,800,000	6,025,000
Notes Payable, Convertible, Discount, Total	$ 308,840	$ 605,000
Notes Payable, Convertible, Discount, OID	96,220	0
Notes Payable, Convertible, Discount, Beneficial Conversion Feature	0	223,607
Notes Payable, Convertible, Discount, Embedded Conversion Option	30,620	0
Notes Payable, Convertible, Discount, Warrants FV	182,000	381,393
Notes Payable, Convertible, Discount, Derivative Liability	212,620	380,000
Notes Payable, Convertible, To Debentures, Principal		600,000
Notes Payable, Convertible, To Debentures, Interest		55,627
Notes Payable, Convertible, Warrants, Intrinsic Value		240,000
Notes Payable, Convertible, To Debentures, Embedded Conversion Option		30,725
Notes Payable, Convertible, To Debentures, Loss on Exchange		105,320
Notes Payable, Convertible, Accretion	173,784	1,098,974
Notes Payable, Convertible, Repayments, Total	564,023	670,000
Notes Payable, Convertible, Repayments, Conversions, Value	135,443
Debentures, Repayments, Total	1,169,299	0
Debentures, Repayments, Cash	542,369	0
Debentures, Repayments, Conversions, Value	626,930	0
Debentures, Repayments, Conversions, Loss on Extinguishment	305,912	0
Convertible Promissory Notes
Covertible Notes Payable, Principal, Cash Repayment	428,580	$ 50,000
Covertible Notes Payable, Principal, To Common Stock	$ 620,000
Convertible Promissory Notes | Minimum
Convertible Promissory Notes, Interest Rate	10.00%
Convertible Promissory Notes | Maximum
Convertible Promissory Notes, Interest Rate	12.00%

Debt Disclosure (Details)

Debt Disclosure (Details)	Dec. 31, 2019USD ($)$ / shares	Dec. 31, 2018USD ($)$ / shares	Dec. 31, 2019USD ($)$ / shares	Dec. 31, 2018USD ($)$ / sharesshares
Notes Payable, Convertible, Principal	$ 760,154	$ 720,154	$ 760,154	$ 720,154
Extinguishment of Debt, Principal			101,367	341,606
Extinguishment of Debt, Gain			$ (927,399)	22,858,009
Convertible Debentures
Debentures, Principal				$ 250,000
Debentures, Warrants | shares				600,000
Debentures, Discount, Total				$ 67,500
Debentures, Discount, OID				25,000
Debentures, Discount, Embedded Conversion Option				12,500
Debentures, Discount, Warrants FV				30,000
Debentures, Discount, Derivative Liability				42,500
Debentures, Maturity (Year)	2,021		2,021
Long Term Debt, Conversion Rate | $ / shares	$ 0.10		$ 0.10
Debentures, Accretion			$ 9,816	2,370
Debentures, Repayments, Cash			212,000	0
Debentures, Repayments, Conversions, Value			158,549	0
Debentures, Repayments, Conversions, Loss on Extinguishment			168,159	0
Note Payable, Bank
Note Payable, Bank, Repayments, Principal			10,379	9,245
Note Payable, Bank, Repayments, Interest			1,423	$ 632
Note Payable, Bank, Interest Rate				7.48%
Note Payable, Bank, Monthly Payment			$ 1,475
Note Payable, Bank, Maturity Date			Jul. 17, 2020
Note Payable, Bank, Principal Balance			$ 18,616
Convertible Promissory Notes
Long Term Debt, Conversion Rate | $ / shares	$ 0.10	$ 0.10	$ 0.10	$ 0.10
Notes Payable, Convertible, Extension Fee		$ 40,000
Notes Payable, Convertible, Principal	$ 184,000	$ 144,000	$ 184,000	$ 144,000
Convertible Promissory Notes | Minimum
Notes Payable, Convertible, Interest Rate			5.00%
Notes Payable, Convertible, Maturity (Year)	2,017		2,017
Convertible Promissory Notes | Maximum
Notes Payable, Convertible, Interest Rate			7.00%
Notes Payable, Convertible, Maturity (Year)	2,021		2,021
Unsecured Debt
Extinguishment of Debt, Principal			$ 95,975	95,975
Extinguishment of Debt, Interest			56,892
Extinguishment of Debt, Gain				$ 152,867
Secured Debt, In Litigation
Extinguishment of Debt, Principal	$ 20,500,000
Extinguishment of Debt, Interest			2,278,281
Extinguishment of Debt, Gain			$ 22,778,281

Debt Disclosure_ Short-Term Sum

Debt Disclosure: Short-Term Summary (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Debentures
Short-Term Non-Related Party Debt	$ 0	$ 724,903
Notes Payable, Non-Convertible
Short-Term Non-Related Party Debt	345,000	0
Note Payable, Bank
Short-Term Non-Related Party Debt	18,616	0
Convertible Promissory Notes
Short-Term Non-Related Party Debt	$ 1,102,364	$ 296,000

Debt Disclosure_ Short-Term Acc

Debt Disclosure: Short-Term Accrued Interest (Details) - Short-Term Debt - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Interest Expense	$ 201,658	$ 270,142
Accrued Interest	$ 105,372	$ 185,741

Debt Disclosure_ Long Term Summ

Debt Disclosure: Long Term Summary (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Long-term Debt	$ 760,154	$ 934,019
Convertible Debentures
Long-term Debt	0	207,500
Debt Discount
Long-term Debt	0	22,630
Convertible Promissory Notes
Long-term Debt	760,154	720,154
Notes Payable, Convertible, Pending Litigation
Long-term Debt	$ 576,154	$ 576,154

Debt Disclosure_ Long-Term Accr

Debt Disclosure: Long-Term Accrued Interest (Details) - Long-Term Debt - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Interest Expense	$ 85,469	$ 739,383
Accrued Interest	$ 234,432	$ 190,386

Debt Disclosure_ Future Maturit

Debt Disclosure: Future Maturities of Long-Term Debt (Details)	Dec. 31, 2019USD ($)
2020
Long Term Debt, Principal	$ 778,770
2021
Long Term Debt, Principal	$ 184,000

Debt Disclosure_ Accrued Intere

Debt Disclosure: Accrued Interest (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Details
Accrued Interest, Current Period	$ 287,127	$ 1,009,525
Accrued Interest	339,804	376,127
Accrued Interest, Extinguished	0	2,335,173
Accrued Interest, Converted to Common Stock	$ 10,398	$ 55,613

Related Party Transactions_ T_2

Related Party Transactions: Table of Related Party Transactios (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Details
Related Party, Cash Advances	$ 796,175	$ 869,859
Accrued benefits and cash advances	312,305	134,861
Related Party, Total Payables	1,108,480	1,004,720
Debentures, Convertible	0	411,006
Related Party, Notes Payable, Convertible	491,100	491,100
Related Party, Notes Payable	759,446	0
Related Party, Total	$ 2,359,026	$ 1,906,826

Related Party Transactions_ Sum

Related Party Transactions: Summary Totals (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Related Party Transactions, Total	$ 2,359,026	$ 1,906,826
Accrued Compensation
Due to Related Parties	796,175	869,859
Accrued Benefits and Cash Advances
Due to Related Parties	312,305	134,861
Debentures, Convertible
Due to Related Parties	0	411,006
Debentures, Convertible, ECO
Due to Related Parties	0	17,125
Notes Payable
Due to Related Parties	759,446	0
Notes Payable, Convertible
Due to Related Parties	$ 491,100	$ 491,100

Related Party Transactions_ Con

Related Party Transactions: Convertible Debt (Details) - Huntington Chase Ltd	12 Months Ended
	Dec. 31, 2019USD ($)
Note Payable, Convertible, Related Party, Principal	$ 491,100
Note Payable, Convertible, Related Party, Interest Rate	7.00%
Note Payable, Convertible, Related Party, Accrued Interest	$ 9,795
Note Payable, Convertible, Related Party, Conversion Price	$ 0.08
Note Payable, Convertible, Related Party, Maturity Date	Dec. 31, 2023

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Accrued Compensation
Due to Related Parties, Increases	$ 1,586,724	$ 1,371,446
Due to Related Parties, Decreases, Payments in Cash	802,500	510,500
Due to Related Parties, Decreases, Conversions to Common Stock	753,510	0
Due to Related Parties, Decreases, Conversions to Preferred Stock	0	450,000
Accrued Benefits and Cash Advances
Due to Related Parties, Increases	399,249	104,151
Due to Related Parties, Decreases, Payments in Cash	221,805	$ 97,587
Due to Related Parties, Increases, Debt Purchase, Proceeds Loaned to Company	575,132
Due to Related Parties, Decreases, Debt Purchase	$ 575,132

Related Party Transactions_ Pro

Related Party Transactions: Promissory Notes (Details)	12 Months Ended
	Dec. 31, 2019USD ($)$ / sharesshares
Huntington Chase Ltd
Convertible Promissory Note, Date	Sep. 30, 2015
Convertible Promissory Note, Principal	$ 631,100
Convertible Promissory Note, Principal, Repayment	100,000
Convertible Promissory Note, Principal, Conversion, Amount	$ 40,000
Convertible Promissory Note, Interest Rate	7.00%
Convertible Promissory Note, Conversion Price | $ / shares	$ 0.10
Convertible Promissory Note, Modified, Date	Dec. 31, 2018
Convertible Promissory Note, Modified, Principal	$ 491,100
Convertible Promissory Note, Modified, Maturity Date	Dec. 31, 2023
Convertible Promissory Note, Modified, Conversion, Amount	$ 437,000
Convertible Promissory Note, Modified, Conversion, Shares | shares	4,370,000
Convertible Promissory Note, Modified, Principal, Increase	$ 437,000
Convertible Promissory Note, Modified, Conversion Price | $ / shares	$ 0.08
Beneficial Owner
Convertible Promissory Note, Principal	$ 337,750
Convertible Promissory Note, Interest Rate	12.00%
Convertible Promissory Note, Conversion Price | $ / shares	$ 0.10
Convertible Promissory Note, To Debentures, Principal	$ 337,750
Convertible Promissory Note, Warrants Issued | shares	3,377,500
Convertible Promissory Note, Discount, Total	$ 337,750
Convertible Promissory Note, Beneficial Conversion Feature	123,850
Convertible Promissory Note, Derivative Liability	213,900
Convertible Promissory Note, Debt Accretion	$ 6,409
Convertible Promissory Note, Warrants, Term	3
Convertible Promissory Note, Warrants, Conversion Price | $ / shares	$ 0.10
Convertible Promissory Note, To Debentures, Date	Nov. 14, 2018
Convertible Promissory Note, To Debentures, Interest	$ 34,090
Debentures, Principal	428,132
Convertible Promissory Note, To Debentures, Embedded Conversion Option	17,125
Convertible Promissory Note, To Debentures, Intrinsic Value of Warrants	135,100
Convertible Promissory Note, To Debentures, Loss on Extinguishment	$ 252,533
Debentures, Interest Rate	10.00%
Debentures, Maturity Date	Feb. 28, 2019
Debentures, Conversion Price | $ / shares	$ 0.12
Senior Secured Notes, Date	Jul. 25, 2019
Debentures, To Senior Promissory Notes, Principal	$ 411,006
Debentures, To Senior Promissory Notes, Interest	42,778
Senior Secured Notes, Principal	$ 759,446
Senior Secured Notes, Interest Rate	8.00%
Senior Secured Notes, Payment 1, Amount	$ 126,152
Senior Secured Notes, Payment 1, Date	Dec. 31, 2019
Senior Secured Notes, Payment 2, Amount	$ 300,000
Senior Secured Notes, Payment 2, Date	Dec. 31, 2020
Senior Secured Notes, Payment 3, Date	Dec. 31, 2021
Senior Secured Notes, Shares Issued | shares	1,380,811
Senior Secured Notes, Shares Issued, Value	$ 131,315
Senior Secured Notes, Warrants Issued, Value	$ 92,150
Senior Secured Notes, Warrants Issued | shares	2,528,413
Senior Secured Notes, Warrants Issued, Term (Yrs)	5
Senior Secured Notes, Warrants Issued, Exercise Price | $ / shares	$ 0.10461
Senior Secured Notes, Loss on Exchange	$ 434,837
Senior Secured Notes, Loss on Exchange, Derivative Liability	$ 2,140

Related Party Transactions_ S_2

Related Party Transactions: Summary (Details) - Notes Payable, Convertible - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Convertible Promissory Note, Principal	$ 1,250,546	$ 491,100
Related Party Notes Payable	$ 491,100	$ 491,100

Related Party Transactions_ Acc

Related Party Transactions: Accrued Interest (Details) - Notes Payable, Convertible - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Convertible Promissory Notes, Related Party, Accrued Interest	$ 105,111	$ 66,840
Convertible Promissory Notes, Interest, Paid	0	798
Convertible Promissory Notes, Related Party, Accrued Interest, To Common Stock	100,132	0
Convertible Promissory Notes, Related Party, Accrued Interest, To Principal	42,778	71,839
Convertible Promissory Notes, Accrued Interest, Total	$ 36,261	$ 74,060

Related Party Transactions_ Sto

Related Party Transactions: Stock Issuances (Details)	Dec. 31, 2019	Sep. 30, 2019	Sep. 18, 2019	Jul. 31, 2019USD ($)	May 15, 2019	Sep. 30, 2018	Aug. 13, 2018	Jan. 11, 2018
Common Stock, Shares, Issued
Shares Issued for Stock Award					3,000,000			6,000,000
Shares Issued for Stock Options							1,071,430
Shares Issued for Debt Exchange				$ 1,380,811
Shares Issued for Debt Conversion			4,370,000
Shares Issued for SAFE Agreement		6,000,000
Shares Issued for Debt Settlement	8,000,000
Common Stock, Shares, Price Per Share
Shares Issued for Stock Award								0.001
Shares Issued for Stock Options							0.05
Common Stock, Shares, Cash Proceeds
Shares Issued for Stock Award								6,000
Common Stock, Shares, Value
Shares Issued for Stock Award					201,300
Shares Issued for Stock Options							187,500
Shares Issued for Debt Exchange				131,315
Shares Issued for SAFE Agreement		375,000
Shares Issued for Debt Settlement	400,000
Preferred Stock, Shares, Issued
Shares Issued for Accrued Comp						90,000
Preferred Stock, Shares, Price Per Share
Shares Issued for Accrued Comp						5
Preferred Stock, Shares, Value
Shares Issued for Accrued Comp						450,000
Preferred Stock, Beneficial Conversion Feature
Shares Issued for Accrued Comp						100,578
Preferred Stock, Warrants, Shares
Shares Issued for Accrued Comp						1,250,000
Preferred Stock, Warrants, Value
Shares Issued for Accrued Comp						75,000
Preferred Stock, Warrants, Life (Yrs)
Shares Issued for Accrued Comp						3
Preferred Stock, Warrants, Exercise Price
Shares Issued for Accrued Comp						0.25
Common Stock, Shares, Vested (Pct)
Shares Issued for Stock Award					0.2500
Common Stock, Warrants, Issued
Shares Issued for Debt Exchange				2,528,413
Shares Issued for SAFE Agreement		6,000,000
Common Stock, Warrants, Value
Shares Issued for Debt Exchange				92,150
Shares Issued for SAFE Agreement		45,600
Common Stock, Warrants, LIfe (Yrs)
Shares Issued for Debt Exchange				5
Shares Issued for SAFE Agreement		3
Common Stock, Warrants, Exercise Price
Shares Issued for Debt Exchange				$ 0.10
Shares Issued for SAFE Agreement		0.25
Common Stock, Conversion of Debt, Amount
Shares Issued for Debt Conversion			437,000

Related Party Transactions_ Agr

Related Party Transactions: Agreements (Details)	12 Months Ended
	Dec. 31, 2019USD ($)$ / sharesshares
Chief Financial Officer
Executive Agreement, Term (Years)	1
Executive Agreement, Compensation, Year 1	$ 216,000
Executive Agreement, Compensation, Signing Bonus	$ 100,000
Executive Agreement, Compensation, Stock Options | shares	1,000,000
Executive Agreement, Compensation, Stock Options, Price Per Share | $ / shares	$ 0.25
Executive Agreement, Compensation, Stock Options, Life (Years)	5
Executive Agreement, Compensation, Stock Options, Vesting Period (Years)	1
Huntington Chase Ltd
Consulting Agreement, Date	Jan. 1, 2018
Consulting Agreement, Term	3
Consulting Agreement, Monthly Fee, Year 1	$ 25,000
Consulting Agreement, Monthly Fee, Year 2	30,000
Consulting Agreement, Monthly Fee, Year 3	$ 35,000
Consulting Agreement, Stock Options | shares	4,000,000
Consulting Agreement, Stock Options, Exercise Price | $ / shares	$ 0.25
Consulting Agreement, Stock Options, Life (Years)	5
Consulting Agreement, Stock Options, Immediiate Vesting, Pct	25.00%
Board Member
Consulting Agreement, Date	Jan. 1, 2019
Consulting Agreement, Term	1
Consulting Agreement, Compensation, Annual	$ 60,000
Consulting Agreement, Compensation, SIgning Bonus	50,000
Consulting Agreement, Compensation, Promissory Note	$ 20,000
Consulting Agreement, Compensation, Promissory Note, Term	1
Consulting Agreement, Compensation, Promissory Note, Int Rate	10.00%
Consulting Agreement, Compensation, Stock Award, Value	$ 70,000
Consulting Agreement, Compensation, Stock Options | shares	1,000,000
Consulting Agreement, Compensation, Stock Options, Price Per Share | $ / shares	$ 0.25
Consulting Agreement, Compensation, Stock Options, Life (Years)	5
Consulting Agreement, Compensation, Stock Options, Vesting Period (Years)	1
Chief Operating Officer
Employment Agreement, Effective Date	May 15, 2019
Employment Agreement, Term	2
Employment Agreement, Compensation, Year 1	$ 250,000
Employment Agreement, Compensation, Year 2	$ 275,000
Employment Agreement, Stock Award, Shares | shares	3,000,000
Employment Agreement, Stock Award, Value	$ 201,300
Employment Agreement, Stock Award, Cash Paid	$ 3,000
Employment Agreement, Stock Award, Initial Vesting (Pct)	25.00%
Employment Agreement, Stock Options, Shares | shares	3,000,000
Employment Agreement, Stock Options, Exercise Price | $ / shares	$ 0.25
Employment Agreement, Stock Options, Value	$ 195,600
Employment Agreement, Stock Options, Term (Yrs)	5
Employment Agreement, Stock Options, Initial Vesting (Pct)	25.00%
Employment Agreement, Stock Options, Expected Term	4 years 9 months
Employment Agreement, Stock Options, Expected Volatility	2.21%
Employment Agreement, Stock Options, Risk Free Interest Rate	2.15%
Employment Agreement, Stock Options, Dividiend Yield	0.00%

Commitments And Contingencies_

Commitments And Contingencies: Revenue Share & Royalties (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Qolpom Shareholders
Contingency, Revenue Share, Maximum Payment	$ 2,000,000
Contingency, Royalty, Percent	3.00%
Contingency, Revenue Share, Present Value	$ 442,000	$ 430,000
Contingency, Royalty, Present Value	318,000	310,000
ProEventa
Contingency, Revenue Share, Maximum Payment	$ 3,000,000
Contingency, Royalty, Percent	3.00%
Contingency, Revenue Share, Present Value	$ 968,000	1,040,000
Contingency, Royalty, Present Value	471,000	$ 690,000
Contingency, Royalty, Maximum Payment	$ 25,000,000

Convertible Preferred Stock_ Au

Convertible Preferred Stock: Authorized and Issued Shares (Details) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Outstanding	977,352	863,691
Preferred Stock
Preferred Stock, Shares Outstanding	977,352	1,013,691

Convertible Preferred Stock_ Pr

Convertible Preferred Stock: Preferred Stock Designations (Details)	12 Months Ended
	Dec. 31, 2019$ / shares
Series A Preferred Stock
Preferred Stock, Voting Rights	no voting rights
Preferred Stock, Conversion Ratio	20
Preferred Stock, Dividend Rate, Percentage	7.00%
Series B Preferred Stock
Preferred Stock, Voting Rights	no voting rights
Preferred Stock, Conversion Ratio	20
Preferred Stock, Warrants, Pct	50.00%
Preferred Stock, Warrants, Life (Yrs)	2
Preferred Stock, Warrants, Exercise Price	$ 0.75
Preferred Stock, Dividend Rate, Percentage	10.00%
Series C Preferred Stock
Preferred Stock, Voting Rights	no voting rights
Preferred Stock, Conversion Ratio	41.67
Preferred Stock, Warrants, Pct	50.00%
Preferred Stock, Warrants, Life (Yrs)	3
Preferred Stock, Warrants, Exercise Price	$ 0.25
Preferred Stock, Dividend Rate, Percentage	8.00%

Convertible Preferred Stock_ Se

Convertible Preferred Stock: Series C Preferred Offering (Details) - Series C Preferred Stock	12 Months Ended
	Dec. 31, 2019USD ($)$ / sharesshares
Preferred Stock, Price Per Share	$ 5
Preferred Stock, Minimum Shares | shares	20,000
Preferred Stock, Minimum ($) | $	$ 100,000
Preferred Stock, Conversion Rate ($)	$ 0.12
Preferred Stock, Conversion Ratio	41.67
Preferred Stock, Warrants, Life (Yrs)	3
Preferred Stock, Warrants, Exercise Price	$ 0.25
Preferred Stock, Warrants, Pct	50.00%

Convertible Preferred Stock_ Ac

Convertible Preferred Stock: Activity (Details)	May 15, 2019USD ($)shares	Apr. 01, 2019shares	Dec. 31, 2019USD ($)$ / sharesshares	Sep. 30, 2019USD ($)shares
Series C Preferred Stock
Preferred Stock, Issued			150,000
Preferred Stock, Shares Issued, Price Per Share | $ / shares			$ 5
Preferred Stock, Shares Issued, Investors			60,000
Preferred Stock, Shares Issued, Investors, Proceeds | $			$ 300,000
Preferred Stock, Shares Issued, Officers			90,000
Preferred Stock, Shares Issued, Officers, Proceeds | $			$ 450,000
Preferred Stock, Shares Issued, Paid In Capital | $			749,850
Preferred Stock, Shares Issued, Beneficial Conversion Feature | $			283,347
Preferred Stock, Shares Issued, Beneficial Conversion Feature, Officers | $			$ 100,578
Series A Preferred Stock
Preferred Stock, Cancelled, Treasury Shares				36,339
Preferred Stock, Cancelled, Treasury Shares | $				$ 100,000
Preferred Stock, Cancelled, Paid in Capital | $				$ 99,964
Preferred Stock-Dividends Paid in Kind		21,121
Preferred Stock.Treasury Shares		57,500
Preferred Stock, Treasury Shares, Reissued	57,500
Preferred Stock, Treasury Shares, Reissued, Proceeds | $	$ 69,000
Preferred Stock, Converted	57,500
Preferred Stock, Shares Issued Upon Conversion	1,150,000
Preferred Stock, Conversion Rate, To Common	20

Common Stock_ Authorized and Is

Common Stock: Authorized and Issued Shares (Details) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares, Outstanding	250,124,755	158,113,141
Common Class A
Common Stock, Shares Authorized	500,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares, Outstanding	250,124,755	158,113,141

Common Stock_ Activity (Details

Common Stock: Activity (Details)	12 Months Ended
	Dec. 31, 2019shares	Dec. 31, 2018shares
Stock Issued During Period, Shares, Period Increase (Decrease)	92,011,614	21,358,611
Common Stock, Shares, Issued
Shares Issued, Conversion of Debt	24,682,217	6,881,130
Shares Issued, Conversion of Debt, Related Party	12,370,000	0
Shares Issued, Exercise of Stock Options	0	846,051
Shares Issued, Exercise of Stock Options, Related Party	0	1,071,430
Shares Issued, Stock Awards	8,756,919	1,750,000
Shares Issued, Stock Awards, Related Party	3,000,000	0
Shares Issued, Cash Subscription	12,500,000	2,000,000
Shares Issued, Debt Service	3,010,811	2,810,000
Shares Issued, SAFE, Total	18,000,000	0
Shares Issued, SAFE, Officers	6,000,000	0
Shares Issued, Officers	0	6,000,000
Common Stock, Conversion of Debt, Amount
Shares Issued, Conversion of Debt	1,735,330	675,614
Shares Issued, Conversion of Debt, Related Party	837,000	0
Shares Issued, SAFE, Officers	375,000	0
Common Stock, APIC
Shares Issued, Conversion of Debt	1,710,649	668,733
Shares Issued, Conversion of Debt, Related Party	824,630	0
Shares Issued, Exercise of Stock Options	0	454,908
Shares Issued, Stock Awards	865,191	277,360
Shares Issued, Stock Awards, Related Party	198,300	0
Shares Issued, Cash Subscription	1,015,000	238,900
Shares Issued, Debt Service	356,504	278,190
Shares Issued, SAFE, Total	1,107,000	0
Shares Issued, Officers	0	984,000
Common Stock, Shares, Value
Shares Issued, Stock Awards	874,548	279,110
Shares Issued, Stock Awards, Related Party	201,300	0
Shares Issued, Debt Service	359,514	281,000
Shares Issued, SAFE, Total	15,000	0
Deferred Compensation
Shares Issued, Stock Awards	20,237	153,000
Shares Issued, Stock Awards, Related Party	198,300	0
Deferred Compensation, Future Expense, Term (Months)
Shares Issued, Stock Awards	9
Shares Issued, Stock Awards, Related Party	9
Common Stock, Proceeds, Cash
Shares Issued, Cash Subscription	1,027,500	240,000
Shares Issued, SAFE, Total	735,000	0
Shares Issued, Officers	0	6,000
Common Stock, Shares
Shares Issued, Conversion of Series A Preferred	1,150,000	0
Shares Issued, Investment	6,666,667	0
Shares Issued, Retirement of Warrants	1,875,000	0
Preferred Stock, Value
Shares Issued, Conversion of Series A Preferred	69,000	0
Common Stock, Paid In Capital
Shares Issued, Conversion of Series A Preferred	67,850	0
Shares Issued, Investment	993,333	0
Shares Issued, Retirement of Warrants	176,825	0
Common Stock, Value
Shares Issued, Investment	1,000,000	0
Shares Issued, Retirement of Warrants	178,700	0

Common Stock_ Restricted Stock

Common Stock: Restricted Stock Awards (Details)	12 Months Ended
	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)shares
Details
Restricted Stock Award, Grants, Shares | shares	3,830,000	3,660,000
Restricted Stock Award, Grants, Value | $	$ 264,350	$ 434,000
Restricted Stock Award, Vested, Shares | shares	4,237,595	6,827,368
Restricted Stock Award, Vested, Value | $	$ 685,553	$ 1,095,193
Restricted Stock Award, Unvested, Shares | shares	4,805,600	5,888,195
Restricted Stock Award, Unvested, Value | $	$ 660,069	$ 1,148,809
Restricted Stock Award, Unvested, Future Expense, Term (Months)	15

Common Stock_ Schedule of Res_2

Common Stock: Schedule of Restricted Stock Units Activity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Restricted Stock Award
Restricted Stock Awards, Outstanding	4,805,600	5,888,195	9,055,563
Restricted Stock Awards, Granted	3,830,000	3,660,000
Restricted Stock Awards, Vested	(4,237,595)	(6,827,368)
Forfeited/Canceled	(675,000)
Deferred Compensation
Restricted Stock Award, Deferred Compensation, Balance	$ 660,069	$ 1,148,809	$ 1,810,002
Restricted Stock Award, Deferred Compensation, Granted	264,350	434,000
Restricted Stock Award, Deferred Compensation, Vested	(685,553)	$ (1,095,193)
Restricted Stock Award, Deferred Compensation, Forfeited	$ (67,537)

Warrants And Options_ Outstandi

Warrants And Options: Outstanding (Details) - shares	Dec. 31, 2019	Dec. 31, 2018
Details
Warrants, Number of Shares	56,785,913	21,232.500
Stock Options, Number of Shares	26,685,000	18,060,000

Warrants And Options_ Activity

Warrants And Options: Activity (Details)	12 Months Ended
	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)$ / shares
Warrants, Granted	40,703,413	14,077,500
Warrants, Expired	300,000	100,000
Warrants, Retired/Canceled	4,850,000	0
Warrants, Value | $	$ 498,840	$ 851,610
Warrants, Yield	0.00%
Minimum
Warrants, Exercise Price		$ 0.001
Warrants, Expiration (Year)		2,020
Warrants, Expected Term (Years)	2
Warrants, Expected Volatility	40.00%
Warrants, Risk Free Interest Rate	1.56%
Maximum
Warrants, Exercise Price		$ 0.60
Warrants, Expiration (Year)		2,024
Warrants, Expected Term (Years)	5
Warrants, Expected Volatility	45.00%
Warrants, Risk Free Interest Rate	2.95%

Warrants And Options_ Deferred

Warrants And Options: Deferred Stock Warrant Compensation (Details)	12 Months Ended
	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Details
Deferred Compensation, Total. Warrants	$ 40,730	$ 113,210
Deferred Compensation, Current Period Expense, Warrants	47,180	73,370
Deferred Compensation,Future Expense, Warrants	$ 92,470	$ 98,920
Deferred Compensation,Future Expense, Term (Months), Warrants	12

Warrants And Options_ Schedule

Warrants And Options: Schedule of Warrants Outstanding (Details)	12 Months Ended
	Dec. 31, 2019USD ($)$ / sharesshares
$0.001
Warrants, Number of Shares | shares	300,000
Warrants, Remaining Life (Years)	3 years 6 months
Warrants, Exercise Price X Number Of Shares | $	$ 300
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.17
$0.01
Warrants, Number of Shares | shares	500,000
Warrants, Remaining Life (Years)	2 years 9 months
Warrants, Exercise Price X Number Of Shares | $	$ 5,000
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.22
$0.01
Warrants, Number of Shares | shares	75,000
Warrants, Remaining Life (Years)	1 year
Warrants, Exercise Price X Number Of Shares | $	$ 750
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.18
$0.10
Warrants, Number of Shares | shares	5,028,413
Warrants, Remaining Life (Years)	4 years 9 months
Warrants, Exercise Price X Number Of Shares | $	$ 502,841
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.21
$0.10
Warrants, Number of Shares | shares	62,500
Warrants, Remaining Life (Years)	3 years 3 months
Warrants, Exercise Price X Number Of Shares | $	$ 6,250
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.29
$0.10
Warrants, Number of Shares | shares	250,000
Warrants, Remaining Life (Years)	1 year 6 months
Warrants, Exercise Price X Number Of Shares | $	$ 25,000
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.19
$0.10
Warrants, Number of Shares | shares	4,877,500
Warrants, Remaining Life (Years)	1 year 3 months
Warrants, Exercise Price X Number Of Shares | $	$ 487,750
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.21
$0.10
Warrants, Number of Shares | shares	250,000
Warrants, Remaining Life (Years)	9 months
Warrants, Exercise Price X Number Of Shares | $	$ 25,000
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.32
$0.12
Warrants, Number of Shares | shares	100,000
Warrants, Remaining Life (Years)	2 years 9 months
Warrants, Exercise Price X Number Of Shares | $	$ 12,000
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.21
$0.12
Warrants, Number of Shares | shares	125,000
Warrants, Remaining Life (Years)	2 years
Warrants, Exercise Price X Number Of Shares | $	$ 15,000
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.21
$0.15
Warrants, Number of Shares | shares	600,000
Warrants, Remaining Life (Years)	4 years 3 months
Warrants, Exercise Price X Number Of Shares | $	$ 90,000
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.19
$0.15
Warrants, Number of Shares | shares	1,000,000
Warrants, Remaining Life (Years)	1 year
Warrants, Exercise Price X Number Of Shares | $	$ 150,000
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.28
$0.17
Warrants, Number of Shares | shares	62,500
Warrants, Remaining Life (Years)	3 years 3 months
Warrants, Exercise Price X Number Of Shares | $	$ 10,625
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.29
$0.18
Warrants, Number of Shares | shares	62,500
Warrants, Remaining Life (Years)	3 years 3 months
Warrants, Exercise Price X Number Of Shares | $	$ 11,250
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.29
$0.20
Warrants, Number of Shares | shares	2,600,000
Warrants, Remaining Life (Years)	4 years 3 months
Warrants, Exercise Price X Number Of Shares | $	$ 520,000
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.19
$0.21
Warrants, Number of Shares | shares	62,500
Warrants, Remaining Life (Years)	3 years 3 months
Warrants, Exercise Price X Number Of Shares | $	$ 13,125
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.29
$0.21
Warrants, Number of Shares | shares	100,000
Warrants, Remaining Life (Years)	9 months
Warrants, Exercise Price X Number Of Shares | $	$ 21,000
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.34
$0.25
Warrants, Number of Shares | shares	6,000,000
Warrants, Remaining Life (Years)	2 years 9 months
Warrants, Exercise Price X Number Of Shares | $	$ 1,500,000
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.20
$0.25
Warrants, Number of Shares | shares	1,050,000
Warrants, Remaining Life (Years)	2 years 6 months
Warrants, Exercise Price X Number Of Shares | $	$ 262,500
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.21
$0.25
Warrants, Number of Shares | shares	10,400,000
Warrants, Remaining Life (Years)	2 years 3 months
Warrants, Exercise Price X Number Of Shares | $	$ 2,600,000
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.20
$0.25
Warrants, Number of Shares | shares	800,000
Warrants, Remaining Life (Years)	2 years
Warrants, Exercise Price X Number Of Shares | $	$ 200,000
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.21
$0.25
Warrants, Number of Shares | shares	3,250,000
Warrants, Remaining Life (Years)	1 year 9 months
Warrants, Exercise Price X Number Of Shares | $	$ 812,500
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.18
$0.25
Warrants, Number of Shares | shares	13,500,000
Warrants, Remaining Life (Years)	1 year 3 months
Warrants, Exercise Price X Number Of Shares | $	$ 3,375,000
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.21
$0.25
Warrants, Number of Shares | shares	475,000
Warrants, Remaining Life (Years)	1 year
Warrants, Exercise Price X Number Of Shares | $	$ 118,750
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.27
$0.25
Warrants, Number of Shares | shares	3,255,000
Warrants, Remaining Life (Years)	9 months
Warrants, Exercise Price X Number Of Shares | $	$ 813,750
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.32
$0.25
Warrants, Number of Shares | shares	1,500,000
Warrants, Remaining Life (Years)	6 months
Warrants, Exercise Price X Number Of Shares | $	$ 375,000
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.39
$0.35
Warrants, Number of Shares | shares	250,000
Warrants, Remaining Life (Years)	9 months
Warrants, Exercise Price X Number Of Shares | $	$ 87,500
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.32
$0.60
Warrants, Number of Shares | shares	250,000
Warrants, Remaining Life (Years)	9 months
Warrants, Exercise Price X Number Of Shares | $	$ 150,000
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.34

Warrants And Options_ Warrant R

Warrants And Options: Warrant Rollforward (Details)	12 Months Ended
	Dec. 31, 2019USD ($)$ / sharesshares
Details
Warrants, Outstanding, Beginnning	7,255,000
Warrants, Outstanding, Beginning, Weighted Avg Exercise Price | $ / shares	$ 0.18
Warrants, Issued in Period	54,780,913
Warrants, Issued in Period, Weighted Avg Exercise Price | $ / shares	$ 0.20
Warrants, Exercised in Period	0
Warrants, Exercised in Period, Weighted Avg Exercise Price | $ / shares	$ 0
Warrants, Expired/Cancelled in Period	(5,250,000)
Warrants, Expired/Cancelled in Period, Weighted Avg Exercise Price | $ / shares	$ 0.21
Warrants, Outstanding, Ending	56,785,913
Warrants, Outstanding, Ending, Weighted Avg Exercise Price | $	$ 0.21

Warrants And Options_ Options,

Warrants And Options: Options, Activity (Details)	12 Months Ended
	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)shares
Stock Options, Granted | shares	10,000,000	6,000,000
Stock Options, Vest Period (Years)	2
Stock Options, Value | $	$ 875,700	$ 833,700
Stock Options, Yield	0.00%
Minimum
Stock Options, Life (Years)	3
Stock Options, Exercise Price	0.05
Stock Options, Expected Term (Years)	3
Stock Options, Expected Volatility	1.82
Stock Options, Risk Free Interest Rate	1.69%
Maximum
Stock Options, Life (Years)	5
Stock Options, Exercise Price	0.25
Stock Options, Expected Term (Years)	4.75
Stock Options, Expected Volatility	2.29
Stock Options, Risk Free Interest Rate	2.78%

Warrants And Options_ Options_2

Warrants And Options: Options Outstanding (Details)	12 Months Ended
	Dec. 31, 2019USD ($)$ / sharesshares
$0.05
Stock Options, Number of Shares | shares	90,000
Stock Options, Remaining Life (Years)	2 years 6 months
Stock Options, Exercise Price x Number of Shares | $	$ 4,500
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.14
$0.05
Stock Options, Number of Shares | shares	1,140,000
Stock Options, Remaining Life (Years)	2 years 3 months
Stock Options, Exercise Price x Number of Shares | $	$ 57,000
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.09
$0.05
Stock Options, Number of Shares | shares	100,000
Stock Options, Remaining Life (Years)	1 year 9 months
Stock Options, Exercise Price x Number of Shares | $	$ 5,000
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.08
$0.05
Stock Options, Number of Shares | shares	60,000
Stock Options, Remaining Life (Years)	1 year
Stock Options, Exercise Price x Number of Shares | $	$ 3,000
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.06
$0.05
Stock Options, Number of Shares | shares	170,000
Stock Options, Remaining Life (Years)	9 months
Stock Options, Exercise Price x Number of Shares | $	$ 8,500
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.12
$0.09
Stock Options, Number of Shares | shares	5,500,000
Stock Options, Remaining Life (Years)	2 years 6 months
Stock Options, Exercise Price x Number of Shares | $	$ 467,500
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.20
$0.10
Stock Options, Number of Shares | shares	500,000
Stock Options, Remaining Life (Years)	9 months
Stock Options, Exercise Price x Number of Shares | $	$ 50,000
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.14
$0.15
Stock Options, Number of Shares | shares	1,000,000
Stock Options, Remaining Life (Years)	9 months
Stock Options, Exercise Price x Number of Shares | $	$ 150,000
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.14
$0.25
Stock Options, Number of Shares | shares	3,125,000
Stock Options, Remaining Life (Years)	4 years 3 months
Stock Options, Exercise Price x Number of Shares | $	$ 781,250
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.22
$0.25
Stock Options, Number of Shares | shares	1,000,000
Stock Options, Remaining Life (Years)	4 years
Stock Options, Exercise Price x Number of Shares | $	$ 250,000
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.23
$0.25
Stock Options, Number of Shares | shares	5,000,000
Stock Options, Remaining Life (Years)	3 years 3 months
Stock Options, Exercise Price x Number of Shares | $	$ 1,250,000
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.16
$0.25
Stock Options, Number of Shares | shares	7,000,000
Stock Options, Remaining Life (Years)	2 years 6 months
Stock Options, Exercise Price x Number of Shares | $	$ 1,750,000
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.16
$0.25
Stock Options, Number of Shares | shares	1,000,000
Stock Options, Remaining Life (Years)	9 months
Stock Options, Exercise Price x Number of Shares | $	$ 250,000
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.15
$0.25
Stock Options, Number of Shares | shares	1,000,000
Stock Options, Remaining Life (Years)	3 months
Stock Options, Exercise Price x Number of Shares | $	$ 250,000
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.10

Warrants And Options_ Options R

Warrants And Options: Options Rollforward (Details) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Details
Stock Options, Beginning, Weighted Average Exercise Price	$ 0.15
Stock Options, Grants In Period	10,000,000	6,000,000
Stock Options, Grants in Period, Weighted Average Exercise Price	$ 0.19
Stock Options, Exercises in Period, Weighted Average Exercise Price	0.18
Stock Options, Expirations/Forfeitures in Period, Weighted Average Exercise Price	0.20
Stock Options, Ending, Weighted Average Exercise Price	$ 0.20	$ 0.15

Warrants And Options_ Options_3

Warrants And Options: Options, Summary (Details) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Details
Stock Options, Grants	10,000,000	6,000,000
Stock Options, Exercises	0	1,973,189
Stock Options, Expirations	0	1,000,000
Stock Options, Forfeitures	375,000	5,641,811

Warrants And Options_ Deferre_2

Warrants And Options: Deferred Stock Option Compensation (Details)	12 Months Ended
	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Details
Deferred Compensation, Total	$ 875,700	$ 649,327
Deferred Compensation, Current Period Expense	718,392	572,870
Deferred Compensation, Future Expense	$ 1,552,774	$ 1,395,466
Deferred Compensation, Future Expense, Term (Months)	12

Income Taxes_ Schedule of Eff_2

Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Details
Income (Loss) from Continuing Operations before Income Taxes, Domestic	$ (12,866,332)	$ 15,608,209
Statutory Rate (Fed & State(s))	30.00%	30.00%
Computed Expected Tax Payable (Recovery)	$ (3,351,800)	$ 4,781,700
Effect of release of net operating loss carryforwards	(2,240,900)	(2,417,700)
Gain on extinguishment of debt-principal	0	(6,124,000)
Impairment losses	299,100	0
Non-Deductible, Stock Option Amortization	830,200	1,048,500
Non-Deductible, Discount amortization	6,000	837,000
Non-Deductible, Other	2,100	1,500
Non-Deductible, Total	1,137,400	(4,237,000)
Change in Valuation Allowance	4,635,300	(1,873,000)
Current Income Tax Expense (Benefit)	0	0
Reported Income Taxes, Federal	0	0
Reported Income Taxes, State	0	0
Reported Income Taxes, Total	$ 0	$ 0

Income Taxes_ Components of D_2

Income Taxes: Components of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Details
Deferred Tax Asset, Net Operating Losses	$ 4,666,500	$ 0
Deferred Tax Asset, Bad Debt Allowance	0	0
Deferred Tax Asset, Officers Accrued Compensation	222,800	243,400
Deferred Tax Asset, Related Party Interest	10,100	20,700
Deferred Tax Asset, Valuation Allowance	(4,899,400)	(264,100)
Deferred Tax Assets, Net of Valuation Allowance	$ 0	$ 0

Income Taxes_ Extinguishment of

Income Taxes: Extinguishment of Debt (Details)	12 Months Ended
	Dec. 31, 2019USD ($)
Details
Extinguishment of Debt, Pricipal	$ 20,522,835

Income Taxes_ Summary of Oper_2

Income Taxes: Summary of Operating Loss Carryforwards (Details)	12 Months Ended
	Dec. 31, 2019USD ($)
2016
Net Operating Loss	$ 1,192,900
Expires	2036
2017
Net Operating Loss	$ 2,117,100
Expires	2037
2018
Net Operating Loss	$ 548,900
Expires	No Expiration
2019
Net Operating Loss	$ 9,165,700
Expires	No Expiration

Income Taxes_ Tax Years Open to

Income Taxes: Tax Years Open to Examination (Details)	12 Months Ended
	Dec. 31, 2019
Details
Years Open to Examination, Beginning Year	2011

Discontinued Operations_ Sche_3

Discontinued Operations: Schedule of Discontinued Operations, Balance Sheet (Details) - RoxSan Pharamcy Inc	May 14, 2018USD ($)
Liabilities Subject to Compromise
Accounts Payable and Accrued Expenses	$ 2,942,012
Related Party Payables	376,430
Note Payable	185,000
Note Payable-Merchant	974,826
Liabilities Subject to Compromise, Total	4,478,268
Liabilities Subject to Compromise, Total, Net of Assets Held For Sale	$ 4,478,268

Discontinued Operations_ Payrol

Discontinued Operations: Payroll Taxes Payable (Details) - RoxSan Pharamcy Inc	Dec. 31, 2019USD ($)
Payroll Taxes Payable	$ 181,580
Payroll Taxes Payable, Penalties	296,959
Payroll Taxes Payable, Interest	$ 50,167

Discontinued Operations_ Sche_4

Discontinued Operations: Schedule of Discontinued Operations, Income Statement (Details) - RoxSan Pharamcy Inc	4 Months Ended
	May 14, 2018USD ($)
Revenue	$ 0
Cost of Goods Sold	0
Gross Profit	0
Sales, Marketing & Pharmacy Expenses	170,630
General & Administrative Expenses	586,993
Operating Loss	(757,623)
Interest Expense	(56,775)
Loss on disposal of equipment	(10,000)
Net Loss	$ (824,398)

Segment Reporting_ Schedule o_2

Segment Reporting: Schedule of Segment Reporting Information, by Segment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue	$ 128,600	$ 11,739
Gross Profit	111,773	(8,600)
Operating Income (loss)	(6,393,688)	(6,634,663)
Deprecation and amortization	120,972	120,620
Interest Expense	582,508	2,164,530
Gain on extinguishment of debt	(927,399)	22,858,009
Loss on fair value adjustments	194,511	(123,875)
Loss on settlements	(4,134,972)	0
Impairment loss	1,002,276
Discount Amortization	20,000	2,805,000
Total Assets	1,359,896	1,364,357
Goodwill	785,060	785,060
Additions to Property and Equipment	2,628	0
Loss on disposal of subsidiary		4,478,268
Discontinued operations		(824,398)
Remote Care Segment
Revenue	1,800	9,399
Gross Profit	480	(10,400)
Operating Income (loss)	(253,391)	(365,426)
Deprecation and amortization	9,196	9,196
Interest Expense	3,111	2,970
Gain on extinguishment of debt	101,367	0
Loss on fair value adjustments	0	0
Impairment loss	0
Discount Amortization	20,000	(340,000)
Total Assets	904,757	913,636
Goodwill	785,060	785,060
Additions to Property and Equipment	0	0
Loss on disposal of subsidiary		0
Discontinued operations		0
Behavioral Healthcare Segment
Revenue	76,800	1,800
Gross Profit	61,293	1,800
Operating Income (loss)	(169,485)	(191,446)
Deprecation and amortization	109,760	109,760
Interest Expense	0	0
Gain on extinguishment of debt	0	0
Loss on fair value adjustments	0	0
Impairment loss	0
Discount Amortization	0	0
Total Assets	439,567	439,567
Goodwill	0	0
Additions to Property and Equipment	0	0
Loss on disposal of subsidiary		0
Discontinued operations		0
Diagnostics/Corporate Segment
Revenue	50,000	0
Gross Profit	50,000	0
Operating Income (loss)	(5,970,812)	(6,077,791)
Deprecation and amortization	2,016	1,664
Interest Expense	579,397	2,161,560
Gain on extinguishment of debt	(1,028,766)	22,858,009
Loss on fair value adjustments	194,511	(123,875)
Loss on settlements	(4,134,972)
Impairment loss	1,002,276
Discount Amortization	0	3,145,000
Total Assets	125,332	11,154
Goodwill		0
Additions to Property and Equipment	2,628	0
Loss on disposal of subsidiary		4,478,268
Discontinued operations		0
Pharmacy Segment
Revenue	0	0
Gross Profit	0	0
Operating Income (loss)	0	0
Deprecation and amortization	0	0
Interest Expense	0	0
Gain on extinguishment of debt	0	0
Loss on fair value adjustments	0	0
Impairment loss	0
Discount Amortization	0	0
Total Assets	0	0
Goodwill	0	0
Additions to Property and Equipment	$ 0	0
Loss on disposal of subsidiary		0
Discontinued operations		$ (824,398)

Subsequent Events (Details)

Subsequent Events (Details)	12 Months Ended
	Dec. 31, 2019USD ($)$ / sharesshares
Convertible Promissory Note
Subsequent Event, Date	Jan. 22, 2020
Convertible Promissory Note, Principal	$ 78,000
Convertible Promissory Note, Interest Rate	12.00%
Convertible Promissory Note, Term (Yrs)	1
Convertible Promissory Note, Conversion Rate, Fixed | $ / shares	$ 0.12
Convertible Promissory Note, Conversion Rate, Variable	65.00%
Stock Issuance, Warrant Exercise
Subsequent Event, Date	Jan. 15, 2020
Warrants Exercise, Shares Issued | shares	1,838,217
Warrants Exercise, Shares Issued, Value	$ 108,455
Stock Issuance, Bonus Award
Subsequent Event, Date	Jan. 27, 2020
Stock Issuance, Shares | shares	1,351,181
Stock Issuance, Shares, Price Per Share | $ / shares	$ 0.001
Stock Issuance, Shares, Proceeds	$ 1,351
Stock Issuance, Shares, Value	$ 67,559
Resignation, Officer
Subsequent Event, Date	Feb. 2, 2020
Managing Director, Monthly Compensation	$ 2,000
Resignation, Shares Canceled, Stock Award | shares	1,450,000
Resignation, Shares Canceled, Stock Options | shares	2,250,000
Resignation, Shares Canceled, Value	$ 207,324
Certificate of Designation, Series B1 Preferred
Subsequent Event, Date	Feb. 12, 2020
Preferred Stock, Series B1, Shares Designated | shares	10,000
Preferred Stock, Series B1, Redemption Pct	120.00%
Preferred Stock, Series B1, Conversion Rate | $ / shares	$ 0.15
Preferred Stock, Series B1, Annual Dividend	10.00%
Preferred Stock, Series B1, Maturity (Yrs)	2
Subscription, Series B1
Subsequent Event, Date	Feb. 12, 2020
Stock Subscription, Shares | shares	69
Stock Subscription, Shares, Price Per Share | $ / shares	$ 10,000
Stock Subscription, Shares, OID	15.00%
Stock Subscription, Shares, Proceeds, Per Share	$ 8,500
Stock Subscription, Shares, Proceeds, Total	$ 586,500
Stock Subscription, Shares, Warrants, Percentage	50.00%
Stock Subscription, Shares, Warrants, Exercise Price | $ / shares	$ 0.25
Stock Subscription, Shares, Warrants, Life (Yrs)	3
Stock Issuance, Litigation Settlement
Subsequent Event, Date	Feb. 12, 2020
Stock Issuance, Litigation, Shares | shares	10,000,000
Stock Issuance, Litigation, Shares, Value	$ 480,000
Stock Issuance, Services
Subsequent Event, Date	Feb. 14, 2020
Stock Issuance, Consultant, Shares | shares	1,000,000
Stock Issuance, Consultant, Shares, Value	$ 62,500
Stock Issuance, Conversion of Debt
Subsequent Event, Period	first quarter 2020
Stock Issuance, Debt Conversion, Amount Converted	$ 65,000
Stock Issuance, Debt Conversion, Shares | shares	3,412,292
Stock Issuance, Debt Conversion, Shares, Value	$ 178,182
Stock Issuance, Conversion of Debt
Subsequent Event, Period	first quarter 2020
Stock Issuance, Debt Conversion, Amount Converted	$ 41,580
Stock Issuance, Debt Conversion, Shares | shares	2,200,000
Stock Issuance, Debt Conversion, Shares, Value	$ 128,000
Stock Issuance, Services
Stock Issuance, Consultant, Shares | shares	246.844
Stock Issuance, Consultant, Shares, Value	$ 9,750
Subsequent Event, Period	first quarter 2020
Subscription, Series B1
Subsequent Event, Date	Mar. 5, 2020
Stock Subscription, Shares | shares	36
Stock Subscription, Shares, Price Per Share | $ / shares	$ 10,000
Stock Subscription, Shares, OID	15.00%
Stock Subscription, Shares, Proceeds, Per Share	$ 8,500
Stock Subscription, Shares, Proceeds, Total	$ 306,000
Executive Agreement, President
Subsequent Event, Date	Apr. 7, 2020
Subsequent Event, Effective Date	Mar. 1, 2020
Executive Agreement, Compensation, Base, Year 1	$ 225,000
Executive Agreement, Compensation, Base, Year 2	250,000
Executive Agreement, Compensation, Base, Year 3	$ 275,000
Executive Agreement, Initial Term (Mos)	6
Executive Agreement, Compensation, Initial Term (Pct)	50.00%
Executive Agreement, Compensation, Stock Award, Shares | shares	2,000,000
Executive Agreement, Compensation, Stock Award, Per Share | $ / shares	$ 0.001
Executive Agreement, Compensation, Stock Award, Immediate Vest (Pct)	25.00%
Executive Agreement, Compensation, Stock Options, Shares	3,000,000
Executive Agreement, Compensation, Stock Options, Exercise Price | $ / shares	$ 0.25
Executive Agreement, Compensation, Stock Options, LIfe (Yrs)	5
Executive Agreement, Compensation, Stock Options, Immediate Vest (Pct)	25.00%